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Abstract
Developing of targeted drug delivery systems is currently a very important topic, 
which can be easily  judged by a great number of  papers published every year. 
Materials  science proposes, among others,  microcapsules as one of the possible 
solutions to the problem. Known for more than a decade by know, microcapsules, 
their properties, methods of encapsulation, release, control where under thorough 
investigation by several scientific groups in the world. Despite the fact that many 
factors were already studied, application of this system to drug delivery provides an 
enormous amount of work yet to be done, lying across several areas of science – 
biology,  chemistry,  physics,  medicine.  To  be  used  as  a  technique  of  targeted 
delivery, not only the microcapsules should meet many constraints on their physical 
and chemical properties, but also the means of their control and release triggering 
irradiation  should  be  applicable  and  harmless  to  living  body.  This  means,  that 
there's a lot more to do than to encapsulate the substances of interest and make 
sure they stay inside the capsules.
This  is  why  this  research  was  devoted  to  investigation  of  stability  of  cargo 
encapsulated  to  layer-by-layer  microcapsules  constructed  on  silica  and  CaCO3 
microparticles using various shell  constructions with synthetic and biodegradable 
polyelectrolytes,  nanoparticles,  DNA,  enzyme  and  other  materials,  methods  of 
microcapsules control by magnetic field, which can be used for navigation of the 
carriers  in-vivo to the place of  interest  and methods of  release of  encapsulated 
substances from the microcapsules, that are friendly to living body. 
The thesis starts with introduction and a literature review to help reader to get a 
better  understanding  on  the  structures  discussed  in  this  work  and  what  have 
already been done in the area. These are followed by a short description of main 
materials and methods used to conduct this research. Three following chapters  of 
experimental  section describe  the  research itself.  Chapter  4  shows feasibility  of 
triggered  IR-laser  and  high-frequency  ultrasound  release,  including  intracellular 
release. Reporting application of cargo using pH-sensitve dye is shown. Ultrasound-
triggered  release  at  parameters,  close  to  that  currently  used  in  medical 
applications, is shown to achieve up to 60% efficiency of previously reported high-
power 20 kHz ultrasonic irradiation.  Feasibility of  laser-induced triggered release 
using microcapsules functionalized photo-sensitive dyes was also shown. In Chapter 
5  retention  of  activity  of  DNA  and  enzyme  molecules  upon  encapsulation  was 
demonstrated. Activity of encapsulated substances was shown to be lower, than of 
free  ones,  but  the  accessibility  and  kinetics  of  reactions  can  be  controlled  by 
adjusting the construction of microcapsules.  In Chapter 6 feasibility of control  of 
cells impregnated with microcapsules functionalized with magnetite nanoparticles 
was shown at distances of up to 10 mm using usual constant magnets.
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1 Introduction
1 Introduction
Nanotechnology can be characterized as a part of materials science. It performs 
research  of  new properties,  obtained by  new micro-  and nano-scaled  materials. 
However,  the  properties  study  is  very  close  connected  with  the  methods  the 
materials  are  obtained.  One  of  such  methods  to  create  the  nano-structured 
materials,  and  later  so-called  nanocomposites,  is  Layer-by-Layer  assembly 
technique,  proposed  not  so  long  ago  by  Decher  et  al,1 employing  electrostatic 
attraction at molecular scale to bond soluble polymers of a specific kind to each 
other to get a multi-layered thin film. The main requirement for the building blocks 
of this approach is the charge, that these substances have to carry on them. This 
requirement  is  met  by  chargeable  polymers  –  polyelectrolytes,  nanoparticles, 
proteins, and many other substances. Therefore, a lot of research was done since 
then,  regarding the  properties  of  LbL  films,  incorporating  these diverse  building 
blocks.
In 1998, this approach was applied to spherical templates by G. Sukhorukov et al.2 
Covering the spherical micrometer-sized template with a film and then dissolving 
the template,  one obtains a cavity in a shell  – a microcontainer,  which became 
known as a microcapsule. Later different methods were developed for encapsulation 
of different substances into these cavities, created by using different templates.3-7 
As  the  shells  of  the  microcapsules  can be made impermeable  for  relatively  big 
molecules, they can act as containers, holding inside some substance, isolating it 
from the environment.
The fact of the substance being locked inside the microcapsule is useful when this 
substance is to deliver to some particular point. This, obviously, can be applied in 
drug delivery.8 However, the capsules, once loaded with the substance (drug) should 
be navigated to a specific point of the organism, and opened there, so that the 
substance would be released. All these tasks by themselves create an enormous 
field  of  research,  as  they  include  encapsulation  and  stability  research  for  very 
different substances of interest, investigation of methods of navigation the capsules 
to  the  point,  and  release  from the  capsules,  which  would  be  harmless  for  the 
organism. There is also a place for a research of cells interactions with the capsules.
The release methods are mostly based on changing the permeability of the capsules 
shells, or even rupturing them, by different kinds of external influence, including pH, 
solvent, heating by laser irradiation, ultrasound, etc. Release methods, significantly 
developed  recently,  include  laser9-11 and  ultrasonic12,13 irradiation  of  capsuled, 
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functionalized with appropriate  agents  (nanoparticles).  The laser-induced release 
effects can employ different physical basis. Shortly, the shell permeability can be 
changed by heating of its constituents, making it more flexible,9,10 or by chemical 
effects,  destroying  the  shell  with  free  radicals.11 Ultrasound  effect  on  the 
microcapsules studies have yet been limited to high-power conventional ultrasound, 
which cannot be used for living body applications for obvious reasons.
Much interest is paid nowadays to targeted drug release, as it will allow low damage 
upon  internal  organs  diseases  treatment  by  non-invasive  methods.  One  of  the 
possible  mechanisms of  drug delivery  is  the  use  of  microcapsules.  These  small 
polymeric  containers,  with  characteristic  dimensions  ranging  from  hundreds  of 
nanometers  to  tens  of  micrometers,  can  be  filled  with  different  substances 
(provided with considerable molecular weight of these substances). The shells of 
microcapsules can be functionalized with various objects, allowing to navigate the 
capsules to the desired point, and making the shells sensitive to different factors, 
allowing therefore the release from the microcapsules in the desired point.
The research of the microcapsules has been lead for the last decade, involving the 
search for the methods of encapsulation, using different templates for the Layer-by-
Layer assembly, incorporating various building blocks into the shells and releasing 
the  encapsulated  species  by  different  types  of  irradiation.  The  uptake  of  the 
capsules  into  the  cells  was  also  investigated.  However,  most  of  the  release 
mechanisms reported, possess low medical  application feasibility due to harmful 
effects to the living body, caused by the irradiation, or difficulties of finding and 
focusing onto the capsules inside the organism.
Thus,  despite the very thorough research on the release methods,  physical  and 
chemical properties of microcapsules, lead recently, there is still a need to develop 
release  methods,  proposing  more  compatibility  with  the  living  body  and  more 
efficiency. These are the main reasons, why this study was devoted to investigating 
the remote methods of control and release, based on potentially in-vivo compatible 
methods,  including  optical,  ultrasonic,  and  magnetic  influences.  This  work  is 
intended to be another small step forward towards creating a complete targeted 
drug delivery system with microcapsules playing a key role,  and towards  in-vivo 
studies from very diverse  in-vitro studies that were performed by the time. This 
system should guarantee that encapsulated substances remain intact throughout 
storage period and during travel through the body to the site of interest. The acting 
substances should keep their activity and start acting at certain place upon certain 
triggering event or possess gradual release, acting like a depot. All the components 
of such system should obviously be human-friendly, including the components of 
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the carriers and the release triggering influences.
According to all mentioned above, this thesis describes experiments on laser and 
ultrasound  triggered  release  of  compounds  from  microcapsules,  including 
intracellular  release, at  parameters,  potentially applicable for medical  treatment. 
Influence  of  magnetic  field  on  cells  with  microcapsules  functionalized  with 
magnetite nanoparticles inside was studied, meaning magnetic field as a driving 
force for navigation of drug carriers towards the site of interest. At the same time, 
the behaviour of encapsulated bioactive species inside the biological environment 
must  be  thoroughly  investigated  to  bring  the  drug  delivery  techniques  to  the 
application. Thus, encapsulated enzyme activity and encapsulated DNA transfection 
(including triggered process) were also studied.
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2.1 Polyelectrolytes
Polyelectrolytes  are  polymeric  molecules,  built  of  charged  (ionized)  or  ionizable 
monomers and low molecular weight counter-ions, maintaining electrical neutrality. 
The monomers dissociate in aqueous solutions, making the polymer charged. Thus, 
polyelectrolytes properties alike ones of polymers and electrolytes (salts). This is 
why  they  are  sometimes  referred  to  as  polysalts.  Polyelectrolyte  solutions  are 
electrically conductive, as salts, and often viscous, like polymers. Polyelectrolytes 
play  a  major  role  in  biology,  as  many biological  molecules  are  polyelectrolytes, 
including polypeptides and DNA.
As acids and bases, polyelectrolytes can be divided into “weak” and “strong” types, 
depending on whether they dissociate completely (as “strong” do) or not in polar 
solutions for reasonably pH values. Weak polyelectrolytes are partially charged at 
intermediate  pH.  In  dilute  solutions,  ionizable  molecule  (simply,  a  pair  of  ions) 
reversibly dissociates
HAH +A­ (Eq. 1.1)
The charge of weak polyelectrolytes is defined by dissociation constant (constant of 
acidity)  Ka of  ionic  group,  severely  depending  on  pH.  The  brackets  denote  the 
concentration of each species.
K a=
[H + ][A­]
[HA]
(Eq. 1.2)
When  logarithm  is  taken,  one  gets  to  a  form  of  the  Henderson-Hasselbalch 
equation:
lgK a=lg [H
+]lg [A
­]
[HA]
lg [H +]= pH , lgK a= pK a
pKa=pH−lg
[A­]
[HA]
(Eq. 1.3)
When the charge density along the polymer chain is taken into account, empirical 
19
2 Literature Review
parameter n arises:
pK a= pH−n⋅lg
[A­]
[HA ]
(Eq. 1.4)
Due  to  coulomb  interactions  (repulsion  of  similarly  charged  groups  in 
macromolecules, and attraction of counter-ions to polyion), the behaviour of linear 
polyelectrolytes  is  substantially  different  from  this  of  both  non-ionogenic 
(uncharged) polymers and low molecular weight electrolytes. Due to electrostatic 
repulsion between similarly charged groups, the molecule tends to unwrap and get 
more asymmetric shape, than one of statistical tangle characteristic to uncharged 
chains. For that reason, polyions have much bigger dimensions and asymmetry in 
solvents,  than the macromolecules of  similar  nature, but lacking in charge.  This 
feature affects, among others, viscosity, diffusion, conductivity, transfer phenomena 
and sedimentation of polyelectrolytes.
The size of polyion in aqueous solutions is dramatically dependent on linear charge 
density  (charge  per  single  monomer  unit).  For  example,  total  dissociation  of 
carboxile  groups  of  high  molecular  weight  polyacrylic  acid,  the  volume  of  the 
molecule in dilute solution without salt raises more than two orders of magnitude, 
compared to the molecule with totally protonated groups.
Conformation  of  polyelectrolytes  is  also  defined  by  presence  of  low  molecular 
weight  electrolytes,  for  example,  salts.  Their  presence  leads  to  screening  the 
charges  of  polyion  molecule  from each  other  and  decreases  the  repulsion,  and 
therefore, unwrapping of the molecule. At considerable concentrations of salt (about 
1M), coulomb repulsion disappears, and the size of the molecule becomes equal to 
that  of  uncharged  one.  Higher  salt  concentration  can  lead  to  separation  of 
polyelectrolyte into a new phase, usually liquid.
Conformations of long polymers can only be described statistically. Several models 
are used to describe the average conformation of a flexible neutral polymer in dilute 
solution. One of the simplest, yet often used, Gaussian model, considers a phantom 
chain,  made  up  of  orientationally  uncorrelated  (freely-jointed)  links,  where  the 
length of any link vector r has a probability distribution.
G  r = 3
2b2

3 /2
⋅exp ­ 3r
2
2b2
 (Eq. 1.5)
where b is the expectation for the link length:
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〈r 2〉=b2 (Eq. 1.6)
The scaling of the end-to-end distance is
〈R2
e
〉~2 N (Eq. 1.7)
Where N is the number of monomers (links) and α is the single monomer size. This  
model describes only uncharged polymers, as their Re is much smaller, than the 
length of  the  extended polymer.  For polyelectrolytes  everything is  slightly  more 
complicated, with commonly used Flory theory for their description.14 The end-to-
end distance h0 is related to persistence lengths of chain.15
〈h2
0
〉=2LP0P e (Eq. 1.8)
Here  P0 is  steric  length,  corresponding to  persistence length of  an equal  length 
uncharged  polymer,  whereas  Pe corresponds  to  electrostatic  contribution. 
Persistence length Is the average projection of the end-to-end vector on the tangent 
to the chain contour at a chain end in the limit of infinite chain length, characteristic 
to  the  so  called  worm-like  chain  model  -  a hypothetical  linear  macromolecule, 
consisting  of  an  infinitely  thin  chain  of  continuous  curvature;  the  direction  of 
curvature at any point is random. The model, sometimes referred to as Porod-Kratky 
chain, describes the whole spectrum of uncharged chains with different degrees of 
chain  stiffness  from  rigid  rods  to  random  coils,  and  is  particularly  useful  for 
representing stiff chains.
The  steric  and  electrostatic  contributions  are  described  as  (the  so-called  Odjik-
Skolnick-Fixmann approach)16
P0= kT ;
Pe=
lB
4 
k−1
A 
2
,
lB=
q2
40 k T
, k−1=
0 kT
2NAe
2 I

1/2
, I=1
2∑ Z
2
i
C i .
(Eq. 1.9)
where:
γ – characterizes elasticity of the polymer chain;
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k – Boltzmann constant;
T – temperature;
lB –  Bjerrum length, the separation at which the electrostatic interaction between 
two elementary charges is comparable in magnitude to the thermal energy scale kT;
k-1 – Debye length, the scale over which mobile charge carriers screen out electric 
fields;
A – distance between elementary charges in the chain;
q – elementary charge;
ε – dielectric permeability of the medium (water);
NA – Avogadro's number;
I – ionic strength of the solution;
Zi – charge valency of ith ion;
Ci – concentration of ion species i.
The main conclusion, which can be made from these relations, is that the addition of 
electrolytes (salt) makes a coiled conformation of polyelectrolyte more favorable, 
that elongated one at relatively low ionic strength.
2.2 Complexes
When mixed, oppositely charged polyions tend to form polyelectrolyte complexes 
(PEC), releasing counter-ions. The driving force for complexation was described in 
terms of either attraction of oppositely charged groups or increase in entropy as 
releasing the counter-ions. However, other interactions such as hydrogen bonding 
or hydrophobic ones may play an additional part. From the energetic point of view, 
PEC formation may even be an endothermic process, because of the elastic energy 
contributions of the polyelectrolyte chains, impeding the necessary conformational 
adaptations of the polymer chains during their transition to the much more compact 
PEC structures. Though entropy considerations would lead to expectation irregular 
structures, the electrostatic effects will tend to drive the system to rearrange itself 
so that the highest possible fraction of charged groups of polyelectrolytes are paired 
up  with  their  opposites.  It's  clear  that  such  rearrangement  should  give  1:1 
stoichiometry  for  linear  polyelectrolytes  of  similar  charge  density,  the  same 
stoichiometry  was  demonstrated  over  a  range  of  charge  density  and  ratios, 
especially when no added low-mass ions are present. However, 1:1 stoichiometry is 
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more characteristic to strong polyelectrolytes,  and tends to vary for  weak ones. 
Nevertheless,  even  if  the  stoichiometry  of  the  ionic  binding  is  1:1,  the  major 
component  may  be  bound  in  excess,  leading  to  an  overcharging  of  the  PEC 
particles.17 Both  types  of  polyelectrolyte  are  affected  by  considerable  salt 
concentrations, as they lead to charge screening, isolating the counter-ions from 
each other.18 The presence of a small amount of salt enables rearrangement and 
exchange processes and shifts  the reaction more to thermodynamic equilibrium, 
leading to  a uniform distribution of  the short  chain components  among all  long 
chains of the counterpart. Stop flow measurements19 showed that PEC formation 
takes place in less than 5 μs, nearly corresponding to the diffusion collision of the 
polyion coils. The further addition of salt leads at first to a shrinking of the PECs due 
to  the  shielding  of  their  charges  by  the  electrolyte.  When  a  critical  salt 
concentration is exceeded, a disproportionation of the short guest chains occurs, 
leading  to  completely  complexed,  precipitating  species  and  pure  host 
polyelectrolyte chains in solution.20 At still higher salt concentration the precipitate 
dissolves again and both components exist as free polyelectrolyte chains in solution. 
Similar effects can be induced by changes of the pH-value.21
One  of  the  theories  about  PEC  structure  and  conformation  was  presented  by 
Michaels and Miekka in 1961.22 These authors suggested that the PECs could be of 
either  ladder-like  (complex  formation  at  the  molecular  level,  provided  that  two 
polyelectrolytes have sufficient flexibility and suitable charge densities, so they can 
zip together in a complementary way) or “scrambled egg” structure (high number 
of chains in a particle), depending on the components and the external conditions 
(Fig.  2.1).22 An  adaptation  of  the  ladder  model  also  appears  to  be  working  in 
explanation of certain complexes, formed of a “host” polyelectrolyte and a “guest” 
polyelectrolyte of much lower molecular mass. 
Ladder-like structure was proposed since ionic sites next to the first reacted ones 
are the most likely to react next. A molecule of DNA is an idealistic example of a 
ladder-like complex. When the complexation proceeds from more than one site, a 
more  cross-linked structure  is  formed.  Most  experimental  structures  lie  between 
these two models, though probably closer to the scrambled egg than the ladder 
model.  The structure formation is  mainly determined by the fast  kinetics of  the 
process  (less  than  5  μs,  mainly  depending  on  the  concentrations  of 
polyelectrolytes), followed by a slower stage in which chains redistribute to a PEC 
conformation closer to equilibrium. Other factors affecting the structure formation 
are  the  mixing  procedure,  medium  conditions  (e.g.,  salt  and  polyelectrolyte 
concentration), and macromolecular characteristics of the polyelectrolytes, such as 
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molecular weight, chain flexibility, and linear charge density. The properties of the 
polyelectrolytes  themselves  are  also  important  and  complexes  formed  from 
different polyelectrolytes, which may seem similar, can behave very differently. For 
example, the complexation of the polyanion polyacrylic acid compared with that of 
the polymetacrylic acid with the same polycation results in complexes with very 
different properties, 
For polyelectrolytes of high molecular mass it's not reasonable to assume that their 
chains can line up in a highly regular “ladders”. Therefore, a “scrambled egg” model 
structure appears in cases of high molecular mass, concentration, and/or flow where 
the rate of irreversible collisions between macromolecules is high relatively to their 
rate of conformational adjustment.
PEC  formation  between  strong  polyelectrolytes  results  in  highly  aggregated  or 
macroscopic  flocculated  systems.  However,  in  extremely  diluted  solutions  the 
aggregation process stops on a colloidal level, offering the possibility to study these 
dispersions of PEC particles in detail .17 
2.3 Layer-by-Layer assembly
At nanoscale, it is very difficult to make simultaneously a huge amount of a very 
precise placing. The less things become, the harder they are to handle. However, 
the nature manages pretty well in doing all these things, when it turns to proteins or 
DNA  self-assembly.  It  makes  things  go  fast  and  right,  thus  self-assembly  is 
commonly  recognized  as  one  of  the  ultimate  goals  of  nanoscience  and 
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Figure 2.1: Polyelectrolytes complexation models: a) "ladder”, b) "scrambled egg".
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nanotechnology.
Layer-by-layer  (LbL)  technique  allows  to  overcome  the  drawbacks  of  two  other 
popular methods – Langmuir-Blodgett (LB), based on van der Waals interaction and 
self-assembled monolayer (SAM), based on the attachment of thiol monolayers to 
the gold surface. While these methods can control molecular order of the film, they 
have restrictions of the thickness, substrates, availability of the building blocks and 
versatility.  LbL  technique,  based  on  alternate  adsorption  of  oppositely  charged 
macromolecules, resulting in self-organization of films, allows thickness control with 
up to 1-2 nm, widely broadens the availability of building blocks and substrates, as 
any charged macromolecules can be assembled.23
The first report on electrostatically driven LbL self-assembly was probably,24 where 
silica and alumina particles were shown to be assembled in multilayer structure by 
alternate immersing of the substrate into two colloidal solutions. In 1990's Decher 
et  al.1 demonstrated  LBL  self-assembly  of  cationic  and  anionic  polyelectrolytes. 
Subsequently,  possibility  of  formation  of  similar  structures,  consisting  of 
combinations of charged colloidal particles and biomacromolecules such as DNA.25-27 
Soon this method became very popular among many research groups, yielding in an 
avalanche of publications regarding application of the method to different types of 
substances.26-39 Papers on modelling of electrostatically-driven LbL process and its 
kinetics have also been published.40,41
The LbL method is often referred to as electrostatic self-assembly (ESA), as is based 
mainly  on  electrostatic  interaction  between  the  neighbouring  layers.  When  a 
polyanion or polycation is dissolved in water, the sodium cations are dissociated 
from molecule backbone at pH, which is away from the isoelectric point, leaving the 
long molecule chain charged. The entire solution stays electrically neutral. When 
charged substrate  is  dipped into  the  polyelectrolyte  solution,  the  ion  molecules 
approach  it  within  Debye  length  and  get  attracted  to  the  surface  by  local 
electrostatic forces. The diffusion lets more and more free ions to get to the surface, 
getting  it  all  covered  by  a  layer  of  molecules,  which  fully  overcompensate  the 
charge of  the  previous layer.  Therefore,  the  surface  charge is  reversed and the 
process can be continued with the polyelectrolyte of the opposite charge.
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Figure 2.2: LbL process schematic.1
Fig.  2.2 shows  the  schematic  of  layer-by-layer  process.  Negatively  charged 
substrate is immersed into polycation solution and is kept there for a time duration, 
optimized for the type of molecules. At this step the process is performed, which 
allows  to  understand  the  moving  force  of  the  self-assemble  technique.  The 
polyelectrolytes from the solution travel to the substrate by diffusion. There they 
meet  opposite  charges,  which  attract  them.  The  way  the  polyelectrolyte  chain 
deposits to the surface depends greatly on the chain conformation. Within a low ion 
concentration, the layer becomes very thin, as the polymers adsorb on the surface 
in a stretched form, and most charges of the chain are paired with the opposite 
charges of the substrate. When the polymers are adsorbed in a coiled form, it's just 
impossible for them to pair all their chain with the substrate's charges, which will 
lead to  formation of  non-adsorbed chain  sections,  which  are  called “loops”  and 
“tails”,  depending on  their  situation  in  the  chain  (Fig.  2.3).  The “loops”  denote 
middle sections, and the “tails” denote end sections, that are not in contact with the 
surface. These impurities form mainly as the deposition is faster, than the chain 
rearrangements. Their presence on the surface results in creating of the charge, 
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opposite to that of the initial substrate. This is the charge overcompensation, one of 
the major keys to the layer-by-layer technique.
Figure 2.3: Polyelectrolyte chain attachment to a charged surface: a) stretched form,  
resulting in a flat nice (uncharged) layer b) coiled form, resulting in formation of  
“tails” and “loops”.
After adsorption of the first layer (Fig. 2.2), the substrate is taken away, thoroughly 
rinsed with deionized water and then is immersed into polyanion solution. By this 
alternate  dipping  process,  multi  layered  film  of  predefined  structure  is  built. 
Washing is a very important process, as helps to get rid of excess molecules and 
also from physically adsorbed molecules,42 which are loosely attached. It prepares 
the surface for the subsequent deposition and also guarantees precise thickness of 
the film.  As mentioned above,  ions are generated when two oppositely charged 
polyelectrolytes create complex. These ions, simply creating excess concentration 
of salt, screening the interactions, associate with polyelectrolyte in solution, leading 
to a more loosely bound structures. This is why the washing process is so important 
not only for removing the excess polyelectrolytes itself.
Such substances as  proteins,  dyes and DNA can also be  parts  of  self-assembly 
process, as polyanions or polycations, depending on their isoelectric point.28,43,44 This 
is very important when talking about creating structures, containing different parts 
to resolve separate tasks.
Commonly,  the  kinetics  of  the  layers  deposition  is  studied  by  quartz  crystal 
microbalance  (QCM)  technique  and  also  by  zeta-potential  measurements.  QCM 
measures the change of resonant frequency of oscillator when depositing the layers 
on it.  Resonance frequency is the function of total oscillating mass, according to 
27
2 Literature Review
Sauerbrey equation45:
M=−KF  (Eq. 1.10)
where ΔM is mass change, K is coefficient, determined by resonator properties, and 
ΔF is resonance frequency change. Thus, the frequency change is linear with the 
mass adsorption. This gives the way to investigate films deposition on a substrate.
The  other  technique  –  zeta-potential  measurements  –  gives  the  knowledge  of 
surface charge of the film. Due to technical restrictions, this method can hardly be 
used for characterizing planar films, but is very useful when investigating deposition 
on  small  templates,  as  when  constructing  microcapsules.  However,  there  is  a 
technique, able to substitute zeta-potential measurements for planar films, Calvin-
probe method, which also measures surface charge on planar samples.46,47
A sample graphs of QCM and zeta-potential measurements, characteristic for self-
assembly, is presented in Fig.  2.4. We can see the frequency falling as more and 
more layers are deposited onto the resonator. At the same time, zeta-potential is 
varied with the numbers of layers, changing its value from positive to negative and 
vise-versa, as polyanionic and polycationic layers are being deposited. The potential 
value should be roughly the same for  even or  odd layers,  if  the charge is  fully 
overcompensated after each deposition step.
Figure 2.4: a) QCM b) Zeta-potential change while depositing layers.5
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By these methods kinetics of the film formation can be studied. And it was shown, 
that the growth of the thickness is non-linear. The polyion absorption is believed to 
consist of two stages: quick anchoring to the substrate and slow relaxation.48 At 
first,  a  large  amount  of  mass  is  adsorbed,  and  then  the  adsorption  goes  to 
saturation region, significantly slowing the film growth.26,42 It was shown, that for 
concentrations of polyelectrolytes of 1-3 mg/mL 87% of the surface is covered in 
first  5  minutes,  taking 3 more minutes to reach 95% coverage.  As  soon as the 
surface  is  completely  covered,  there  is  no  reason to  keep the  substrate  in  the 
solution for any extra time. Most publications, regarding self-assembly, report 10-20 
minutes dipping time.
The kinetics of the whole film growth isn't linear, either. While the latter layers are 
adsorbed evenly, the first ones aren't.42,49 With the first two or three layers, less 
mass of  polyion molecules is adsorbed. It  was proposed,50 that the first  layer is 
adsorbed on a weakly charged substrate, forming isolated islands. As more layers 
are deposited, the islands grow and finally form the entire surface, allowing the next 
layers to form linearly. For that reason the precursor film approach26,49 is commonly 
used for planar films, to cover the substrate with uniformly charged layer. Usually 
PEI and/or PSS are used to form precursor layer, either solely or together.
Later  it  was  discovered,  that  not  only  linearly  growing,  but  also  exponentially 
growing (with the number of layers) systems exist.51-54 At present, the explanation of 
their build-up process is based on the diffusion “in” and “out” of the whole film 
during each bilayer deposition step of at least one of the PEs constituting the film. 
In the case of HA/PLL, it was found that during each deposition step HA interacts 
only with the upper layer of the film, whereas PLL diffuses in and out of the entire 
film structure54. Later it was found, that exponential growth becomes linear after 
some considerable number of layers.55,56 Moreover, usually linearly growing systems 
(such as  PAH/PSS)  can  be  forced to  be  growing exponentially  by  adjusting  salt 
concentration.57,58 It was proposed, that this behaviour is due to film restructuring, 
that forbids the diffusion as  the number of  the layers increases.  Based on this, 
authors59 proposed, that the  film may be subdivided in three main domains (Fig. 
2.5).
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Figure 2.5: Schematic representation of the multilayer build-up mechanism by the  
model of three zones.60 (a) At the beginning of the film buildup, the deposition of the  
first layers strongly depends on the properties of the substrate surface. This region is  
composed of only the first pairs of layers in the vicinity of the substrate surface and  
corresponds here to domain I. (b) The number of deposition steps increases, and the  
diffusion process takes place in domain III, leading to exponential growth of the film  
thickness. (c) As the construction goes on, the film undergoes a restructuring of the  
bottom layers of zone III, leading to the formation of a restructured zone denoted as  
zone II. Because this new zone is supposed to become impermeable for the diffusion  
process, domain III reaches a limited thickness, and the film grows linearly with the  
number of deposition step.
Domain  I  corresponds  to  the  initial  buildup  phase  and  is  in  contact  with  the 
substrate, domain III is in contact with the solution, and domain II corresponds to 
the internal part of the film that is surrounded by domains I and III. These authors 
assume that at least one of the PEs can diffuse into the entire domain III during 
each deposition step. They further assume that the composition of domain III is a 
function of  the polycation and polyanion concentrations  of  the buildup solutions 
only. During the exponential growth phase, the thickness of domain III increases. 
However, when this zone becomes too thick, diffusion is no longer able to transfer 
material  everywhere  into  this  zone  when the  time  allowed  for  diffusion  is  kept 
constant.  From this  point  on,  domain  II  appears  and  develops.  This  scenario  is 
nothing else than the consequence of the diffusion process: in a given time lapse, 
the diffusing species can reach only a finite depth in the film. That's were the linear 
growth begins.60 Data from investigations of growth kinetics for nonlinear systems, 
obtained by authors,60 confirmed this hypotheses.
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For  the  common pair  of  polyelectrolytes,  PAH/PSS,  a  regular  buildup regime,  in 
which the thickness increment per layer is constant, is reached after the deposition 
of the first six polyelectrolyte layers, which gives an indication of the extension of 
zone I. In addition, when a multilayer built up in salty solutions is brought in contact 
with pure water, it expands, indicating that the rinsing step mainly affects zone III of 
the multilayer, which appears thus to behave like a polyion layer. The structural 
changes of the multilayer consecutive to the replacement of the salt solution by 
pure water occur with characteristic times ranging from a few tens of minutes to 
several hours depending on the initial salt concentration. Finally, it is also found that 
the  structural  modifications  of  the  film  are  fully  reversible  so  that  the  initial 
multilayer structure is recovered when water is replaced again by the initial salt 
solution.
Growth  process  was  also  found  to  be  dependent  on  the  mutual  charge  of 
polyelectrolytes, which also leads to change of the growth kinetics with pH and salt 
concentration in the polyelectrolyte solutions.61 The molecules were found to desorb 
when  the  next  layer  was  being  adsorbed,  being  pulled  by  the  polyelectrolyte 
solution. The threshold of the charge density, when the LbL process in impossible, 
was also found.62
The dependence of layer thickness on polyelectrolyte concentration does not seem 
to be so important:48 concentration range of 0.1-5 mg/mL yields the same bilayer 
thickness for the same adsorption time. Lowering the concentration below that will 
lead to decrease of layer thickness, whereas the increase of concentration up to 20-
30  mg/mL  will  resolve  in  non-linear  growth  of  adsorption  rate,  especially  if 
intermediate rinsing isn't sufficient.
The  parameters,  controlling  the  growth  of  the  films,  were  thoroughly 
investigated.63,64 Single  layer  thickness  was  found  to  grow  noticeably  with  salt 
concentration,  and  only  slightly  with  the  raise  of  polyelectrolyte  concentration 
(which  is  straightforward).  Then there  is  a  temperature  effect  on thickness  and 
roughness, with onset at about 0.05M NaCl concentration, leading to increase in 
thickness by a factor of 3 on heating the deposition solution with 1M NaCl from 5 to 
60 ᵒC.
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2.4 Nanocomposites
One of the main advantages of LbL process is that not only polyelectrolytes, but 
also any charged substances can be assembled by this method. This is very useful 
when  creating  tailor-made  materials  and  coatings.  By  incorporating  some 
substances  into  the  polymeric  film,  one  creates  multifunctional  nanocomposite, 
which, in addition, may also exhibit  unique new properties,  not characteristic to 
parental bulk materials,65-67 owing to confined quantum effects and large surface 
area.  Nanoparticles,  dyes,  proteins,  viruses,  nanowires,  nanotubes  and  other 
objects68-80 can  be  incorporated  into  multilayered  film  in  controlled  order,  with 
intermediate  soft  polymers  acting  like  a  chemical  glue,  making  the  interface 
smooth, and surface charge uniform, and isolating neighbouring layers from each 
other  and  from the  environment.  Many  unique  optical,  magnetic,  catalytic  and 
mechanical  properties  were  studied  by  different  research  groups  in  last  two 
decades.65,67,81-83
When a new material is to be incorporated, there's a need to study its properties 
and create a standard procedure, optimizing the assembly conditions, based on this 
study results.  The main factor,  influencing the assembly process,  is  the  surface 
charge of the material, which is largely dependent on the pH of the solvent.84 Zeta-
potential usually changes with pH and there is an isoelectric point, in which the 
surface isn't charged at all, making LbL assembly impossible. Therefore, right pH 
regime should be selected for the standard procedure. This can be done by utilizing 
zeta-potential, QCM, UV-Vis spectroscopy and other measurement techniques.
Incorporating  nanoparticles  into  the  multilayer  is  one  of  the  popular  research 
topics.69, 76, 81-83 Particularly, gold nanoparticles can be applied, as due to synthesis 
method, they normally have noticeable negative zeta-potential about -35 mV.84 This 
allows alternate adsorption of polycation with Au nanoparticles. The deposition time 
(or colloid concentration, which is effectively the same), necessary to adsorb the 
nanoparticles, tends to be more for the particles, than for the polyelectrolytes,85 as 
the concentration of the nanoparticles is relatively low, limited by their synthesis 
method. However, it's not always necessary to create a dense covering, sometimes 
just  some  spots  of  nanoparticles  in  the  film  are  enough,  and  it  shortens  the 
deposition time dramatically, as less number of particles is to be transferred. But in 
this  case,  the  surface  charge,  created  by  previous  polyionic  layer,  wouldn't  be 
overcompensated, making further assembly impossible. The simple decision is to 
adsorb other polyanion (PSS for example) from the solution of normal concentration, 
which will resolve the charge problem.
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For  magnetite  nanoparticles  the  situation  is  more  or  less  similar,  but  the 
concentration of nanoparticles is usually much greater, which allows more dense 
and fast surface filling.
2.5 Microcapsules
Layer-by-Layer technique can be used not only on flat substrates, as this method is 
indifferent to the type of substrate, as long the latter is electrostatically charged. 
When this technique is applied to particulate templates,  providing the deposited 
film is stiff enough to withstand the template removal, and the template is dissolved 
somehow and discharged from the covering film, one gets hollow polymeric shells. 
Few decades ago, this method was applied to colloidal template particles of 0.1-20 
µm in diameter, to get the structures, which are known as microcapsules.2 However, 
the  very  first  publication,  regarding  encapsulation  inside  polymeric  hollow 
structures was published as early as in 1964.86
With capsules properties and application widely varying and depending strongly on 
the  core  and  shell  materials,  the  template  cores  should  be  monodisperse  and 
completely  dissoluble  by  appropriate  solvent.87 Microcapsules  have  several 
significant  advantages  over  other  types  of  microcontainers,  such  as  micelles, 
liposomes and inorganic hollow shells, including mechanical stiffness and the ease 
of  controlling their  shells  parameters,  such  as  composition,  thickness,  diameter, 
roughness and so on.
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Figure 2.6: Nanocomposite structure schematic.
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2.5.1 Construction
Microcapsules' shells are constructed by a LbL assembly, just as it's done with the 
planar substrate. The use of colloidal particles as substrates, however, influences 
the  way  the  solutions  are  changed.  The  need  to  maintain  the  stability  of  the 
particles also requires optimizing solutions pH, ionic strength and polyelectrolyte 
concentration to prevent aggregation. As soon as the desired number of layers is 
deposited, the LbL process finishes, and the core is dissolved, to get the hollow 
capsule. Figure 2.7 shows the schematic of the process.
Very many objects were reported to be used as templates, including solid particles, 
liquid droplets, microbubbles,88-90 and even living cells.91 Solid sacrificial templates 
can be inorganic (CaCO3,92, 93-97 SiO26, 7, 98-100) or organic micro- and nanoparticles.5,6 
The use of microparticles is much more common, than other objects, as they are 
more or less easy to handle while constructing the sample, less tend to aggregate, 
yet allowing to make research in very diverse areas. The lower limit of the template 
size is set by the stability reasons, and is about 15 nm nowadays.101 The upper limit, 
caused by osmotic pressure effect on the shell when dissolving the large core, is set 
to about 1 mm,88 which can be reduced by cross-linking the shell on the hydrogel 
bead  before  core  dissolvation.102 Ultrasonication  can  be  used  to  withstand 
aggregation of the particles and also to create the particles themselves.90
Monodisperse organic particles are convenient for the LbL assembly upon them, but 
have some disadvantages. For example, weakly-crosslinked melanine formaldehyde 
(MF) microparticles, sometimes used as templates for microcapsules, are dissolved 
in  HCl103 or  polar  solvents  as  N,N-dimethylformamide  (DMF)  or  tetrahydrofurane 
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Figure 2.7: Microcapsules construction process schematics: 1) positive charged 
polyelectrolyte adsorption as odd layer, 2) negatively charged polyelectrolyte  
adsorption as even layer, repeated several times to get 3) particles, covered with shell  
by alternate polyelectrolyte deposition to a desired number of layers, 4) dissolution of  
the template, 5) hollow microcapsule.
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(THF), leave the oligomers, with the molecular weight, depending on the age of the 
MF particles. At the same time, high molecular weight molecules cannon penetrate 
the  polymeric  shell,  at  least  as  fast  as  they are  generated upon the  dissolving 
process. Therefore, they tend to damage and even rupture the shells,104 and, which 
isn't good either, to leave significant residues inside the ready capsules, which can 
change  their  properties  and  lead  to  poor  reproducibility.103,104 The  other  type  of 
organic  particles,  polystyrene  particles  (PS),  tend  to  affect  the  multilayered 
structure of the shells and induce their swelling upon the dissolving.105
Inorganic particles, in contrast, can be fully dissolved and removed from the shells, 
as they don't produce large organic molecules.3,93-101,106 CaCO3 particles produce CO2 
and ions upon dissolution, which can easily leave the shell, with the only difficulty of 
taking the gas away from the reactor. The cores are usually dissolved in HCl or EDTA 
solutions. The other advantage of the calcium carbonate microparticles is that they 
are very cheap and easy to synthesize,96 as long as MF, PS and SiO2 particles have 
to be purchased. However, CaCO3 particles do have a disadvantage of peing porous, 
polydisperse and sometimes having irregular shapes. These lead to formation of 
thick shells with uneven inner structure. Therefore, polydisperse capsules with thich 
irregular shells are obtained.
Silica (SiO2) particles are monodisperse and not porous, but they require hazardous 
substances (NH4F or HF) in order to dissolve. Their use is not only dangerous, but 
also  can  lead  to  aggregation  of  the  microcapsules  when  using  weak 
polyelectrolytes.107,108 Still,  when  using  appropriate  polyelectrolytes,  nice 
reproducible with thin shell are produced.
The shell  usually consists of a pair of oppositely charged polyelectrolytes, either 
synthetic or biodegradable. However, other charged substances can also be applied, 
such as biomolecules, including polysaccharides and DNA, nanoparticles, etc.
The  polyelectrolytes  can  be  changed  in  two  ways:  by  conventional 
centrifugation/wash procedure,109 or by using a micro-filtration setup,110 allowing to 
remove  the  supernatant  without  centrifugation,  which  is  very  handy  when  the 
covered particles tend to aggregate easily upon centrifugation. As described above, 
the LbL process requires thorough washing between depositing the polyelectrolytes 
to get rid of excess unbound substances and provide good attachment for the next 
layer. Theoretically, it is also possible to add exactly the amount of the substances 
needed for  each layer,  without washing steps,  which would be especially  useful 
when working with small and fragile objects, which cannot stand the centrifugation 
or  even  the  microfiltration.  However,  it's  practically  impossible  for  the 
35
2 Literature Review
microcapsules,  as  the  precise  total  surface  area,  adsorbing  the  polyelectrolytes, 
cannot be determined.
2.5.2 Encapsulation
Encapsulation processes can be divided into 2 main groups, depending on whether 
the  encapsulation  takes  place  before  or  after  LbL  assembly.  The  latter  one, 
obviously,  incorporates  shell  permeability  changing  by  some  kind  of  extrernal 
stimuli, to fill the cavity of the capsule with the substance, travelling through the 
microcapsules walls. Insoluble substances, forming crystals, nanoparticles or their 
aggregates  can  be  encapsulated  by  direct  LbL  assembly,  using  the  substances 
themselves as  the  templates,7,111 thus  making it  the  method of  the  first  group. 
Porous particles, such as CaCO3 particles,96 or mesoporous silica particles6 can be 
used to adsorb water-soluble substances into pores of formed particles and then 
covered with polyelectrolytes (Fig. 2.8). Carbonate particles can also be used for co-
precipitation of soluble substances,112 which leads to incorporation of the substance 
into the core at the template formation step. Co-precipitation is convenient in cases 
of  big  molecules,  which  cannot  travel  through  the  polymeric  shell,  and  for 
substances, too sensitive to the conditions of other methods. Co-precipitation can 
be repeated more than once, allowing to obtain multi-compartment capsules, where 
the substance “1” is encapsulated in small capsules, situated in a bigger capsule, 
filled also with substance “2”. This is done by co-precipitation of substance “1”, 
followed by LbL assembly, and then second co-precipitation of the covered particles 
obtained  together  with  substance  “2”  to  get  templates  for  the  second  LbL 
assembly.113,114 Furthermore, the carbonate particles can be obtained in conjunction 
with emulsification procedures.115
36
Figure 2.8: Schematic of encapsulation prior to LbL 
assembly: a) adsorption b) co-precipitation.
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Calcium carbonate microparticles have a very porous structure, as can be seen in 
Fig. 2.9.
Figure 2.9: SEM images of calcium carbonate microparticles:  
a) external view, the image suffers from charging defects, b)  
cross-cut of the core (panel b reprinted from Ref. [96]).
The other type of encapsulation process is based on shell permeability change after 
the LbL process is complete, and the template is dissolved. Such a technique is only 
applicable for the substances, that can penetrate through the shell when it's in it 
initial condition. Obviously, it's impossible to encapsulate macroscopic objects (such 
as nanoparticles and their aggregates) in this process. The factors, that change the 
shell  permeability,  include  temperature,  pH  and  ionic  strength.  Also,  the 
encapsulation  can  be  achieved  by  resuspending  the  capsules  in  different 
solvent.116,117,118,119
Encapsulation by adjusting the pH is based on a fact, that capsules, made of at least 
one weak polyelectrolyte,  are stable only within a limited range of pH values.106 
When the pH is set beyond this range for one of the polyelectrolytes (about 11 for 
PAH),120 its  charge  density  decreases,  together  with  the  electrostatic  attraction 
between  the  layers.  At  the  same  time,  the  second  polyion's  charges  become 
relatively higher and cannot be overcompensated by the first polyion. This leads to 
repulsion between the layers, which, in conjunction with the previous factor, makes 
the shells less dense and more penetrable and the shell diameter is increased.117,121 
When left for a long time at inappropriate pH, the capsules can totally disassemble.
Resuspending  the  capsules  in  polar  organic  solvent  also  changes  the  shell 
permeability. This effect is based on the solvent dielectric constant change, which 
consequently  changes  the  electrostatic  interactions  between  polyions.  The 
37
2 Literature Review
reversibility of this method is in doubt.122,123 However, this approach was used to 
make the PAH/PSS film penetrable for urease by switching the solvent to ethanol 
and making it impenetrable again by switching the solvent back to water.123
Ionic  strength  of  the  solution  can  be  changed  by  addition  of  salt,  allowing  to 
encapsulate the molecules,  which normally cannot penetrate the polyionic shell. 
Low ionic strength makes the shell penetrable, weakening the polyions interactions, 
still  maintaining  the  structural  integrity.124 At  high  ionic  strength,  the  shell 
restructuring takes place, and the capsules tend the shrink, as the hydrophobic part 
of the polymer main chain gains a significant force, reducing the capsules' exposure 
to water.116 For example, the PAH/PSS structure can be triggered between “open” 
and “close” states for up to ~70 kDa molecules by crossing the 0.5-2·10-2 M salt 
concentration barrier.124 The drawback of  the salt  addition technique is  that  the 
capsules become very fragile,  and can even totally dissolve when the excess is 
added.
The  effect  of  temperature  on  the  LbL  was  investigated  first  on  planar  films, 
appearing to reversibly increase the growth rate with temperature.125 The fact, that 
it takes place for both weak126 and strong127 polyelectrolytes, suggests, that this is 
not due to electrostatic interactions, as in case of ionic strength or salt, but due to 
some secondary interactions.
The impact of temperature was thoroughly investigated by Köhler et al.107,128,129-133 As 
the temperature is increased, the capsules can shrink or swell, depending on their 
construction. Capsules shrink upon temperature raise if they have even number of 
layers and appropriate solution conditions are present. Shrinking is accompanied by 
permeability decrease, as the shells become thicker and denser.130,131,134
The  shrinking  takes  place  above  the  glass  transition  temperature  of  the 
polyelectrolytes. It was demonstrated, that the shrinking happens when the balance 
of  electrostatic  force  of  charges and hydrophobic  force  of  main  chain is  shifted 
towards  the  latter.  When  the  whole  charge  of  the  shell  is  close  to  neutral,  as 
happens  for  even-layered  shells,  the  electrostatic  repulsion  between  similarly 
charged layers can be neglected. Heating microcapsules in these conditions leads to 
change in the shell  structure, happening under the influence of the hydrophobic 
forces, tending to decrease the surface area of the shell, exposed to the solvent. 
When the number of the layers in uneven, the process is driven by the electrostatic 
forces, as the hydrophobic ones become relatively small, and is resulted in swelling, 
which can even lead to deconstruction of the shells. Once again, the temperature 
raise  helps  these  processes,  as  it  makes the  polymers  more  flexible,  when the 
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temperature comes somewhat close to glass transition temperature.
Thus, the heating can be used to encapsulate the substances into the shells with 
even number of layers, after the LbL process is complete and the core is dissolved 
(Fig. 2.10).
Figure 2.10: Encapsulation by heat-shrinking.
2.6 Release methods from the capsules
One of the main tasks for investigations in field of targeted delivery are release 
methods from the containers. For microcapsules, the release is based on changing 
the permeability or rupturing its polymeric walls. This can be achieved either by 
methods, described above, applied for encapsulation,  or  can be done in a more 
irreversible way by some external trigger, such as light or ultrasonic irradiation.
It is also worth noticing, that the release methods can be divided into individual, 
where particular microcapsules are targeted, and group. The first  ones deliver a 
good research model, allowing to observe the behaviour of individual microcapsules 
and to regulate very well the amount of released substances (provided this amount 
is not very high, though). Group methods, though worse controlled, can instantly 
release greater amount of substances, and, probably, are more applicable  in-vivo, 
where it is impossible to gain control upon individual microcapsules.
2.6.1 Laser irradiation
Laser-induced release can be carried out by two main mechanisms: 1) by heating, 
happened  upon irradiation  absorption  by  some agents  (nanoparticles),  or  2)  by 
photochemical reactions.
The first mechanism is based on heat generation when the radiation is adsorbed. As 
the  microcapsules  shells  are  held  electrostatically,  the  temperature  increase 
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changes their permeability properties or can even rupture them, as it was described 
above.  The  agents  of  radiation  adsorption  can  be  different.  Roughly,  any 
substances, adsorbing in the region of interest, can be used. However, these objects 
have  to  be  incorporated  into  the  microcapsules  shells,  which  introduces  some 
requirements of  size and charge of  the substances to make their  LbL assembly 
possible. The schematic of the process is shown in Fig. 2.11. The laser irradiation is 
heating the  nanoparticles,  which leads to  release.  However,  the  release can be 
achieved without  actual  rupturing the shells,  but  just  by reversible  permeability 
change.
Figure 2.11: Laser-induced release by heat generation.
Mostly nanoparticles are used as heat-adsorbing agents,99,135 but the use of carbon 
nanotubes and silver coating was also reported, provided by their broad adsorption 
spectra.9,136 Actually it  was silver coating that was used for triggered release by 
Antipov  et al in 2002.9 Also, silver was reduced on the microcapsules by focused 
laser beam (Fig. 2.12c). It can be seen from TEM images (a,b) that the layer of silver 
is  almost  opaque,  meaning  that  there  is  significant  amount  of  metal  in 
microcapsules.  It  contrasts  with later  developed technique of  gold nanoparticles 
use, especially when pre-aggregated nanoparticles are utilized.
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The  nanoparticles  use  for  this  application  is  caused  by  the  adsorption  feature, 
characteristic for some metal nanoparticles, such as gold and silver, which is called 
surface plasmon resonance, found only in small metal particles.137 This adsorption 
with a narrow peak at  specific  position is  caused by electrons oscillation in the 
electromagnetic  field  of  the  irradiation.  Since  the  electrons  oscillation 
characteristics are determined by the nanoparticle properties, mostly the size, the 
position  of  the  adsorption  peak  can  be  adjusted  (see  Fig.  2.13).  Adsorption 
properties are also influenced by the environment, to which the nanoparticles are 
exposed.137
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Figure 2.12: Silver reduced on microcapsules shells: a), b) TEM images of silver  
coating reduced before (a) and after (c) dissolution of cores; c) optical microscopy  
image of microcapsules irradiated with focused laser beam in presence of Ag ions.9
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Figure 2.13: Gold nanoparticles plasmon resonance peak 
dependence on their size.
The usual positions of plasmon resonance peaks for Ag and Au nanoparticles are 
around 420 and 520 nm, respectively. However, biomedical applications require the 
peak in IR region, where the tissues are more transparent, than for visible or UV 
light.105 The aggregation of the nanoparticles also helps here, as the plasmons of the 
nanoparticles situated nearby are coupled, significantly shifting the adsorption peak 
to the red. Thus, controlled aggregation of nanoparticles can also be used for peak 
adjustment.137 Other particles geometries, such as nanorods, can also be used for 
radiation adsorption, being relatively efficient,139 but they require a large amounts of 
stabilizers, making it challenging to incorporate them into the LbL assembled shells.
The first studies of release feasibility from the microcapsules involved the use of a 
very  large  amount  of  nanoparticles  and  pulsed  laser  source,140,141 resulting  in 
destruction of the containers. However, the energy density, used in these studies 
with IR radiation, was by a factor of three more, then in later research, involved 840 
nm  pulsed  laser,  focused  onto  an  individual  microcapsule.113 CaCO3 based 
microcapsules and liposomes were also reported as possible for release by pulsed IR 
laser.142,143 The explosive character of release, possible toxicity of the nanoparticles, 
still high energy density and not always understood effects of pulsed lasers led to 
focus  the  research  on  significant  decrease  of  energy  density  and  nanoparticles 
concentrations.
Skirtach and co-workers made steps in this direction, incorporating relatively low 
amounts of pre-aggregated gold and using constant laser with average intensity 
much lower, than the single pulse intensity of pulsed lasers.10,141,144
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The other mechanism of release involves the photochemical reactions.  Porphyrin 
and phtalocyanine  dyes,  the  members  of  the  group  of  porphyrinoid  conjugated 
cyclic systems145 of methine groups, have a strong adsorption regions at 400-500 
nm. They are used in photodynamic therapy and induce oxidation reactions when 
irradiated with light.146,147 Phtalocyanines display strong adsorption bands in around 
670 nm, being at the same time transparent in 400-600 nm region. Their adsorption 
in red region is useful for biomedical applications.
The incorporation of these substances into films and microcapsules, their optical 
properties and applications have already been reported.148 Singlet oxygen, produced 
when the phtalocyanines are illuminated,  is  extremely reactive and possesses a 
relatively  long  half-life,  making  it  an  ideal  oxidizing  molecule.  This  oxygen  is 
supposed  to  be  used  for  the  capsule  shell  damaging.  However,  while  the 
incorporation of the dyes inside the capsules walls was shown,11,141,149,150 their use for 
release still has not been reported.
2.6.2 Ultrasound
Ultrasound of low power and high frequency (~1 MHz) is widely used nowadays in 
medicine for diagnosis and increasingly for treatment of diseased or injured organs 
or bodily structures which is quite distinct from diagnostic ultrasound applications. 
One such area is focused ultrasound where high frequency ultrasound waves can be 
targeted at specific defined locations within the body.151 High-frequency ultrasound 
has the advantage of focusing ability over low-frequency ultrasound. Thus, several 
high frequency ultrasonic transducers can be focused to create a relatively high 
power intensity in a small region, without exposing body tissues in their path to 
harmful  energy  levels.  Together  with  some mechanism of  targeted delivery,  for 
example,  magnetite  nanoparticles  embedded into  the  microcapsules'  shells,  this 
could provide an ideal release system.
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Figure 2.14: Fluorescence spectra of FITC-dextran in the  
supernatant solution of capsules suspension before and after 1  
min of ultrasonic treatment at 100 W.13
There have been some publications regarding the use of ultrasound to affect release 
from  microcapsules  and  other  containers,13,152,153 but  these  all  employed  low-
frequency,  high power ultrasound.  Such high energy ultrasound cannot be used 
within the human body because of the general damage to collateral tissue which 
would  inevitably  result.  There  are  also  publications  on  targeted  delivery  of 
microcapsules via blood vessels utilizing ultrasound as the moving force.154
Influence  of  different  shells  construction  on  susceptibility  of  microcapsules  to 
ultrasonication was also studied.12,155,156
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Effect of ultrasound on microcapsules in micro scale was also studied.12,13,157 Shells 
rupturing was observed by SEM and LSCM, connected with release of materials. 
Rupturing was shown to be dependent on time and power of irradiation.
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Figure 2.15: Microcapsules sensitivity to ultrasound for different number of layers and 
template diameter (left) and for different number of nanoparticles layers in shells.155 
Figure 2.16: Optical, confocal and SEM images of AuNP/PAH (top) and PAH/PSS 
(bottom) microcapsules irradiated with ultrasound.157
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Ultrasonic  oscillations  of  matter  are  mechanical  in  nature.  It  seems,  that  to 
maximize  effect,  the  microcapsules  size  should  be  relevant  to  wavelength  of 
oscillations, which, for water dispersion, would be about 7 cm for 20 kHz and 1.4 
mm for 1 MHz. For this reason it might be expected, that higher frequencies would 
be  more  effective  as  the  wavelength  is  closer  to  the  size  of  the  object  being 
irradiated. Furthermore, some change in effect would be expected to occur when 
introducing some rigid media (nanoparticles) inside soft polymeric shells, because 
they  can  increase  the  movements  of  the  shells,  stimulating  release  from 
microcontainers.  Moreover,  the  presence  of  nanoparticles  will  also  favour  the 
formation of bubble nuclei decreasing the cavitation threshold.158 In summary, with 
high frequencies we get the possibility of more effective (in effect/power terms) 
focused irradiation using several transducers, each of them having harmless power 
by itself.
2.6.3 Other methods of release
To release content from the microcapsules, it is needed to change (either reversible, 
or not) the permeability of the shell. This can be achieved by a number of ways. The 
common principle is either to rupture the shells (as it is done by laser irradiation) or 
to destabilize the complex of the polyelectrolytes that from the walls. Release and 
encapsulation processes have many common features and often are based on the 
same principles. Chemistry, that is hidden behind them, was well investigated and 
described.159 Some of these methods are more, the other are less applicable in-vivo, 
but in a whole, they give a good overview of what could be potentially done with the 
microcapsules.
Probably, the most straightforward way of destabilize the shells is to change ionic 
strength of solution by the pH. Effect of salt and pH change on microcapsules was 
thoroughly investigated to build up micromechanical theory of pH and ionic strength 
dependent capsules swelling consistent to experimental data by Biesheuvel  et al 
(see  Fig.  2.17).118,  121 In  this  regard,  effect  of  pH  on  mechanical  properties  of 
microcapsules was also studied using AFM-like system, where a single microcapsule 
deformation was studied under known applied force and different pH levels.160
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Rubiner  et  al described  the  influence  of  pH  on  on  the  charge  density  and 
morphology of PAH based planar multilayers.161 They observed pores formation on 
films exposed to acidic environment, while the layers In normal circumstances were 
smooth. These investigations were then followed by study on microcapsules (Fig. 
2.18).87 The pores can be clearly seen in the shells after acidic solution treatment 
(a). pH dependent integrity of polyelectrolytic shells makes their permeability also 
pH dependent. This reversible pores generation was used by Sukhorukov  et al to 
diffuse FITC-dextran from the outside into microcapsules by immersing them to low 
pH environment.162
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Figure 2.17: Swelling of {PVP/PMA}5 microcapsules at different pH and salt  
concentration.121
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Use of one or two weak polyelectrolytes to create pH sensitive microcapsules was 
also reported for different types of microcapsules.105,117 Swelling of the capsules as 
pH  shifted  towards  pKa  of  one  of  the  polyelectrolytes  was  observed.  PSS/PAH 
capsules  started  to  swell  at  pH  above  11  and  totally  disassembled  when  pH 
exceeded 12.
Déjugnat  et al120 reported reversible pH dependent swelling on PAH/PSS capsules. 
After short exposition of capsules to pH above 11, the capsules swell and become 
permeable to high molecular weight substances. After lowering the pH, the capsules 
shrink, returning to the initial state. This change can be used both as encapsulation 
and release methods. This technique could potentially be applied in-vivo to deliver 
drugs to locations with pH lower than that of serum,163 however the gap between 
the pH levels is very small (6.8 and 7.4), which makes a design of suitable shells a  
very challenging task.
The  first  report  on  salt  responsive  polyelectrolyte  microcapsules  was  made  by 
Caruso et al,164 where capsules from DNA/spermidine were fabricated. It is known, 
that the DNA-spermidine interactions are reduced in high ionic strength solutions, so 
when the capsules are immersed in 5 M salt solution, the multilayers are dissolved, 
which obviously  leads to  destruction of  the capsules.  Change of  permeability of 
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Figure 2.18: SFM images of capsules treated with pH 3.5 (a) and pH 12 (b) buffers  
before drying.87
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PAH/PSS shells for high molecular weight substances at salt concentration higher 
then  10  mM  was  also  reported165 with  the  explanation  that  the  permeability 
happened not due to the pores, as in case of pH-dependent process. Several other 
salt responsive systems was proposed later,166 however such capsules will hardly 
find  their  way  to  in-vivo applications,  as  there  are  no  such high  ionic  strength 
variations in human body.
Hydrogen-bonded  microcapsules  (PMA/PVPON)  cross-linked  with  ethylenediamine 
with  PVPON removed  after  cross-linking  were  also  shown to  be  pH  sensitive.167 
These capsules, being single-component, exhibit swelling at acidic and basic pH and 
were smallest at pH 5.5. The release was also sensitive to NaCl concentration at pH 
5.5.  Then,  tannic  acid  microcapsules  through  hydrogen  bonding  with  acceptor 
polymers  were  shown  to  be  stable  in  a  wide  range  of  pH  (from 2  to  10)  and 
exhibited pH-sensitive permeability changes to dextran.168
Another approach to targeted drug delivery is use of sugar-sensitive microcapsules. 
This  technique  is  valuable  due  to  the  key  role  of  sugars  in  a  broad  range  of 
biological  functions.  A system analogous to  pH-sensitive  one,  where the linkage 
between polymeric molecules of the shell is broken in the presence of sugar would 
be a fantastically rational design of targeted drug delivery system. A number of 
papers have been published regarding the development of such systems,169 and 
most of them are focused on glucose-triggered release of insulin as a main concern 
in  sugar-sensitive  drug  delivery  development.170 However,  many  different 
mechanisms and reactions were proposed for such systems.171
Alternating magnetic field is one other solution of release problem. Use of Co@Au 
nanoparticles was reported to change the permeability of microcapsules walls under 
oscillating magnetic field.172 Domains in ferromagnetic nanoparticles twist under the 
applied field and disturb the structure of polyelectrolyte microcapsule wall, making 
it possible for macromolecules to diffuse through the shell (see Fig.  2.19). It was 
shown, that the effect happens only when the capsules shell have single layer of 
nanoparticles,  and no effect is observed when using several layers. Permeability 
change was monitored for 4 kDa FITC-dextran.
It  should  be  noted  though,  that  the  parameters  at  which  the  treatment  is 
performed, make the use of this approach in therapy hardly possible, as the field is 
rather high (1200 Oe), and the exposure time was about 30 min, during which the 
microcapsules dispersion temperature was increased by 30  °C. This temperature 
increase  will  most  likely  destroy  bio-  and  chemically  active  compounds, 
encapsulated into the cavity and subjected to targeted delivery.
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Another  approach,  that  was  used  on  microcapsules,  is  irradiation  with 
electromagnetic field in radio frequency band, which could be adsorbed by some 
agents embedded into the shells. Gorin  et al employed 8 nm silver nanoparticles 
and electromagnetic field oscillating with frequencies from 2.45 to 8.2 GHz at power 
density ranging from 1.8 mW/cm2 to 13.5 W/cm2.173 Such high-frequency field is able 
to penetrate deep into the human body, and, provided that the power is not too 
high, can be considered as rather harmless. However, authors could see effect only 
at higher powers at 2.4 GHz (see Fig. 2.20).
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Figure 2.19: Use of oscillating magnetic field (120 Hz, 1200 Oe) to induce permeability  
of microcapsules shells functionalized with Co@Au nanoparticles.172
Figure 2.20: SEM images of microcapsules with Ag 
nanoparticles before (left) and after (right) irradiation at 2.4  
GHz 13.6 W/cm2 for 3 minutes.173
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One  more  possible  answer  for  EM-triggered  release  could  be  use  of  carbon 
nanotubes or other conductive materials, which would find themselves not in the 
small spots, but throughout the whole shell of a microcapsule. This could make the 
adsorption of energy from the oscillating field much more efficient, than in case of 
nanoparticles. Recent publications report use of carbon nanotubes in composite LbL 
films. Satarkar  et al show heating of nanocomposite with RF fields (Fig.  2.21).174 
Chen  et al demonstrated that only 4-5% wt carbon nanotubes in polystyrene are 
capable to adsorb 94% of radiofrequency energy.175 Besides using nanoparticles or 
carbon  nanotubes,  more  homogeneous  structures  can  be  possibly  employed, 
including conductive polymers, such as polypyrrole, which were reported as possible 
solution  for  creating  EMI-shielding  polyelectrolyte  structures  by  LbL  assembly.176 
Shielding against both electric and magnetic fields using different techniques was 
reported to lower with frequency, achieving 80 dB at 1 MHz, decreasing to 30 dB at 
300 MHz.177 Microencapsulation with shells  containing such substances was also 
reported.178 Even more developed nanocomposite microcapsules with polypyrrole, 
magnetite and carbon nanotubes were also described.179
Rather specific way to release of encapsulated substances is by their mechanical 
deformation.180 The schematic of the experiment performed is shown in Fig.  2.22. 
AFM probe was used to induce pressure upon single PDADMAC/PSS microcapsule 
performing series of deformation cycles with maximum force measured to be 0.6 μN 
in  the  first  cycle  to  more  than  8.4  μN in  the  last  push-cycle.  The  release  was 
observed by measuring the fluorescence intensity of the microcapsule interior, filled 
with AF-488.
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Figure 2.21: Heating of nanocomposite with carbon nanotubes.174
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Figure 2.22: Schematic of experiment  
on mechanical release from individual  
microcapsules.180
The measurements showed, that intense release is happening when the capsule is 
deformed to its 20% diameter. The two regimes of deformation – i.e. before and 
after release start are designated by authors as elastic and plastic deformation, to 
correlate the release behaviour with the mechanical properties.
2.7 Microcapsules for drug delivery
Recently,  as  the  research  on  microcapsules  moves  from their  physico-chemical 
properties and common release methods, much more publications is devoted to 
targeted drug delivery techniques. These include speculations on the mechanisms 
of  delivery,  navigation  and  release,  experiments  on  cytotoxicity  and  fate  of 
microcapsules in the cells and in-vivo and many others.
D.  Barthès-Biesel181 has  recently  published  a  review  devoted  to  studies  of 
microcapsules behaviour inside liquid flows. The research of this kind is somewhat 
unique due to the fact that most of papers published on microcapsules describe 
experiments performed, rather than theoretical studies of what and how is actually 
happening  in  this  micro  world.  Paper  describes  many  factors  including  osmotic 
effects, capsule dynamics in flow, membrane mechanics all from physical point of 
view. With no doubt this is very important information for modelling of capsules 
behaviour in such complex systems like blood vessels. The fact is that it is really 
often easier to set up an experiment to get a precise answer to a question «what 
if?». However, when moving to in-vivo applications, it gets a bit harder. Also, these 
theoretical  studies potentially  can provide answers when unclear or  inconsistent 
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experiment outcome is observed.
Goldenstedt  et  al proposed  use  of  shock  waves  as  a  driving  force  for  gelatin 
capsules  navigation.154 Authors  base  their  finding  on  previously  developed 
phonophoresis principle, which is applicable to free solutions. Driving force is a peak 
of  pressure  happening due to  180 kHz ultrasonic  irradiation.  Thorough study of 
effects caused is undertaken. This principle is proposed to apply fo targeted drug 
delivery.
2.7.1 Delivery of bioactive substances
Most of papers published by now regarding encapsulation of species regard use of 
simple substances, such as BSA or dextran. Those are easy to use and cheap model 
substances that can be used for studies of encapsulation ratio or release. However, 
the  idea  of  microcapsules  as  a  drug  delivery  system  demands  research  of 
encapsulation of bioactive substances. And with time more and more sophisticated 
studies with complex substances are published.
Caruso111 reported encapsulation of enzyme (catalase) into PAH/PSS microcapsules 
in 2000 and shown that it demonstrate high load factor and retains stability very 
well, even after treatment with protease, whereas unpreserved enzyme lost 90% of 
its activity after same type of treatment. In 2001 Lvov et al reported encapsulation 
of  urease.123 Authors  studied  its  activity  in  encapsulated  form by  characteristic 
photometric assay and compared its kinetics to that of free enzyme. As predicted, 
the kinetics of encapsulated urease was shown to be delayed.
Nucleic acids of various types are one other object for encapsulation studies,  as the 
ir delivery is primal goal for gene therapy, aiming to introduce new genes or replace 
defect genes182 and also due to their polyionic nature, that makes them rather easy 
to  encapsulate  by  LbL  assembly.  First  encapsulated  into  the  shells  of 
microcapsules,164 DNA  made  its  way  to  the  core  of  calcium  carbonate  based 
microcapsules.92 Caruso group has elaborated on the use of hydrogen bonding to 
incorporate oligonucleotides either in the cavity or  in the wall  of  polyelectrolyte 
capsules.  Amine  modified  mesoporous  silica  microspheres  could  accumulate 
oligonucleotides through electrostatic interactions into their pores and multilayer 
build-up  of  hydrogen  bonded  poly  (methacrylic  acid)  and  poly(vinylpyrrolidone) 
followed  by  etching  of  the  silica  core  templates  yielded  hollow  capsules  with 
oligonucleotides  stably  encapsulated  within  their  cavity.183,184 Various  factors 
regarding filling of microcapsules, retaining activity and characteristic features of 
different  sorts  of  nucleic  acids  were  studied  to  provide  best  results  from 
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technological point of view.
More complex system, employing one of the main advantages of microcapsules — 
feasibility of encapsulation of several agents — was proposed by Borodina et al in 
2007.92 Authors synthesized microcapsules that contained DNA together with mix of 
proteases in the cavity. Provided that the shells were made to be biodegradable, 
they  started  degradation  immediately  upon  dissolving  calcium  carbonate  core, 
trapping enzymes. The speed of process was regulated by the amount of proteases 
encapsulated,  thus  making  a  system  with  gradual  release  of  DNA  at  certain 
adjustable (from hours to days) rate.
However,  there  are  not  many  reports  on  functional  biological  experiments  with 
polyelectrolytic  microcapsules  for  gene  delivery.185,186 It  is  obvious  that  the 
investigations on using microcapsules for gene therapy are still at a very first stage, 
and on of the significant reasons is that the capsules end up inside the endosomes 
upon internalisation, and for successful transfection DNA molecules need to get to 
the  nuclei.  Difficulties  here  are  from  both  sides  —  rather  large  nucleic  acid 
molecules need to leave the capsule, so there should be a mechanism of opening 
the shell wide enough for them to leave, and on the other hand, DNA molecules 
need to find their way through the endosome and cell interior towards the nuclei. 
Microcapsule, though, through internalisation provides means for solving other big 
problem for DNA molecules — entering the cell from outside.
2.7.2 Intracellular and in-vivo delivery
An obvious step from  in-vitro to  in-vivo is starting experiments with cell cultures, 
which helps to understand what would happen when the system is put to the living 
body. First experiments were devoted to studying intake process and stability of 
microcapsules once internalised by cells. It was found that despite their relatively 
large size, microcapsules are readily internalised not only phagocytes (DCs187-189 and 
macrophages190), but also breast cancer cells, hepatoma cells, fibroblasts,191 human 
embryonic kidney cells and many others. Intake process itself still remains not very 
much studied, however various factors were found to influence it and subsequent 
trafficking  of  microcapsules  inside  the  cell.187,192,193 De  Koker  et  al recently 
demonstrated structural  integrity of DS/PARG microcapsules upon uptake by DCs 
using TEM. Following uptake, the microcapsules could be distinguished as hollow 
particles with an electron dense shell which was clearly surrounded by a membrane. 
After  a 24 h incubation period,  the  microcapsules’  shell  ruptured,  possibly  as  a 
consequence of enzymatic degradation, and cytoplasmatic content invaginated the 
microcapsules’ hollow core, which however remained separated from the cytoplasm 
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at all times by a membrane.187
Intake of microcapsules filled with pH-responsive substances was shown to prove 
that  microcapsules  find  themselves captured in  an endosome immediately  after 
internalisation. Figure 2.23 shows confocal images obtained by Kreft  et al showing 
internalisation  of  microcapsules  with  SNARF-dextran  by  two cell  lines.194 SNARF-
dextran is pH-sensitive dye, changing its fluorescence spectra according to pH of 
environment.  As  microcapsules  enter  the  cells,  SNARF is  subjected to  an  acidic 
environment of endosome. This is proven by the fact that the resulting colour of 
capsules in LSCM images (i.e. fluorescence spectra) is different at these positions. 
Other pH-sensitive dye, FITC, was also used for experiments by Reibetanz et al who 
employed FACS measurements to estimate the percentage of capsules residing in 
the endolysosomal compartment from the fluorescence intensity decrease caused 
by  acidification.195 Capsules  attached  to  the  extracellular  surface  of  the  plasma 
membrane were identified by trypan blue quenching. At the same time the number 
of  capsules  in  the  cytoplasm  was  shown  to  be  rather  small,  being  below  the 
detection limit of the method, which proposes that microcapsules do not tend to 
leave endosomes, at least in some cell lines. Later authors returned to experiments 
of this kind and included dsDNA as a reporting agent for drug delivery together with 
FITC for intracellular trafficking to the capsules.185
Microcapsules were also studied in cells cultures embedded in 3D collagen matrices 
that mimic tumour environments by An  et al.196 The study was mainly devoted to 
cytotoxicity investigations and effect  of  microcapsules presence on invasion and 
growth of C6 spheroids.
Later intracellular release of encapsulated dextran by 830 nm from microcapsules 
functionalized  with  gold  nanoparticles  in  MDA-MB-435s  breast  cancer  cells  was 
shown.197 Results achieved are presented in Fig. 2.24 (reprinted). Cargo release and 
viability/cytotoxicity  experiments  with  capsules  filled  with  blue  Cascade  Blue 
dextran as cargo and AuS2 particles embedded in their walls are shown. Capsules 
were illuminated with (a) low laser power (2.3 mW), the minimum power needed to 
open the capsules, and (b) high laser power (31 mW), the maximum power output 
reachable with the laser diode used in these experiments. Phase contrast images 
show cells that have incorporated capsules (yellow arrows) before and after laser 
illumination. Blue fluorescence images display the fate of capsule’s cargo at high 
and low laser power. Red fluorescence images show nuclear permeation (Ethd-1) in 
the  case  where  capsules  trapped  in  cells  were  excited  with  high  laser  power, 
whereas  at  low  laser  power,  no  nuclear  permeation  can  be  detected.  Green 
fluorescence images indicate decrease of esterase activity in cells where capsules 
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were excited with high and low laser power respectively. Fig. 2.24c shows sketch of 
the geometry of capsules with Cascade Blue dextran (blue ellipsoids) in their cavity 
and AuS2 particles (black circles) embedded in their walls. 197
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Figure 2.23: SNARF-loaded capsules change from red to green fluorescence upon 
internalization by cells.194
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Szarpak  et  al reported  preparation  of  biodegradable  microcapsules  made  up  of 
hyaluronic acid and a polycationic polymer, poly(allylamine) or poly(lysine).190 These 
microcapsules were shown to release their content much faster than in the previous 
studies  of  biodegradable  microcapsules.  For  the  experiments,  FITC-labelled 
microcapsules were introduced to raw mouse macrophage cells. Cellular lysosomes 
were stained with LysoTracker Red (a fluorescent dye emitting red fluorescence, 
which  selectively  accumulates  in  acidic  cellular  vesicles).  Both  types  of 
microcapsules were shown to be intact while being outside cells and become largely 
deformed and break-up when internalized within the cells (see Fig.  2.25). For all 
phagocyted capsules, complete co-localization between green capsule fluorescence 
and red lysosomal fluorescence is observed, indicating that the capsules end-up in 
lysosomal vesicles. However, the deformation kinetics of the internalized capsules 
(few hours) is remarkably faster compared to earlier reported capsules. This feature 
of  microcapsules to remain stable outside the cells but readily break open once 
internalized by cells, suggests their use as carriers for intracellular drug delivery.
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Figure 2.24: Cargo release and viability/cytotoxicity experiments with capsules filled  
with blue Cascade Blue dextran as cargo and AuS2 particles embedded in their walls.197
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In  2007 De Koker  et  al presented intracellular  delivery  of  biodegradable  poly-L-
arginine/dextran sulphate microcapsules to dendritic cells.93 In-vitro cytotoxicity was 
measured  by  MTT  assay  and  it  was  found  that  at  moderate  numbers  of 
microcapsules (up to 125 microcapsules per cell) cytotoxicity is reasonable (more 
than 60% of cells survive). Much more complicated in-vivo biocompatibility studies 
by ubcutaneous injection of mice with microcapsules consisting of four bilayers of 
dextran sulphate/poly-L-arginine were also undertaken to show that inflammation 
remained local and no necrosis was observed. Furthermore, fate of microcapsules 
after in-vivo injection was studied by confocal microscopy for 30 days (Fig. 2.26). It 
was found that microcapsules are very slowly internalized by the cells,  and it  is 
mostly  phagocytic  cells  that  appear  on  site  with  delay  that  demonstrate  most 
uptake. Internalised microcapsules were observed to deform and shrink in contrast 
to the microcapsules outside the cells, that kept their shape even after 18 days of 
incubation.
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Figure 2.25: Confocal microscopy images of (a) cross-linked HA/PAH and (b) cross-
linked HA/PLL capsules after 2 h coincubation with RAW mouse macrophages.190
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Figure 2.26: Confocal microscopy images of tissue sections taken at different time  
points after subcutaneous injection of microcapsules consisting of two bilayers of  
dextran sulphate/poly-L-arginine.93
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The  left  column  shows  a  large  area  of  the  injection  site  as  an  overlay  of  red 
fluorescence (due to RITC labelled poly-L-arginine) and blue fluorescence (due to 
staining of nuclei with DAPI). The middle and right columns show a more detailed 
view of the injection spot. Middle: the red and blue fluorescence overlay at a higher 
magnification  where  individual  cells  and  capsules  can  clearly  be  distinguished. 
Right: an additional DIC overlay for the right column to visualize cellular contours. 
DS/PARG capsules were also explored as antigen delivery vehicles for pulmonary 
immunisation,188 which  recently  has  draw a  lot  of  attention  as  it  allows  a  non-
invasive route of delivery and might harbour the benefit of inducing local mucosal 
immune responses in addition to systemic immunity. Pulmonary delivery of DS/PARG 
capsules  induced  a  transient  inflammatory  response  with  recruitment  of  mainly 
monocytes  and  granulocytes.  Particles  were  rapidly  taken  up  by  alveolar 
macrophages, but also by DCs that transported them to the draining mediastinal 
lymph nodes. By encapsulating high molecular weight FITC-dextran, the capsules’ 
fate  was  followed  over  time.  Intact  capsules  were  visible  inside  alveolar 
macrophages two days following instillation. One week after instillation however, 
most of  the capsules  had leaked their  content  although some heavily deformed 
capsule debris could still be distinguished. Two weeks after delivery, no capsules 
were visible any more and the FITC-dextran appeared spread throughout the cells. 
In 2008 Han et al reported encapsulation of anti-cancer drug daunorubicin and its 
application  for  tumour  treatment  for  in-vitro and  in-vivo studies.198 Experiments 
demonstrated that the encapsulated DNR can effectively induce the apoptosis of 
BEL-7402 tumour cells and has better efficacy than that of the free drug in terms of 
tumor inhibition in a 4 week in-vivo culture period. This publication seems to be the 
first one where microcapsules are used as actually acting agents for in-vivo drug 
delivery applications.
A  hydrophobic  photodynamic  therapy  drug,  hypocrellin  B  was  reported  to  be 
accumulated in water- solubilized natural polyelectrolyte microcapsules by Wang et 
al.199 Encapsulated it was taken up by cancer cells. These intracellular drug-loaded 
microcapsules presented biocompatibility under darkness and high cytotoxicity after 
irradiation which provides the possibility of controlled delivery and release of drugs. 
Liu  et  al have  shown  gradual  release  of  this  drug  encapsulated  to  MF-based 
microcapsules and its in-vitro cell bioactivity was observed.200 Factors that influence 
the  release  and  toxicity  were  determined  and  included  feeding  concentration, 
temperature and salt concentration.
There  are  also  many  diverse  publications  on  microcapsules  use  for  in-situ cell 
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delivery,  where  polyelectrolytic  microcapsules  are  intended  to  be  used  as  cell 
carriers.201
Ever growing wave of publications on cell  and  in-vivo research on microcapsules 
shows that great attention, interest and possibilities that microcapsules have for 
creation of drug delivery systems. Once again, provided by the multifunctional and 
multicompartmental nature of microcapsules they propose enormous possibilities of 
adjustment  of  their  properties  and  behaviour  to  specific  circumstances  and 
techniques. These vast abilities and features, in turn, mean that there is a great 
field of work still to do before microcapsules become safely applicable in medical 
treatment of human diseases.202
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2.8 Motivation and Aims
It  can be clearly seen,  that by the time microencapsulation is  highly developed 
technique, especially when it comes to control of chemical and physical properties 
of microcapsules. With its great advantages – feasibility of encapsulation of various 
particles, molecules and other objects, either into the cavity of microcapsule or to 
its  shells,  possibility of  triggered release of  encapsulated substances by various 
methods,  and,  very  importantly,  possibility  of  combination  of  different  species 
inside a single microcapsule – these are a very promising agent for nano- and bio-
related applications.  Encapsulated substances act significantly different from the 
way they would do being evenly dispersed in the same environment. In general, LbL 
technique delivers a vast possibilities for a low level and low scale construction, 
being implemented in microcapsules or other microcontainers (microemulsions, for 
example).
One of the most possible applications supposed for microcapsules, is obviously drug 
delivery. This means, that suitable methods of formulation, injection, navigation and 
release need to be developed for this system. However, most of research lead is 
devoted to investigations of chemical and physical properties of microcapsules as 
such, in-vitro. Without any doubt, the data obtained in these studies is essential, but 
not enough to put the microcapsules into the living body. Moreover, even prior to 
starting  in-vivo experiments,  research  has  to  be  performed on encapsulation  of 
bioactive substances, as most results reported employ using of rather simple model 
species,  which often are used just  as labels  or  indicators.  Bioactive substances, 
probably,  would  need  much  more  efforts  to  retain  desired  activity  once 
encapsulated and delivered to the site. Also, they will need some gentle mechanism 
of triggered release, that would not put these substances to extreme conditions. 
Together with that, it is the living body itself that needs the delivery and release 
system to be rather friendly and harmless.
For these reasons the topics of research were chosen to be ones that are a small 
step forward towards to microcapsules as drug delivery system. To investigate the 
retention of bioactivity of encapsulated substances, effect of encapsulation on DNA 
and  luciferase  function  was  thoroughly  investigated.  The  idea  was  to  find 
parameters at which these would be isolated and protected from the environment, 
yet fulfil their function when demanded. With DNA, finding of more effective ways of 
nucleic acid delivery to the nuclei compared to currently existing was intended, with 
opportunity to trigger the transfection by an external force and the advantages of 
multicompartmental carriers.
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IR-laser  triggered  Intracellular  release  of  encapsulated  species  was  therefore 
needed to be investigated to control individual carriers intracellularly. Neuronal cells 
are particularly interesting for studies of that kind as they communicate with each 
other by electrochemical signalling, therefore by triggered releasing materials inside 
one cell, its communication with other can be controlled. Currently, neuron internal 
activity is generally triggered using perfusion micropipette systems which can be 
rather  elaborate,  may damage cell  membrane  and can also  lead to  leakage  of 
solution into extracellular  environment.  Doing that non-destructively,  i.e.  without 
affecting metabolism of  living  cells,  and without  damage to  the  cell  membrane 
would  open  extensive  opportunities  in  terms  of  studying  important  intracellular 
processes  and  neuron  network  signalling.  A  separate  study  was  performed  on 
triggered release of pH-sensitive dye to check whether it could serve as a sensor 
upon releasing to investigate the parameters of various compartments of the cells.
As  there  are  some concerns about  application  of  metal  nanoparticles  in-vivo.  A 
proof-of-concept study was undertaken on laser-induced release from microcapsules 
functionalized with photodynamic dye.
One of the triggers that can be used for releasing cargo from numerous carriers at a 
single time is ultrasound. There are various types of ultrasonic radiation, and some 
of  them  are  currently  used  in  medicine,  including  surgery.  Based  on  earlier 
publications it was decided to study the feasibility of release from microcapsules at 
parameters, close to that currently applied  in-vivo. The aim was to determine the 
sensibility  of  microcapsules  to  irradiation  and  possibility  of  its  enhancing  by 
introduction of nanoparticles to the shells.
From point of view of carriers delivery to the site of interest, magnetic field seems 
very  appropriate,  as  it  can  penetrate  human  body,  and  previous  publications 
demonstrated  sensibilization  of  microcapsules  by  functionalizing  them  with 
magnetite nanoparticles. However microcapsules by themselves face some troubles 
when  immersed  into  the  blood  stream,  tending  to  accumulate  inside  particular 
organs like lungs and kidney. Therefore it was decided to perform experiments on 
impregnating cells with microcapsules to sensibilize whole cells to magnetic field.
The ultimate goal of all the experiments was to explore the ways of application and 
construction of microcapsules that would lead to better performance in delivery and 
activity retention of encapsulated cargo, compared to currently existing techniques, 
using the methods that can physically be applied in human body.
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3.1 Materials
3.1.1 Chemicals
Monodisperse 4.99 µm silica particles (SiO2, 5% weight dispersion) were purchased 
from Microparticles, GmBH (Germany).
Gold colloid solutions (5 nm G1402, 20 nm G1652) were purchased from Sigma.
Bovine serum albumin (BSA, molecular weight ~66000, Cat. No. A3902), Rhodamine 
B  Isothiocyanate  dye  (RBITC,  283924),  Boric  acid  (B6768), 
Ethylenediaminetetraacetic  acid  disodium salt  (EDTA,  03680),  HAuCl4, citric  acid 
were purchased from Sigma.
Calcium  chloride  dihydrate  (CaCl2·2H2O,  22,350-6),  sodium  carbonate  (Na2CO3, 
22,353-0),  sodium bicarbonate (NaHCO3,  S6014),  sodium chloride (NaCl,  S7653), 
sodium citrate (S1804) and luciferase solutions  (20% and 95%) were purchased 
from Sigma.
Sodium  hydroxide  (NaOH,  71691),  Iron(III)  chloride  (FeCl3·6H2O,  44944),  Iron(II) 
chloride (FeCl2·4H2O, 44939) were purchased from Fluka.
Luciferase assay substrate was purchased from Promega Corporation, USA.
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Poly(allylamine hydrochloride)  (PAH,  Sigma 283223,  molecular  weight  ~56 kDa), 
poly-dimethyldiammonium chloride (PDDA, Sigma 409022, molecular weight 200 – 
350 kDa), Poly-L-Arginine hydrochloride (PLA, Sigma P7762, molecular weight 15-70 
kDa), Poly-L-Lysine hydrobromide (PLL, Sigma P2636, molecular weight 30-70 kDa), 
FITC-labelled poly-L-Lysine (FITC-PLL, P3543 Sigma, molecular weight 15-30 kDa), 
poly(sodium 4-styrenesulfonate) (PSS, Sigma  243051, molecular weight ~70 kDa) 
and dextran Sulfate Sodium Salt (DS, Sigma 66786 molecular weight ~100 kDa) 
were used as  polyelectrolytes to  construct  microcapsules shells.  Their  structural 
formulas are presented in Fig. 3.1.
Trypsin solution, Dulbecco's phosphate buffered saline, Dulbecco's modified eagle's 
medium, trypan blue, chloroquine, ATA and fetal bovine serum, used for routine cell 
culturing,  were  purchased  from Sigma.  Fugene-6  and  Amaxa,  DNA  transfection 
agents, was purchased from Roche and Lonza, respectively.
DRAQ5 dye for plasmid DNA staining was purchased from Biostatus Ltd. DiOC18(3) 
cell stain and SNARF-dextran (70 kDa) were purchased from Invitrogen.
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Figure 3.1: Structural formulae of polyelectrolytes used for microcapsules  
formation during studies.
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3.1.2 Consumables
35 mm µ-dishes for cells incubation were purchased from Ibidi, Germany. Lab-Tek®II 
8-well  chamber  #1.5  German coverglass  system (Nalge Nunc International)  was 
purchased from VWR. ULA flasks for cells incubation (25 cm2, 75 cm2) and pipettes 
(Corning) were purchased from Appleton Woods.
0.2 µm syringe filters (cellulose acetate membrane) were purchased from VWR.
25 kD cut-off dialysis membranes, pH indicator paper were purchased from Roth.
Disposable 4.5 mL and 1.5mL cuvettes for UV-Vis-NIR spectroscopy and fluorimetry 
were also purchased from Roth (8128, 4.5 mL Acryl; Y196.1, 4.5 mL PMMA; Y197.1, 
1.5 mL PMMA).
Cuvettes  for  zeta-potential  and  zeta-size  measurements  were  purchased  from 
Malvern.
3.2 Methods
3.2.1 RCA cleaning protocol
To clean SiO2 particles and slides from organic  contamination before use,  RCA-1 
cleaning protocol  was used. The substrates were transferred to 5:1:1 solution of 
water:NH4OH:H2O2.  Then  the  solution  was  heated  to  boil  in  the  water  bath, 
uncovered, for 10 minutes. After that the substrates were thoroughly rinsed with 
deionized water and dried under nitrogen flow. Silica particles were left dispersed in 
water after washing.
3.2.2 Nanoparticles synthesis
For some experiments, synthesized in the lab nanoparticles were used. They include 
magnetite  and  gold  nanoparticles.  Their  size  and  zeta-potential  were  controlled 
after  synthesis  by  means  of  TEM and  zeta-size  measurements.  Both  magnetite 
(Fe3O4) and gold nanoparticles should have negative zeta-potential, and the lower it 
is, the better for the LbL assembly process.
3.2.2.1 Gold nanoparticles
For most of experiments, gold nanoparticles were purchased from Sigma. However, 
for some studies on ultrasound-induced release, nanoparticles were synthesized by 
a simple citrate-reduction method.203 For this, 500 mL of 1 mM HAuCl4 solution in 1 L 
round-bottom flask was brought to boiling under condenser and stirring. 50 mL of 
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38.8 mM sodium citrate was rapidly added. The colour of  the solution was very 
slowly changed to burgundy. After that boiling was continued for 10 minutes, when 
heating was taken off,  and stirring continued for  another 15 minutes.  When the 
solution reached the room temperature, it was filtered through 0.2 µm syringe filter.
The size of the nanoparticles obtained could be judged, in addition to TEM, zeta-
potential  and  zeta-size  techniques  (Fig.  3.2),  by  UV-Vis  measurements, 
characterizing the size with plasmon resonance peak location. 
3.2.2.2 Magnetite nanoparticles
Magnetic nanoparticles used for the studies were synthesized by functionalizing the 
surface  of  particles,  obtained  by  Massart’s  co-precipitation  method,  with 
tricarboxylic citric acid.204 In a typical reaction, 0.86 g FeCl2 and 2.35 g FeCl3 were 
mixed in 40 mL of water and heated to 80 ᵒC under argon in a three-necked flask. 
While vigorously stirring the reaction mixture, 5 mL of NH4OH mixed with 5 mL of 
water to raise it's boiling temperature, to prevent its immediate evaporation upon 
the introduction into the reactor, was very slowly (in about 30 minutes) introduced 
by a syringe and heating was continued for 30 minutes. Following that, 1 g of citric 
acid in 2 mL of water was introduced, and the temperature raised to 95  ᵒC. The 
stirring then continued for an additional 90 minutes. Since the as-formed reaction 
product  contained  an  excess  of  citric  acid,  the  nanoparticle  dispersion  was 
subjected to dialysis against water (changed three times a day) in a 25 kD cut-off 
membrane for 6 days to remove the excess unbound citric acid.
Once obtained, the nanoparticles were characterized by means of TEM and zeta 
measurements (Fig. 3.3).
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Figure 3.2: Synthesized gold nanoparticles characterization: a) TEM, b) Zeta-potential,  
c) Zeta-size.
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3.2.3 Protein and polymers labelling
For aims of LSCM and fluorimetry, labelled protein (BSA), to encapsulate into CaCO3-
based capsules, and labelled polymer (PAH or PLA) to stain microcapsules shells, 
was necessary. For that, they were labelled with RBITC dye.
Labelling was performed by a simple mixing of substance to label and dye solution, 
mostly following.205 For that, polymer or protein was dissolved in a buffer at pH 8-9 
(which may be simply 0.1M borate acid solution,  titrated with NaOH, or  a 1:2:3 
mixture of 0.2M Na2CO3:0.2M NaHCO3:water). The dye was dissolved in ethanol at 
1mg/ml concentration. Dye solution was slowly added to protein/polymer solution 
while stirring with magnetic stirrer, and then left to stir for 12 hours. After that, the 
solution  obtained  was  put  into  25  kDa  cut-off  dialysis  membrane  and  dialysed 
against  deionized water  for  1  week  or  till  the  water  outside  show fluorescence 
traces.  Water  was changed twice a  day,  and the dialysis  was performed in the 
fridge, while stirring.
After dialysis, the solution was filtered with 0.2 µm syringe filter, and the volume of 
solution was adjusted to fit  the necessary concentration.  Appropriate amount of 
NaCl was added, when needed (when labelling polymer).
3.2.4 Concentration measurement assays
Concentrations  of  many  substances  can  be  determined  by  adsorption  or 
fluorescence measurements. Usually for all kinds of such calculations a calibration 
curve is used, where known concentrations of the same substance are measured at 
first  to  get  experimental  data,  from  which  a  formula  is  derived  which  binds 
respective reading and concentration.
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Figure 3.3: Synthesized magnetite nanoparticles characterization: a) TEM, b) Zeta-
potential, c) Zeta-size.
3 Materials, Methods and Instrumentation
Adsorption  measurements  were  used  to  determine  concentration  of  magnetite 
nanoparticles,  provided  that  their  adsorption  spectra  does  not  overlap  with  the 
polyelectrolytes adsorption, which also were in solution under investigation. Thus, 
amount of nanoparticles per capsule could be determined.
Protein concentration was determined by fluorimetry and Bradford assay. In case of 
fluorescence  measurements,  a  label  was  used  (TRITC)  which  was  bond  to  the 
protein molecules, whereas in the latter case a special chemical – Bradford reagent 
–  was  mixed  with  the  solution  and  adsorption  at  595  nm  was  measured  to 
determine the concentration. In both cases, calibration curves were plotted prior to 
measuring the parameters of solutions with unknown concentrations of protein.
DNA concentration can be calculated based on solution adsorption at 260 and 320 
nm:
C (µg /ml )=(A260nm – A320) x50 Eq. (3.1)
Purity of DNA can also be estimated: a good sample would give A260/A280 ratio of 1.7-
2.0 and A260/A230 ratio of greater than 1.5.
Due to the need to perform UV-adsorption measurements usually is a small volume 
or  at  tiny  concentrations,  special  instruments  are  commonly  used  for 
characterisation of DNA solutions. In this work ThermoScientific NanoDrop 1000 and 
Cecil CE 2021 spectrophotometers were used.
As a more specific and sensitive solution, Invitrogen Qubit dsDNA HS Assay was 
used,  where  fluorescence of  reaction  product  of  dsDNA with  reagent  specific  to 
dsDNA is measured using special Qubit fluorimeter. HS (high sensitivity) Qubit assay 
has a linear detection rnge of 0.2-100 ng/μL and is selective for dsDNA. For the 
assay, 190 μL of working solution is mixed with 10 μL of sample in a clear 500 μL 
PCR tube, thus dropping the concentration by 20 fold. The mixture is vortexed for 2-
3 seconds and left still for 2-minutes. Following that, the tube is measured in the 
Qubit  fluorimeter which tells the concentration of  dsDNA in the tube. The initial 
concentration of dsDNA in the sample investigated is therefore 20 fold more. For 
calibration  of  the  fluorimeter,  supplied  standard  0  ng/μL  and  10  ng/μL  dsDNA 
solution can be used following the same protocol as for the unknown samples. This 
technique was found to be exceptionally useful when measuring the supernatants 
from LbL assembly of microcapsules shells, when the samples contained various 
chemicals, making the conventional adsorption-based assays leading to inconsistent 
and contraversal results.
69
3 Materials, Methods and Instrumentation
3.2.5 Microcapsules preparation technique
Microcapsules dispersions were prepared on demand for each experiment, always 
following the same protocol, fitting it to meet exact needs. Several bilayers (usually 
3-4) of oppositely charged polymers were deposited over the template, and then 
the template was dissolved.
Microcapsules shells could be functionalized with nanoparticles, embedding them 
into one of the layers. As negatively charged nanoparticles were usually used, they 
were  deposited  after  positively  charged  polymer  layer  (PAH,  PDDA,  PLA,  PLL), 
following by negatively charged polymer to fully overcompensate positive charge of 
the  previous  layer,  as,  for  obvious  reasons,  nanoparticles  cannon  cover  whole 
surface of the microcapsule shell when using reasonable volumes of dispersions.
For  LSCM observations,  labelled  polymer  (RBITC-PAH,  RBITC-PLA,  FITC-PLL)  were 
used for one of the layers (usually one in the middle, as placing labelled polymer 
layer on the outside of the structure tended to aggregate microcapsules), while all 
the other layers were unlabelled.
To  form the  layers,  2  mg/mL solutions  of  polyelectrolytes  were  used.  Synthetic 
polymers (PDDA, PAH, PSS) were dissolved in 0.5M NaCl, while biodegradable ones 
were dissolved in 0.15 M NaCl water solution. FITC-PLL was used at 1 mg/mL. DNA 
and luciferase were usually adsorbed from 1 mg/mL solutions, however in many 
cases they were diluted to increase the total volume of dispersion. Depositing was 
performed while stirring for 15 minutes. After each layer, triple wash/centrifugation 
steps were performed.
3.2.5.1 CaCO3 cores based microcapsules
Synthesis of CaCO3 cores was performed according to chemical reaction Eq. 3.2.
CaCl2Na 2CO3CaCO32NaCl  (Eq. 3.2)
0.33 M solutions of  CaCl2 and Na2CO3 were taken in 1:1 proportion.  Na2CO3 was 
added rapidly to the CaCl2, while vigorously stirring with magnetic stirrer.
If there was a need to encapsulate some species, these were precipitated, i.e. were 
mixed with CaCl2 before addition of Na2CO3.
After 20 sec stirring, the solution was left still  for 10 seconds. After that,  fast 3 
centrifugation/washing steps were undertaken. The capsules were sedimented by 
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centrifugation at 3000 rpm for 30 sec. This should lead to 3-5 µm particles. Particles 
dispersion was controlled by means of optical  microscopy if  they are round (not 
squarish), and reasonably monodisperse.
Polyelectrolytic  shells  were deposited on top of  washed templates following LbL 
assembly procedure, by alternate deposition of oppositely charged species. Specific 
constitution of shells was chosen according to experimental requirements.
After  desired number of layers is deposited, the cores were dissolved in 0.2 M EDTA 
solution  at  pH  about  7,  controlled  by  indicator  paper,  adjusted  by  addition  of 
appropriate amount of 1 M NaOH solution (2-3 mL of NaOH solution per 50 mL of 
EDTA solution). First, capsules were redispersed in 1 mL of EDTA solution (in 2 mL 
tube), as a lot of gas is produced in reaction. After stirring for 7 minutes, 1 mL of  
EDTA  was  added  and  stirred  for  another  7  minutes.  After  that,  some  steps  of 
centrifugation/redispersion at  4000 rpm for  2 minutes  in  EDTA were  undertaken 
(usually 2-3) until no gas generation was observed. The dissolving was followed by 3 
centrifugation/washing steps. Figure 3.4 shows SEM images of CaCO3 microparticles 
and microcapsules prepared using them as templates.
3.2.5.2 SiO2 cores based microcapsules
Usually  200-400  µL  of  stock  particles  solution  (purchased  from  Microparticles, 
GmBh) was used. Before deposition of layers, particles were cleaned, following RCA-
1 procedure. Then polymeric layers were deposited. Centrifugation was performed 
at 5000 rpm for 3 minutes.
Following  that,  shells  were  formed  following  the  LbL  procedure,  starting  with 
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Figure 3.4: SEM images of CaCO3 particles (a,b) and {PAH/PSS}3 microcapsules 
prepared using these particles (c). Images obtained by the author and are presented just  
to show general appearance of CaCO3 particles and microcapsules prepared on them.
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positively  charged  PDADMAC  layer.  Pre-aggregated  gold  nanoparticles  were 
adsorbed instead one of  PSS layers  for  sensibilization  of  microcapsules  to  laser 
irradiation. However, to better attach the nanoparticles and prevent their desorption 
when  next  positively  charged  layer  is  adsorbed,  and  to  assure  surface  charge 
overcompensation,  PSS  was  adsorbed  immediately  after  nanoparticles,  without 
intermediate washing. Resulting shell structure was PDADMAC/PSS/PDADMAC/AuNP/ 
PSS/PDADMAC/PSS.
After depositing polymeric layers, the cores were dissolved in 0.3M HF solution. For 
that, the capsules dispersion was put dropwise into the excess of acid for 1 hour. 
This  was  followed  by  sedimentation  at  2000  rpm  for  1  hour  and  several 
wash/centrifugation  steps  (at  the  same  parameters),  until  pH  of  supernatant 
reached 6, as measured using indicator paper. Figure 3.5 shows SEM images of SiO2 
microparticles (4.99 μm), partially dissolved microparticles covered with shell, and 
ready microcapsules.
Encapsulation was performed by heat-shrinking. For that, microcapsules dispersion 
was mixed with 1 mg/mL solution of substance to encapsulate (labelled dextran) 
and shaken with the vortex for 30 minutes. Then it was incubated for 10-15 minutes 
at 60-70 °C in pre-heated water bath. After that, the solution was taken off the bath 
and let cool down at room temperature. This was followed by centrifugation for 10 
minutes at 2000 rpm and washing.
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Figure 3.5: SEM images of 5 µm SiO2 microparticles (a), partially dissolved particles  
with LbL shell {PDADMAC/PSS}3 (b) and ready microcapsules (c).  Images obtained by  
the author and are presented just to show general appearance of SiO2 particles and 
microcapsules prepared on them.
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3.2.6 Sample chambers for optical experiments
When performing laser irradiation of microcapsules solution, the capsules need to 
be prevented from moving. For this, sealed chambers were created. On a thin (0.13-
0.17 mm) 24x60 mm microscope slide, washed following the RCA-1 protocol, a layer 
of  PEI  or  PDDA  was  deposited  by  dipping,  thoroughly  washing  the  excess  and 
drying. This was done to stick the capsules (having usually positive outermost layer) 
to  it  to  prevent  them  from  moving.  20  µl  of  capsules  solution  of  desired 
concentration (rather low) was dropped onto the slide, and then covered with 18x18 
mm cover glass. The upper slide was fixed to the lower one by sealing it around 
with nail polish. After this, the capsules can survive several months without drying, 
moving or any other changes, if kept in appropriate conditions.
3.2.7 Cells
Research  involving  cell  culturing,  treatment  and characterisation  was  performed 
during  the  project.  Cell  culture  work  needs  special  precautions  and  sterile 
appliances. Cell cultures were kept in the incubator at 37 oC and 5% CO2:95% air. 
Culture manipulations were performed in laminar flow fume hood. All the equipment 
and packaging of consumables (pipette tips, boxes, etc) used was sprayed with 70% 
ethanol solution prior to be placed to the fume hood.
For  experiments,  involving  confocal  imaging  or  laser  treatment,  the  cells  were 
cultured in 35mm μ-Dish (Ibidi GmbH), allowing to observe and irradiate them with 
high magnification lens (up to 100x), and also very useful for life support of the 
cells, isolating them inside friendly environment during experiments. Once desired 
cell density was achieved, the culture medium was changed to the 1% FBS solution 
to stop cell division.
For  DNA  transfection  experiments  and  enzyme  activity  studies,  involving 
luminescence measurements, the cells were cultured in 96-well plates. To ensure 
results  integrity,  the number of  cells  in each well  was controlled by counting in 
haemocytometer chamber. In each experiment, the number of cells per well was 
maintained the same, based on the cells concentration, i.e. the same volume of 
cells dispersion was added to each well. To distinguish alive cells from dead ones, 
the cells were mixed with trypan blue solution, a diazo dye used as vital  stain, 
penetrating only through the membranes of the dead cells, hence showing them in 
a distinctive blue colour under the microscope, so only alive cells can be calculated 
in haemocytometer chambers.
Several  cell  types  were  used for  different  experiments.  Short  details  of  specific 
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features of work with each of them are provided here.
3.2.7.1 B50 and 293 cells
B50  rat  neuronal  cells  were  obtained  from  European  Collection  of  Animal  Cell 
Cultures (ECACC, Porton Down,  UK).  These cells are an ethylnitros urea induced 
tumor cell line that has neuronal morphology. 293T cells are are derived from the 
293 cell  line into which the temperature-sensitive gene for  SV40 T antigen was 
inserted.206,207 These cells are a cell line of human kidney epithelial cells, and used 
for research in very distinct areas, including DNA transfection.208 Both types of cells 
demonstrate rather high adhesion to the substrate they are cultured on and a high 
rate of division (at a proper fetal bovine serum concentration).
The cells of both types were handled in the same manner. They were cultured in 
Dulbecco’s minimum essential media (DMEM, Sigma  51435C) supplemented with 
10% fetal bovine serum (10% FBS, Sigma F2442) and penicillin-streptomycin (1%, 
Sigma P4333).209 To maintain the number of  cells  in the dish,  the cultures were 
washed with PBS to remove the nutritious medium and then treated with trypsin 
solution from porcine pancreas (Sigma T4674) for 3 minutes to detach them from 
the  dish  bottom.  Following that,  1/5-1/3  part  of  them was resuspended in  10% 
culture medium. As the trypsin stops its influence in presence of nutritious medium, 
the cells attach to the dish once again. After that the cells start to divide again. This 
procedure was repeated once in 3-4 days (judging mainly on the surface covered by 
cells) to prevent their overgrowth.
To freeze down an aliquot of cells, trypsinized cells should be centrifuged at 1000 
rpm for  5  minutes  and resuspended in  2  mL  of  freeze  mix  –  10% of  dimethyl 
sulphoxide (DMSO, Sigma D2650) in FBS - per aliquot and pipetted into labelled 
cryovials. Cryovials should then be frozen at -20 °C for several hours or overnight 
and then transferred to liquid nitrogen. Slow freezing and rapid thawing of cells is 
important in order to maintain cells integrity.
For  cells  thawing  from  frozen  state,  a  vial  should  be  removed  from  the  liquid 
nitrogen and the cap should be loosen slightly to prevent pressure build up. After re-
tightening the cap, the vial should be held in 37 °C water bath. When the cells are 
about  75% thawed,  the  vial  should  be  sprayed with  ethanol  and transferred  to 
culture hood. A little warm culture medium should be added to the vial to complete 
thawing and then all the contents of the vial should be transferred to the tube with 
about 20 mL of warm medium to dilute out the DMSO. Following that,  the cells 
should be centrifuged at 1000 rpm for 5 minutes, and then resuspended in fresh 
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warm culture medium.
3.2.7.2 Raw 264.7 cells and HeLa cells
Raw cells (mouse leukaemic monocyte macrophage cell line) were obtained from 
European Collection of Animal Cell Cultures (ECACC, Porton Down, UK) and used for 
DNA  transfection  experiments.  They  were  also  cultured  in  Dulbecco’s  minimum 
essential media (DMEM, Sigma 51435C) supplemented with 10% fetal bovine serum 
(10%  FBS,  Sigma  F2442)  and  penicillin-streptomyosin  (1%),  at  37  oC  and  5% 
CO2:95% air. However, the processing technique is completely different. To control 
the population of the cells, they were scraped using plastic scrapers, rather than 
trypsinized.  After  scraping,  the  cells  dispersion  was  aliquoted  to  96  well  plates 
according to needs and reattached to the substrate with time.
3.2.7.3 Dendritic cells and fibroblasts
Dendritic  cells  (DC)  were  used  for  experiments  with  magnetic  field  in  Ghent 
University  (Belgium)  and  were  prepared  by  Stefaan  De  Koker  (Department  of 
Molecular  Biomedical  Biology,  Ghent  University)  according  to  earlier  published 
protocol.187
Female  C57BL/6  mice  for  BM-DC  preparation  were  purchased  from  Janvier  (Le 
Genest Saint Isle, France), and OT-I and OT-II transgenic mice were provided by Prof. 
Van Kooyk from the VU University Medical Center (Amsterdam, Netherlands) and 
housed in a specified pathogen-free facility in micro-isolator units. At 12–16 weeks, 
mice were euthanized with CO2. Bone marrow was isolated from tibia and femurs, 
and OT-I and OT-II cells from spleens. All mice experiments were approved by the 
local ethical committee.
Bone-marrow-derived  DCs  (BM-DCs):  Dendritic  cells  were  generated  using  a 
modified Inaba protocol.210 Bone marrow was flushed from the femurs and tibias 
obtained from euthanized twelve to sixteen weeks old C57BL/6 mice. After lysis of 
red blood cells with ACK lysis buffer (BioWhittaker, Wakersville, MD), granulocytes 
and  B  cells  were  depleted  using  Gr-1  (Pharmingen)  and  B220  (Pharmingen) 
antibodies,  respectively,  and  low-toxicity  rabbit  complement  (Cedarlane 
Laboratories Ltd., Hornby, Ontario, Canada). Cells were seeded at a density of 2·105 
mL-1 in 175 cm2 Falcon tubes (Becton Dickinson) in DC medium (RPMI 1640 medium 
containing 5% LPS-free FCS, 1% penicillin/streptomycin, 1% l-glutamine, and 50 mm 
b-mercaptoethanol) containing 10 ng/mL IL-4 and 10 ng/m LGM-CSFF (both from 
Peprotech, Rock Hill, NJ). After two days and again after four days of culture, the 
non-adherent cells were centrifuged, resuspended in fresh medium, and replated to 
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the same Falcon tubes. On the sixth day, non-adherent cells were removed and 
fresh medium containing 10 ng/mL GM-CSF and 5 ng/mL IL-4 was added. On day 8 
of culture, non-adherent cells were harvested and used for the experiments.
HCA2-hTERT human fibroblasts were obtained from ATCC (CRL-2522) and cultured in 
Dulbecco’s Minimum Essential Medium supplemented with 10 % FBS, L-glutamine, 
sodium pyruvate and antibiotics (penicillin and streptomycin). The cells were kept in 
a humidified environment with control of CO2 (5 %). These cells were used for cell 
viability studies only.
3.2.7.4 Cell viability assays
In many situations it is necessary to determine whether the cells are alive or not. 
The simplest situation is when a certain number of cells is needed, and one needs 
to distinguish alive cells from the dead ones in hemocytometry (or flow cytometry) 
measurements. For this purpose trypan-blue solution (Sigma) was used, which is a 
diazo dye, labelling only dead cells. Therefore, all the dead cells become coloured 
after application of the chemical.
For  more  sophisticated  studies,  where  the  influence  of  an  object  on  the  cells 
viability is under the question, other assays can be used. There are many assays 
kits  commercially  available,  falling  in  several  groups  by  the  analysis  principle: 
cytolysis or membrane leakage assays, mitochondrial activity or caspase assays, 
functional assays and genomic and protoemic assays. In this study the Abacus Cell 
Proliferation  Kit  (Clontech,  PT1700-1,  K2020-1),  which  is  based  on  assay  of 
intracellular acid phosphatase and provides a simple colorimetric method that can 
be  performed  directly  in  96-well  microtiter  plates  was  used.  The  substrate  p-
nitrophenyl  phosphate (pNPP) is converted by acid phosphatase to water-soluble 
product p-nitrophenol, which has a strong adsorption at 405 nm (yellow).
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Figure 3.6: P-nitrophenyl phosphate structural formula and p-
nitrophenol synthesis reaction.
Protein phosphatase, enzyme that control the removal of phosphate (PO43-) group 
from protein molecules, regulates many fundamental cellular process such as cell 
attachment,  proliferation,  differentiation  and  apoptosis.  Colour  intensity  is 
conveniently measured using a multiwell plate reader. The Abacus Cell Proliferation 
Kit offers a practical, attractive, and economical alternative to other types of cell 
proliferation assays, including those based on tetrazolium dyes.
3.2.8 DNA and enzyme studies
3.2.8.1 Plasmid DNA preparation
Plasmid DNAs were prepared by Dr.  David Gould (Bone and Joint  Research Unit, 
Barts  and  The  London,  Queen  Mary's  School  of  Medicine  and  Dentistry, 
Charterhouse  Square,  University  of  London,  London,  UK)  as  a  part  of  our 
collaboration.
Plasmid DNA was propagated in DH5-α Escherichia coli and was purified using a 
standard Plasmid Mega Kit (Qiagen Ltd., Crawley, West Sussex, UK); when DNA was 
prepared for in-vivo application, the EndoFree™ Plasmid Mega Kit (Qiagen Ltd.) was 
used.207
The plasmids pcLuc+ and pEGFP were constructed according to published method.211 
To  facilitate  cloning,  the  sense  and  anti-sense  oligonucleotides  of  sequences 
GATCTTAAGCCATACCCGGGATCGGGATC-CGACTTGG  and 
TCGACCAAGTCGGATCCCGATCCCG-GGTATGGCTTAA,  respectively,  containing 
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restriction  sites  for  BamHI,  SmaI,  and  AflII,  were  annealed  and  cloned  into  the 
plasmid pGL2-Basic (Promega Corporation, Madison, WI, USA) restricted with BamHI 
and SalI, producing the plasmid pGLinker. The MIK cassette containing the improved 
tetracycline transactivator (rtTA2S-M2) and the repressor tetR-KRAB from an SV40 
promoter along with the upstream zeo gene were removed from pMIK/ZeoSV2 by 
restriction with MscI and AflII  and cloned into pGLinker cut with PshA1 and AflII, 
producing  the  vector  pGMIK.  The  self-contained  plasmid  pGTLMIK  was  then 
generated by removing Ptet-Luc from pGTL with XhoI-EcoRV and was cloned into 
pGMIK restricted with the same enzymes. Finally,  pGTTMIK encoding dTNFR was 
constructed by removing Ptet-Luc from pGTLMIK with the enzymes MluI-EcoNI and 
by replacing it with Ptet-dTNFR removed from pGTRTT with the same enzymes. The 
EGFP gene was removed from pGTRTE by restriction with ClaI and re-ligation of the 
plasmid formed pGTRTEmpty. 
3.2.8.2 Plasmid DNA transfection
For plasmid DNA transfection, several approaches were used – with encapsulated 
plasmid, following conventional  calcium phosphate co-precipitation technique, and 
using transfection agents – Fugene-6 (Roche Molecular Biochemicals) and Amaxa 
(Lonza), which help the molecules of DNA to penetrate the membranes of the cells. 
The reason to use an agent is that free DNA molecules would be rejected by the 
membrane,  while  encapsulated  DNA  finds  its  way  into  a  cell  together  with 
microcapsule, that is internalized.
Microcapsules were introduced to the cells after centrifugation and resuspension in 
the cell medium. The number of capsules, introduced to each well, was controlled 
by  haemocytometry  and  chosen  to  match  the  amount  of  DNA,  added  in  the 
investigations with Fugene-6 transfection agent.
For Amaxa-assisted transfection, usual protocol recommended by supplier (Lonza) 
for use with 293T cells was followed. Cells were trypsinized, and then trypsin was 
neutralized by addition of 10% FBS supplemented culturing medium. To each well of 
96 well plate 175 µL of culture media was added, and plates were pre-incubated in 
37 °C/5% CO2 incubator. Cells were aliquoted to desired concentration (20000 cells 
per  sample),  centrifuged  and  supernatant  was  completely  removed.  Cells  were 
resuspended in 20 µL Nucleofector solution per sample. Desired amount of plasmid 
DNA in range 0.2-1 µg was mixed with cells in wells, and then 20 µL of cells with 
substrates were transferred to 96 well  Nucleocuvette modules,  which were then 
processed using 96 well Shuttle system. After that, cells were resuspended with 80 
µL of pre-warmed medium, gently mixed by pipetting up and down, and plated by 
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transferring 25 µL of solution per sample with addition of 175 µL of pre-warmed 
medium, and incubated until analysis.
For calcium phosphate assisted transfection, protocol published by Gould et al was 
used.207 Culturing medium was replaced with fresh one. For each transfection, 50 µL 
of HEPES-buffered saline was put in a sterile tube, and appropriate amount of DNA 
was put to each tube and mixed. Following that 3 µL of 2.5M CaCl2 was introduced 
to each tube, vortexed and set still for 20 minutes. After that transfection mix was 
added to wells with cells dropwise and gently mixed by rocking back and forth. Cells 
were incubated for overnight and then culture media was replaced again. Cells were 
analysed 48-72 hours later.
For Fugene-6 induced transfection, the supplier's protocol was followed. Fugene-6 
was mixed with serum-free medium, vortexed for 1 second, incubated for 5 minutes 
at room temperature. After that, DNA was introduced to this solution, vortexed once 
again and incubated for 1 more minute. After that, equal portions of solutions were 
introduced to the cells by pipetting.
Transfection of  luciferase-encoding DNA was measured macroscopically  following 
luciferase activity assay. The other way to observe plasmid DNA transfection was to 
use confocal microscope.
3.2.8.3 Luciferase assay
Firefly luciferase (Fig. 3.7a) generates light from luciferin in a multistep process. First, 
D-luciferin is adenylated by MgATP to form luciferyl  adenylate and pyrophosphate. 
After activation by ATP, luciferyl adenylate is oxidized by molecular oxygen to form a 
dioxetanone ring. A decarboxylation reaction forms an excited state of oxyluciferin, 
which tautomerizes between the keto-enol form. The reaction finally emits light as 
oxyluciferin returns to the ground state.212 Schematic of this process is presented in 
Fig.  3.7b. Therefore, luciferase needs two main components for the reaction to take 
place – D-luciferin and ATP, which are supplied as a substrate in assay measurements.
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Luciferase  activity  was  determined  using  the  luciferase  assay  system (Promega 
Corporation).  Most  of  the measurements  were performed using MLX Microtiter® 
Plate  Luminometer  (Dynex  Technologies,  Chantilly,  VA,  USA)  (Fig.  3.8a).  For 
measurements,  samples  were  plated into  disposable  96-well  plates  (Fig  3.8b,c). 
Plates with transparet bottoms were used for measuring luciferase activity in alive 
cells, attached to the surface. Opaque plates were used In all other cases, including 
measurements  of  lysed  cells,  free  luciferase  solutions  (for  calibration)  and 
microcapsules.
Figure 3.8: Luciferase activity measurements equipment: a) MLX Microtiter® Plate  
Luminometer with plate fitted in, b) plates with opaque wells bottoms, c) plate with  
transparent wells bottoms.
When measuring cells  lysates,  cells  were washed twice with phosphate-buffered 
saline (PBS) and were then lysed at various time points with 100 µL of passive lysis 
buffer (in 96 well plate) at room temperature for 15 minutes and frozen at -20 °C. 
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Figure 3.7: Firefly luciferase structure (a) and reaction mechanism (b).212
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All the lysates were then measured at a single time. For that, the lysates were de-
frozen, centrifugated with ALC Multispeed Centrifuge PK121, for 2 minutes at 1300 
rpm and aliquoted (10 µL) to disposable measurement plate. For measurement, 50 
µL of luciferase assay substrate solution in luciferase assay buffer was added to 
each well, containing 10 µL of lysate, and light emission was integrated through 10 
seconds 2 seconds after addition of substrate. Protein concentrations of cell lysates 
could be determined using the Bradford protein assay (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA), to express values of luciferase activity as relative light units 
(RLU) per microgram of protein.
For luciferase activity measurements in alive cells, usually 50 µL of luciferase assay 
substrate  solution  in  luciferase  assay  buffer  was  added  to  each  well  and  light 
emission was integrated through 10 seconds 2 seconds after addition of substrate. 
However,  due to  the  fact  that  activity  is  measured inside  alive  cells,  potassium 
luciferin  was used as ATP-dependant  substrate,  which can penetrate  the cells  and 
does not have ATP, because there is ATP readily available in cells cytosol.
When sensitivity of MLX Microtiter® Plate Luminometer was not enough to measure 
luciferase activity in cell  cultures, plates were photographed with high-sensitivity 
CCD camera and the output was digitized using special software.
3.2.9 Laser irradiation setup
For  irradiation  of  samples  with  laser,  a  homemade  optical  setup  was  used. 
Schematics of it are shown in Fig. 3.9. Setup was used in two modes: conventional 
and inverted. Conventional mode was used when irradiating sample chambers, i.e. 
just capsules, and at these times it was coupled with a simple optical microscope, 
providing necessary rigidity for the components and also simple XY and Z moving 
stages.  Using  microscope  eased  the  justification  of  the  system.  When  used  in 
inverted mode, the setup was assembled solely of Thorlabs supplied parts, including 
XYZ moving stage. The main idea of the setup is to irradiate the sample at the 
specific point with focused laser beam, providing the image of irradiation site at the 
same time. The laser beam travels through the lens, focuses and hits the sample. 
Small part of the beam is reflected back and goes into the camera, together with 
the optical image of the sample, viewed through the same lens which focus the 
laser beam. Therefore, when justified and focused on a sample, one can see sample 
image together with a small dot of the laser beam. Actually, the laser is focused 
slightly above the plane, where the image is visualized.
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Figure 3.9: Laser irradiation setup schematic.
The light on the sample was provided with 150 W halogen lamp when operating in 
inverted mode, and by collimated light of microscope lamp, when in conventional 
mode. Highly sensitive b/w 720p analog camera, connected to the computer via 
digitizing interface, was used to capture the images.
For experiments, regarding irradiation of gold nanoparticles aggregates, regulated 
power of up to 100 mW laser diode with mean wavelength of 840 nm and fixed 
power 5 mW 633 nm and 4.5 mW 670 nm laser diodes were used for irradiation in 
different experiments. Precautions were taken to avoid any harm due to power of 
100 mW IR laser, especially being invisible, enough to damage retina.
3.2.10 Ultrasound irradiation setup
High-frequency (850 kHz)  ultrasonication of  samples was performed in Coventry 
University with Meinhardt bath. The volume of the samples, kept in glass flasks, was 
chosen to be 10 mL, to make them more or less thermostable. The bath was chilled 
during  the  experiments  at  20  °C  using  a  cooling  system.  The  power  of  high-
frequency  irradiation  was  measured  by  calorimetry  method  before  irradiation 
experiments with microcapsules. Calorimetry measurements and experiments with 
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microcapsules were all performed using the same glass beaker to ensure correct 
power estimation is used.
Conventional 20 kHz ultrasonication was done at QMUL, using GEX 750 ultrasound 
processor with attached CV33 probe (Sonics & Materials, Inc.) at power of 70 W. The 
volume of the samples was chosen to be 10 mL. The samples were chilled during 
experiments with ice-cold water, because the power of irradiation (70 W) is high 
enough to cause fast temperature increase.
After irradiation (for both regimes), each sample was sedimented by centrifugation 
for  5  minutes  at  9000  rpm and  the  supernatant  was  taken  for  fluorimetry.  As 
centrifugation by itself could not remove the capsules and debris produced by their 
processing (judging by the very big and irrelevant fluorescence intensity values and 
emission peak shift) supernatants were left standing in the fridge for several days. 
The fluorescence was then measured to get much more reliable data.
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Figure 3.10: 850 kHz ultrasound irradiation bath photo.
3 Materials, Methods and Instrumentation
3.3 Instruments
3.3.1 Fluorescence Microscopy
Fluorescent  microscopy  is  based  on  the  ability  of  luminescence  which  is 
characteristic  for  some  species.  Luminescence  is  producing  light  of  longer 
wavelength  when  irradiated  with  a  shorter  wavelength  external  light  source 
(excitation). Produced light (emission) waves are always shorter due to Stokes rule.
Fluorescent  microscope  (Fig.  3.11)  differs  from  a  conventional  optical  one  by 
presence of a powerful short-wavelength light source (usually mercury lamp) and a 
system of band-pass filters. Also, the sample under investigation has to contain the 
luminescent material, which, actually, will be visualized. One other feature is, that 
the  excitation  light  is  delivered  to  the  sample  through  the  lens.  This  helps  to 
increase the excitation light intensity, and, subsequently, the intensity of emitted 
light.  The  excitation  filter  lets  through  only  the  light  with  specific  wavelength, 
matching the excitation characteristics of the stain, used for sample preparation. 
The emission filter helps to cut-off the excitation light from the observer, letting only 
the emitted light through, increasing the contrast ratio of the image.213
Figure 3.11: Fluorescent microscope schematics.
Leica DM2500P,  Nikon and Olympus ix71 fluorescent  microscopes with attached 
cameras  were  used  for  general  observations  and  imaging  during  all  course  of 
project work.
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3.3.2 Laser Scanning Confocal Microscopy
Laser scanning confocal microscopy (LSCM) is a non-destructive imaging method, 
commonly  used  for  biomedical  research,  allowing  obtaining  of  high  resolution 
images,  and 3d reconstruction.  The advantage of  the  LSCM over  the  traditional 
optical microscopy and fluorescent microscopy is that only the objects in focus are 
visualized, with only a small fraction of the out-of-focus emission finding its way to 
the camera. This is achieved by introducing 2 pinholes (see Fig.  3.12) and using 
fluorescent  dyes,  irradiated  with  laser  beam  as  visualization  agents.  LSCM 
technique can be thought of as a result of development of fluorescent microscopy.
Confocal  images  were  taken  with  Leica  TS  laser  scanning  confocal  microscope, 
using 63x f/1.4 oil-immersion lens.
Figure 3.12: Laser Scanning Confocal Microscopy 
schematics.214
3.3.3 Electron microscopy
Electron  microscopy  methods  allow  very  high  resolution  investigations  of 
morphology,  topology  and  chemical  compositions  of  samples.  The  imaging  is 
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obtained  by  accelerating  an  electron  beam towards  the  sample  surface  in  the 
vacuum. The higher resolution of the electron microscopy is related to the fact that 
DeBrogile  wavelength of  accelerated electron  is  shorter  than the  wavelength of 
light, used in conventional microscopy (including confocal).
3.3.3.1 Scanning electron microscopy
In scanning electron microscopes the focused electronic beam scans the surface of 
the sample with the back-scattered electrons registered by the detector. This allows 
imaging of the surfaces, investigating their  roughness, quality and their “visual” 
appearance. In order to get the electrons back-scattered, the sample have to be 
covered  by  grounded  conductive  film.  Usually  gold  or  carbon  are  applied  by 
sputtering them in vacuum. Lack of the covering results in image defects, caused by 
charging of the surface by the irradiating electron beam.
Scanning Electron Microscopy (SEM) and Scanning Transmission Electron Microscopy 
(STEM) images were taken with FEI Inspect F microscope (Fig.  3.13). Experiments 
with  ion  etching  were  carried  out  using  FEI  Quanta  3D  FEG  scanning  electron 
microscope. Gold was sputtered on the samples to create conductive coating, as for 
microcapsules  samples  it  delivers  better  imaging  than  carbon,  based  on  the 
experience. 10 kV acceleration voltage was usually used. Specimens were prepared 
by attaching a circular glass slide (which delivers clean and smooth surface) on an 
aluminium sampleholder (Fig. 3.13c) with cement and pipetting a small aliquot (~10 
μL) of dilute capsules dispersion with subsequent drying at room temperature (or at 
slightly raised temperature in cases when the liquid should be evaporated rapidly to 
prevent unwanted reactions, such as in case of CaCO3 microparticles microscopy). 
Next day the specimens are sputtered with gold and analysed with SEM.
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Figure 3.13: FEI Inspect F scanning electron microscope photographs: a) microscope  
general view, b) vacuum chamber with specimens fitted, c) sampleholder with  
specimens close-up.
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3.3.3.2 Transmission electron microscopy
In transmission electron microscope, the accelerated electrons irradiate the sample, 
and the detector is placed underneath the sample. Thus, it registers the electrons, 
penetrated  through  the  sample.  Provided  by  the  higher  acceleration  voltage 
(hundreds of kV), this method delivers higher resolution. The contrast of the image 
is due to different materials densities in the sample. Thus, it is very useful when 
there is a need of imaging of aggregated or even individual nanoparticles. TEM can 
even resolve the crystal lattice.
TEM images were taken using JEOL-JEM 2010 transmission electron microscope (Fig. 
3.14).  Samples  were  prepared  by  pipetting  a  very  small  amount  (~5  μL)  of 
dispersion on the special copper grid with polymeric film (Fig.  3.14d), which was 
then installed to sampleholder (Fig.  3.14b,c). Then the liquid was evaporated, and 
the  specimen  was  put  into  the  vacuum chamber  and  analysed  at  acceleration 
voltage of 200 kV and magnifications of up to 300000. Images were recorded to 
light-sensitive plates, then developed and scanned using plate scanner, or later by 
digital CCD camera fitted.
3.3.4 UV-Vis-NIR spectroscopy
Most organic materials are transparent in UV, visible and IR, spanning around 200 to 
800  nm.  Thus,  the  spectroscopy  method  provides  non-destructive  method  for 
investigating the substances, which do adsorb in this region, incorporated into the 
transparent solutions. This technique can also be used for quantification purposes, 
measuring film thickness, DNA concentration, or proteins concentration, either by 
determining the  adsorption of  the  material  itself  (as  in the  case  of  DNA)  or  by 
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Figure 3.14: Photographs of JEOL-JEM 2010 TEM microscope. a) Common view of  
microscope, b) sampleholder, c) close-up of sampleholder, d) copper grid for specimen.
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adsorption peak position change of the specific agents (such as Bradford method for 
measuring proteins concentrations).
In this study, the UV-Vis-NIR spectroscopy was used to control the aggregation of 
gold  nanoparticles  prior  to  their  incorporation  into  the  capsules  shells,  protein 
concentration  measurements  by  Bradford  assay,  and  other  substances 
concentration  measurements,  such  as  concentration  of  nanoparticles.  The 
measurements  were  performed  using  Perkin-Elmer  Lambda  950  UV/VIS  and 
Shimadzu UV-1650PC spectrophotometers.
For  DNA  concentration  measurements,  based  on  260  and  280  nm  adsorption, 
ThermoScientific NanoDrop 1000 and Cecil CE 2021 spectrophotometers were used. 
The first one is capable of measuring tiny amounts of samples (microliters), whereas 
the latter can be used for measurements of very diluted samples, using a quartz 
cuvette (3 mL).
It should also be noted, that the selection of appropriate cuvette is essential to get 
reliable  data,  as  different  materials  have  various  optical  properties  in  distinct 
spectra  areas.  So,  for  UV  measurements  (DNA  concentrations  studies)  quartz 
cuvette was used, which is transparent in that range, whereas for optical  range 
much cheaper and disposable PMMA cuvettes were used.
3.3.5 Fluorescence spectroscopy
Fluorescence measurements were used to determine release from microcapsules at 
macroscopic  level.  This  technique  is  based  on  more  or  less  linear  fluorescence 
increase with dye concentration. The dye is bonded to the protein molecules, which 
are encapsulated. As the protein is released, its concentration in supernatant grows, 
as  does  it  of  the  dye.  Therefore,  the  release  can  be  judged  by  fluorescence 
measurements.  To  perform  numeric  investigations,  the  calibration  curve  is 
measured, allowing to refer fluorescence intensity values to concentration of the 
substance  under  investigation.  It  should  be  kept  in  mind,  that  when  the 
concentration  of  the  dye  is  too  high,  the  quenching  takes  place,  shifting  the 
emission peak wavelength.
Fluorimetric measurements were performed with FluoroMax and Perkin-Elmer LS55 
fluorescence spectrophotometers. Usually, as the RBITC labelled BSA was used as 
protein to encapsulate and investigate its release, the excitation was at 560 nm, 
while  emission  was  measured  around  580  nm  (according  to  measurements  of 
labelled BSA solution when determining the calibration curve).
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3.3.6 Zeta-potential and Zeta-size
Zeta potential is the charge that develops at the interface between a solid surface 
and its liquid medium. This potential, which is measured in mV, may arise by any of 
several mechanisms. Among these are the dissociation of ionogenic groups in the 
particle  surface  and the  differential  adsorption  of  solution  ions  into  the  surface 
region.  The net charge at  the particle surface affects the ion distribution in the 
nearby region,  increasing the concentration of  counterions  close  to  the surface. 
Thus,  an  electrical  double  layer  is  formed  in  the  region  of  the  particle-liquid 
interface.
This double layer (upper part of figure) consists of two parts: an inner region that 
includes ions bound relatively tightly to the surface, and an outer region where a 
balance  of  electrostatic  forces  and  random  thermal  motion  determines  the  ion 
distribution. The potential in this region, therefore, decays with increasing distance 
from the surface until,  at  sufficient distance,  it  reaches the bulk solution value, 
conventionally taken to be zero (Fig. 3.15). This decay is shown by the lower part of 
the figure and the indication is given that the zeta potential  is the value at the 
surface of shear.
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Figure 3.15: Potential distribution near the particle surface.
In an electric field, as in microelectrophoresis, each particle and its most closely 
associated ions move through the solution as a unit, and the potential at the surface 
of  shear  between  this  unit  and  the  surrounding  medium is  known  as  the  zeta 
potential. When a layer of macromolecules is adsorbed on the particle's surface, it 
shifts the shear plane further from the surface and alters the zeta potential.
Zeta potential  is  therefore  a  function of  the  surface charge of  the  particle,  any 
adsorbed layer at the interface, and the nature and composition of the surrounding 
suspension medium. It can be experimentally determined and, because it reflects 
the effective charge on the particles and is therefore related to the electrostatic 
repulsion  between them,  zeta-potential  has  proven to  be  extremely  relevant  to 
practical  study  and  control  of  colloidal  stability  and  flocculation  processes  (Fig. 
3.16).
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Figure 3.16: Zeta-potential dependence on pH.
When a voltage is applied to the solution in which particles are dispersed, particles 
are attracted to the electrode of the opposite polarity, accompanied by the fixed 
layer and part of the diffuse double layer, or internal side of the "sliding surface". 
Zeta potential is considered to be the electric potential of this inner area including 
this conceptual "sliding surface". As this electric potential approaches zero, particles 
tend to aggregate. Smoluchowski's formula (Eq. 3.3) gives connection between the 
electrophoretic mobility of the particles and the Zeta-potential.
=4

xU x 9⋅107 ,
U= L
V
 (Eq. 3.3)
Here ξ is Zeta-potential  (mV),  η – solution viscosity,  ε – dielectric  constant,  U – 
electrophoretic mobility, ν – speed of particle (cm/s), V – voltage (V); L – distance 
between electrodes.
Dynamic  light  scattering,  also  known  as  zeta-size  measurements,  is  used  to 
determine small  particles distribution in solutions.  When a beam of light passes 
through a colloidal dispersion, the particles or droplets scatter some of the light in 
all directions. When the particles are very small compared with the wavelength of 
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the light, the intensity of the scattered light is uniform in all directions (Rayleigh 
scattering);  for  larger  particles  (above  approximately  250  nm  diameter),  the 
intensity is angle dependent (Mie scattering).
If  the  light  is  coherent  and  monochromatic,  as  from a  laser  for  example,  it  is 
possible to observe time-dependent fluctuations in the scattered intensity using a 
suitable detector such as a photomultiplier capable of operating in photon counting 
mode.
The time dependence of the intensity fluctuation is most commonly analysed using 
a digital correlator. Such a device determines the intensity autocorrelation function 
which can be described as the ensemble average of the product of the signal with a 
delayed version of itself as a function of the delay time. The "signal" in this case is 
the  number  of  photons counted in  one sampling  interval.  At  short  delay  times, 
correlation is high and, over time as particles diffuse, correlation diminishes to zero 
and  the  exponential  decay  of  the  correlation  function  is  characteristic  of  the 
diffusion coefficient of the particles. Data are typically collected over a delay range 
of 100ns to several seconds depending upon the particle size and viscosity of the 
medium.
Particle size distributions can be calculated either assuming some standard form 
such as log-normal or without any such assumption. In the latter case, it becomes 
possible,  within  certain  limitations,  to  characterise  multimodal  or  skewed 
distributions.  The size range for  which dynamic light scattering is  appropriate is 
typically submicron with some capability to deal with particles up to a few microns 
in diameter. The lower limit of particle size depends on the scattering properties of 
the particles concerned (relative refractive index of particle and medium), incident 
light intensity (laser power and wavelength) and detector / optics configuration.
Dynamic light scattering (also known as Quasi Elastic Light Scattering [QELS] and 
Photon Correlation Spectroscopy [PCS]) is particularly suited to determining small 
changes in mean diameter such as those due to adsorbed layers on the particle 
surface or slight variations in manufacturing processes.
Malvern Nano ZS zetasizer was used for zeta-size and zeta-potential measurements 
inside disposable cuvettes.  Readings were usually averaged from 3 cycles of 10 
individual measurements with instrument software.
92
3 Materials, Methods and Instrumentation
3.3.7 General lab equipment
IKA Vortex Genie 2 and IKA Vortex Genie 3 shakers, IKA Werke RET Basic C magnetic 
stirrer,  Eppendorf  5417C and Eppendorf  5418 centrifuges,  Elma S15H Elmasonic 
ultrasound bath, Salter ANDER-180A weighing scale, PHM21 STANDARD Meter Lab 
pH meter were used for daily lab work.
ALC Multispeed Centrifuge PK121 and Heraeus Labofuge 400R centrifuges, Sanyo 
MCO-15AC incubator (37 °C, 5% CO2) and BioWright laminar flow fume hood (Atlas 
Air Clean Ltd.) were used for cells incubation and handling.
Microcapsules  counting  (for  concentration  measurements)  was  performed  using 
improved neubauer  haemacytometer  counting  chamber  (Weber,  purchased from 
Camlab).
All  water  used  for  all  experiments  was  de-ionised  using  an  ELGA  Purelab  UHQ 
machine to have resistivity not less than 18 MΩ·cm.
Optical  setup  appliances,  fittings,  rods,  cage  system and  laser  diodes  for  laser 
irradiation setup were purchased from Thorlabs.
Bioluminescence imaging for enzyme in-vivo experiments was performed using the 
IVIS 100 system.
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4 Triggered release from microcapsules
One of the main problems to solve on the way to use of microcapsules for targeted 
drug delivery is development of the release mechanisms to get the encapsulated 
substances out at the place of interest. Depending on the type of release kinetics 
one wants to achieve, different requirements are set for the release technique. One 
common feature of all  the methods used for medical  applications is the need of 
being friendly to the living body, so that the treatment itself will not lead to harmful 
consequences. The other requirement is that the method can technically be applied 
to  the  living  organism,  meaning that  the  influence  can penetrate  the  organism 
being treated. For these reasons ultrasonic and laser irradiations were selected to 
be studied as the mechanisms of triggering influence to release the encapsulated 
compounds.
Laser irradiation was performed in IR range, where the biological tissues are most 
transparent for optical radiation. This kind of influence helps to achieve opening and 
release from individual microcapsules, making it a very good system for microscopic 
studies of the processes happening. However, this advantage has a drawback of 
very limited release dynamics – it is just impossible to use focused laser beam to 
release  materials  from a  big  number  of  carriers.  This  means,  that  this  kind  of 
influence, though hardly applicable in real world for medical treatment, is a good 
model for understanding of what is happening as soon as release starts on the level 
of individual cells and capsules. Laser irradiation was used to trigger release with 
help of  aggregated gold nanoparticles and photosensitive dye,  producing singlet 
oxygen upon irradiation with light of certain wavelength.
Ultrasound presents absolutely different type of irradiation, of mechanical kind. It 
has very broad area of applications, and is already used for medical treatment and 
diagnostics.  Being  a  mechanical  in  nature,  ultrasound  application  diversity  is 
decided  by  two  main  parameters  –  power  and  frequency.  Its  main  advantage 
compared to optical and radio electromagnetic fields is that it can penetrate deep 
into the living body. This is why it was selected as another type of influence for 
studying the release from the microcapsules. The experiments performed utilized 
ultrasound  of  high  frequency  and  small  power,  which  can  be  used  for  medical 
applications. With all these advantages it is ultrasound which is the most probable 
kind of influence for real world medical applications and creating a targeted drug 
delivery system based on microcapsules, where the triggering event would be not 
the chemical environment at the place of interest, but rather an external influence.
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4.1 Ultrasound effect on microcapsules
Low frequency ultrasound (around 20 kHz) is not used in medicine except for cutting 
in dentistry. However, high frequency low power ultrasound of around 1 MHz and 
above is widely used in medicine for physiotherapy, imaging and more recently in 
focused  ultrasound  surgery.17 In  the  last  of  these  applications  high-frequency 
ultrasound at low power is passed through the body as individual beams, none of 
which cause any permanent damage but they are directed at a focus where the 
energy is much higher and can be used to kill  cells.  It  is for this reason that a 
frequency of 850 kHz was chosen for the study because it  is directly related to 
medical ultrasound of the type used in focused ultrasound surgery. Two types of 
microcapsules were used, with and without the inclusion of gold nanoparticles in the 
shell. The presence of such nanoparticles makes the capsules more sensitive to the 
stimuli and opens the way to the incorporation of a range of different nanoparticles 
to tailor the microcapsule properties. One target in the future might be the inclusion 
of magnetite so that the microcapsules could be directed by a magnetic field to the 
affected part of the body.
There have been a few publications regarding the use of ultrasound to affect the 
release of  substances from microcapsules and other containers,  but all  of  these 
have used low-frequency, high power irradiation. Such ultrasound is unsuitable for 
in-vivo applications in therapy because of the general damage to collateral tissue it 
would cause. Ideally, release from microcapsules should be triggered by using the 
equipment that is already been used for medical treatment, for example, ultrasonic 
surgery or kidney stones removal, operating at frequencies of megahertz range and 
powers  of  up  to  20  W.  There  are  also  publications  on  targeted  delivery  of 
microcapsules via blood vessels utilizing ultrasound as the directing force but in 
such applications the power used is too low to trigger drug release.154
As with all  sound transmission ultrasound passes through a medium through the 
oscillation of molecules within the medium and is mechanical in nature. In aqueous 
systems the driving force for  the chemical  and mechanical  effects of  sonication 
(sonochemistry) is acoustic cavitation. The frequency of the ultrasound dictates the 
size of the cavitation bubbles and the energy liberated on their collapse. In general 
lower frequencies of ultrasound (around 20–40 kHz) produce larger bubbles which 
collapse with greater energy and cause more mechanical damage than those at a 
higher frequency. At 20 kHz the wavelength of ultrasound in water is 7 cm and the 
bubble size according to  Minneart’s  equation is  150 mm whereas at  1 MHz the 
corresponding parameters are 1.4 mm and 3 mm, which is much closer to the size 
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of microcapsules (~3 to 5 μm). In the case of microcapsules with polymeric shells a 
further  parameter  that  can  affect  fracture  is  the  presence  of  some rigid  media 
(nanoparticles) within their soft polymeric shells. These will cause a reduction in the 
capsule elasticity and thus making them more prone to breakage during cavitation. 
The  presence  of  nanoparticles  within  a  liquid  will  also  favor  the  formation  of 
cavitation bubble nuclei  by decreasing the cavitation threshold.  In summary the 
ultrasonic release of drugs contained in such microcapsules for  in-vivo use will be 
favored by a combination of high frequency sonication coupled with the presence of 
nanoparticles in the capsule shell.
In order to investigate this, several samples of microcapsules were prepared with 
different  shell  compositions,  all  containing  encapsulated  labelled  protein.  These 
were  irradiated  at  different  power  levels  and  for  various  times.  The  effect  of 
changes  in  the  ultrasonic  parameters  on  the  capsules  was  monitored  by  the 
supernatant  fluorescence  intensity  change  (related  to  protein  release),  whilst 
morphological changes of the microcapsules were determined by scanning electron 
microscopy (SEM) and laser scanning confocal microscopy (LSCM).
This  work  was  carried  out  in  collaboration  with  Dr.  Veronica  Saez,  Dr.  Andrew 
Cobley, Dr. John Graves and Dr. Timothy Mason from Coventry University, Coventry, 
UK. They helped with irradiation of samples with high-frequency ultrasound at their 
lab  in  Coventry  University.  Main  experiments  for  detailed  data  acquisition  were 
carried  out  with  my  personal  participation  during  my  visit  to  Coventry.  Initial 
irradiation  experiments  were  carried  out  by  Dr.  John Graves.  All  the  fluorimetry 
measurements and data analysis and confocal and SEM imaging were carried out by 
me.
4.1.1 Samples preparation and characterization
Microcapsules prepared for investigations, were constructed on calcium carbonate 
microparticles,  according  to  the  procedures  described  in  Chapter  3.2.5.  RBITC-
labelled BSA was encapsulated by co-precipitation to the particles. All the samples, 
except the control, had shell structure {PAH/PSS}2/PAH/NP/PSS/PAH/PSS, where NP 
was  a  layer  of  nanoparticles.  Control  sample  was  prepared  similarly  with  shell 
structure {PAH/PSS}4. Nanoparticles used for study were synthesized 13 nm gold 
nanoparticles,  5  and  20  nm  gold  nanoparticles  purchased  from  Sigma,  and 
magnetite  nanoparticles.  Gold  and  magnetite  nanoparticles  were  synthesized 
according to protocols described in Chapter 3.2.2.
Samples with 5 and 13 nm gold nanoparticles and with magnetite nanoparticles 
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were prepared for early experiments (see Fig. 4.2).
For main investigations, 4 samples were prepared, which differed by the portion of 
gold nanoparticles (AuNP) embedded into the shells. The number of nanoparticles in 
the shells was regulated by the volume of the gold colloid suspension added while 
producing the sample, i.e. 0, 2, 4 and 8 mL (stock solution). Therefore, the number 
of nanoparticles, deposited on a single microcapsule was characterized as 0, N, 2N 
and 4N.  The  number,  standing  behind  N,  was  estimated by  counting  individual 
nanoparticles  at  scanning  transmission  electron  microscopy  (STEM)  images, 
analysing 3 images for each sample. A square grid was overlayed above the image, 
and number of nanoparticles inside several cells was counted. This figure was then 
multiplied  by  the  number  of  cells,  covering  the  microcapsule.  In  this  way  the 
number N of nanoparticles per microcapsule (nppm), for the sample with 2 mL of 
gold  colloid  stock  solution  deposited,  was  rather  roughly  estimated  to  be 
approximately  250.  However,  it's  important  to  note,  that  the  capsules  are  not 
monodisperse, and so the number of nanoparticles in a single capsule's shell differs 
depending  on  the  microcapsule  size,  and isn't  very  constant.  Nevertheless,  the 
number of nanoparticles per single capsule was estimated to be proportionally in a 
good agreement with the volumes of gold colloid dispersion, that was added while 
preparing the samples. This confirms, that all  the samples have more or less an 
equal number of microcapsules and nanoparticles distribution among them. Still, it's 
impossible to provide the exact amount of nanoparticles on a single capsule for 
every sample. Instead, it's suggest, that the samples had N, 2N and 4N nppm, with 
N somewhere about 250 nppm.
In order to rationalise statistics, 2 batches were created for each sample, resulting 
in a total of  8 dispersions. For each batch of all the samples created, cores were 
prepared by mixing 12 ml of protein solution, 12 ml of Na2CO3 and 12 ml of CaCl2 
solutions, keeping the dilution factor equal for all the samples to get comparable 
fluorimetric data. Therefore, every possible effort was taken to make all the samples 
similar in terms of microcapsules and encapsulated protein concentration.
Each sample was then diluted to get 10 separate solutions of 10 ml each, resulting 
in  a total  of  80 solutions.  This  was enough to  allow individual  sample  for  each 
power-time point  for  8 samples  (2  batches,  4 shell  structures,  plus  8 untreated 
controls).
The  concentration  of  capsules  in  the  dispersions  was  determined  using 
haemocytometer counting chambers.
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Figure 4.1: RBITC-BSA calibration curve measured by fluorimetry
4.1.2 Initial experiments
Before starting thorough investigations on the effect of high-frequency ultrasound 
on microcapsules,  some rough idea on power and time of  irradiation needed to 
release the encapsulated substances was necessary. Several types of microcapsules 
on CaCO3 cores were constructed, varying by the presence of nanoparticles in the 
shells – without nanoparticles, with 5, 13 and 20 nm gold nanoparticles, and with 10 
nm magnetite  nanoparticles.  RBITC-BSA was encapsulated by  co-precipitation to 
measure release by fluorimetry. These capsules dispersions were first irradiated at 
0.42  W/cm3 power  intensity  to  see  whether  something  happens  at  maximum 
available  power,  and  confocal  imaging  was  performed  to  see  the  effect  of 
ultrasound on the  shells  integrity,  and microcapsules  concentration  change was 
monitored by haemocytometry. Fluorimetry measurements were also performed on 
the  samples  to  determine whether  encapsulated RBITC-BSA is  released into  the 
solution after irradiation.
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Effect of ultrasonication on the microcapsules concentration can be seen in Fig. 4.2. 
It can be seen, that the decrease is more or less the same almost for all the types of 
nanoparticles, embedded into the shells, excluding the 13 nm synthesized in the lab 
nanoparticles, which demonstrated significantly lower decrease in concentration.
Together with the concentration change, fluorescence raise, caused by free RBITC-
BSA was measured. The results are presented in Fig.  4.3a. The data was obtained 
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Figure 4.3: Supernatant fluorescence change upon irradiation: a) immediately after  
ultrasonication, b) after sedimentation.
Figure 4.2: Effect of 10 min 850 kHz ultrasound irradiation at 0.42 W/mL. Optical  
microscope images of microcapsules dispersion before (a) and after (b) irradiation;  
microcapsules with shells of various types concentration change upon irradiation (c).
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after sedimentation of the microcapsules by centrifugation, as the solutions before 
sedimentation produced very high and unstable readings. Interesting feature of the 
effect of the sedimentation can be seen in Fig.  4.3b, which shows the decrease of 
fluorescence after sedimentation of capsules and their ruptures. It can be seen, that 
for treated samples this decrease is several fold higher. This can be explained by 
the presence of small shell ruptures with attached RBITC-BSA in the dispersions of 
treated capsules, which increase the fluorescence signal.
Then, initial fluorimetry investigations were carried out to determine the necessary 
power and time of irradiation (Fig.  4.4). These experiments included irradiation of 
the dispersion, and measuring the supernatant fluorescence at several time points, 
for different powers applied. It was found, that the release (fluorescence increase) 
takes place at different time for different power and sample composition (with or 
without nanoparticles in the shells). Based on these results power and time values 
were chosen for more thorough investigations.
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4.1.3 Effect of power and time of 850 kHz ultrasound irradiation
The effect of ultrasonic irradiation on protein release from the polyelectrolyte based 
capsules was studied by varying parameters such as time and power of irradiation 
along with the different portion of gold nanoparticles in between the layers.
Figure 4.5 shows the change of microcapsules appearance under confocal and SEM 
microscopes  irradiation.  In  the  LSCM  images  (Fig.  4.5,  top)  the  microcapsules 
appear as bright red circles, which means, that most of the encapsulated labelled 
protein is captured by the inner side of the shell, which is usual for microcapsules on 
CaCO3 cores.96,153 Significant  change  can be  seen in  the  images after  ultrasonic 
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Figure 4.4: Supernatant fluorescence increase with time after irradiation of  
microcapsules at different power for samples with 20 nm particles 2N nppm 
(a,b,c) and sample without nanoparticles (d) in shell. a) 1.4 W, b) 2.25 W, c) 3.19  
W, d) 3.19 W no nanoparticles. No errorbars present as single experiments were  
performed. Data shown in this graphs was generated by Veronica Saez (Coventry  
University), as part of our collaboration.
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treatment. Some ruptures and ruptured microcapsules are evident in the confocal 
microscope images, and their number grows with the power and time of treatment.
The  microcapsules  were  not  very  mono-disperse,  which  is  typical  for  CaCO3 
cores.96,115 It is clear from the SEM images, that larger capsules are more sensitive to 
ultrasonic irradiation as they tend to become ruptured at lower powers and shorter 
times. The confocal image indicates microcapsules of very different size, which is 
mostly because microcapsules lie in  different Z-planes, and their Z cross-sections 
will therefore have different diameters.
In  general,  the  appearance of  the  microcapsules  changed after  irradiation,  and, 
perhaps  not  surprisingly,  this  effect  was  most  significant  at  higher  powers  and 
longer treatment times, reaching a point (10 min in Fig.  4.5), where a significant 
number of microcapsules are ruptured. Since the dilution was kept the same for all 
the  samples,  a  significant  decrease  in  the  microcapsules  concentration  after 
treatment was observed. Measured by hemocytometry, the concentration of intact 
microcapsules was found to be 2-3 times (and up to 10, as observed during prior 
investigations with 1 hour irradiation times) lower after 10 min of treatment at 3.19 
W at 850 kHz.
Fluorimetric  investigations  were  carried  out  in  order  to  estimate  the  amount  of 
protein released from the microcapsules.  The fluorescence of supernatant,  taken 
from  centrifuged  microcapsules  dispersions,  was  measured.  As  it  has  been 
102
Figure 4.5: LSCM (top) and SEM (bottom) images of microcapsules before and after 1,  
5 and 10 min of 3.19 W ultrasonic irradiation at 850 kHz.
4 Triggered release from microcapsules
previously  reported,215 the microcapsules loose some small  part  of  encapsulated 
species even without any treatment due to defects in their structure. For this reason 
non-zero  fluorescence  in  the  supernatant  of  untreated  dispersions  must  be 
determined. By measuring the fluorescence increase after treatment, the portion of 
released protein can be also calculated.
Results  of  the fluorimetry  measurements for  samples without  (a)  and with least 
concentration  of  20  nm  gold  nanoparticles  (b)  are  presented  at  Fig.  4.6.  The 
increase in fluorescence is calculated by taking the fluorescence measurement after 
treatment and dividing this by its value before sonication.
For all the samples, the character of the change in fluorescence is almost the same: 
fluorescence increases with power and time of irradiation. 
There  is  also  a  dependence  on  the  applied  power,  with  a  significant  difference 
between the lower powers and maximum power of 3.19 W. This implies, that there 
is a lower power limit below which almost no release happens from microcapsules in 
a reasonable time. On the other hand, 0.319 W·cm-3 power intensity at 850 kHz is 
enough to observe significant fluorescence increase.
It  should  also  be  mentioned,  that  while  fluorescence  (i.e.,  release  efficiency) 
increases  much  above  linear  with  time,  the  decrease  of  microcapsules  number 
doesn't.  This  suggests,  that  effect  of  high-frequency  ultrasound  on  the 
microcapsules is based not only on rupturing of the capsules' shells, but also on 
making them penetrable for encapsulated protein.
During initial investigations, the dependence of fluorescence increase on irradiation 
time at different powers was studied. This work demonstrated that fluorescence was 
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Figure 4.6: Supernatant fluorescence change after microcapsules irradiation (FN/F0):  
a) no nanoparticles, b) 20 nm nanoparticles, portion of N nppm.
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almost constant after 5 minutes of irradiation at 3.19 W at 850 kHz for 2N nppm 
sample. For 2.25 W fluorescence stops increasing after 7 minutes. For this reason 10 
minutes was selected for more thorough research as maximum treatment time.
From  fluorimetry  measurements  results,  concentration  of  protein  in  the 
supernatants  can  be  calculated,  using  calibration  curve  for  labelled  protein 
measured at known concentrations. This allows for the calculations of the actual 
amount  of  protein  released.  If  the  initial  concentration  of  protein  at  the  cores 
preparation step is known to be 1.75 mg/mL, and its volume is 12 ml, then it can be 
said, that 16.8 mg of RBITC-BSA was totally encapsulated in each sample. Taking 
into account the fact,  that not all  the protein stayed inside during the capsules 
preparation process, and estimating encapsulation efficiency to be 80%, according 
to our experience, the portion of released protein can be calculated and related to 
its initial amount. So, for N nppm, after 10 min treatment at 3.19 W 850 kHz, 20% of 
initial protein amount was released into supernatant.
Still,  measured as  supernatant  fluorescence raise,  efficiency of  release is  lower, 
than the real one should be. This is because much of protein is adsorbed to the 
shells from inner side of the capsules and remains trapped there even when the 
capsule is totally destroyed as can be clearly seen from LSCM images. The debris 
from the  capsules  are  stained with  red  fluorescence  indicating  the  presence  of 
protein. Therefore, some considerable part of labelled protein is excluded from the 
supernatant fluorescence increase, although it has in fact been released.
To determine, how much of the encapsulated protein was really released, one more 
experiment was carried out.  Two more samples of microcapsules were prepared, 
using  the  same  protocol  and  dilution  factors  as  described  for  the  previous 
experiments. The samples (one of them with, and the other without 20 nm gold 
nanoparticles in the shell, 2 experiments for each sample) were exposed to 20 kHz 
70 W conventional  probe ultrasonic  irradiation  for  1  min.  The  parameters  were 
chosen to make it comparable to the data obtained in previously published results.
The  fluorescence  was  measured  before  and  after  irradiation  to  determine  the 
increase due to protein release. The measurements showed (Fig.  4.6), that high-
power  20  kHz  ultrasonic  treatment  releases  a  maximum  of  three  times  than 
obtained when using a sonication time of 10 min at 3.19 W 850 kHz ultrasound. 
High-power  ultrasound  also  demonstrates  the  dependence  of  the  effect  of 
sonication on microcapsules shell structure. The efficiency of protein release from 
the microcapsules with nanoparticles in the shells (all the other parameters being 
equal) was more than doubled. However, compared to the most efficient conditions 
104
4 Triggered release from microcapsules
using  low  power  high-frequency  ultrasound  and  utilizing  a  shell  structure  with 
nanoparticles, 70 W at 20 kHz was only 1.6 times more efficient. Furthermore, it 
might  be expected,  that high-power ultrasound will  remove more of  the protein 
trapped on  the  inside  of  the  shell,  causing  the  release efficiency  to  apparently 
increase.
4.1.4 Effect of nanoparticles portion
Several  different  microcapsules  dispersions  were  prepared,  that  had  various 
amounts nanoparticles embedded into their shells. This enabled the study of the 
effect of nanoparticles in the shells on protein release, as previous work had shown 
such a relationship when using high-power low-frequency ultrasound for release.155 
This  effect  could  be  related  to  shell  rigidity,  which  is  affected  by  presence  of 
nanoparticles in it. STEM image of a capsule from 4N nppm sample is shown in Fig. 
4.7a. Comparison of the fluorescence measurements results is shown in Fig.  4.7b. 
An  increase  in  fluorescence  is  seen  for  all  the  powers  and  all  portions  of 
nanoparticles  in  the  shells.  The  results  obtained  utilizing  the  20  kHz  70  W 
ultrasound probe irradiation and the most effective N nppm sample are shown for 
comparison, as these were previously found to be the most efficient for release. It 
can be seen, that every curve has a peak, suggesting, that release is most efficient 
for some specific amount of nanoparticles. For low powers this amount seems to be 
bigger, than for 3.19 W.
Mechanical  properties  of  microcapsules  shells  were  shown  to  depend  on  the 
presence and portion of nanoparticles in their shells. However, this dependence is 
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Figure 4.7: a) STEM image of a 4N nppm microcapsule; b) fluorescence raise  
dependence on nanoparticles portion in microcapsules shells.
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not uniform. Thus, Young's modulus, characterizing the shell stiffness, was shown to 
increase with addition of YF3 nanoparticles156 whereas in others12 it is shown to 
non-linearly decrease with the portion of ZnO nanoparticles. This proposes some 
rather complicated character of changes, happening in structure of the shells.
It is obvious, that the presence of nanoparticles enhance the release rate. However, 
the question of the number of particles is not straightforward. In this work it is the 
release that was actually monitored, not the rupturing and breakage. The release 
most probably happens through the small pores, that open when the microcapsules 
are irradiated. However, these pores at initial stages can be very small, since they 
cannot be observed in SEM images corresponding to short durations of irradiation. 
Moreover, small pores should “heal” themselves almost immediately after the strain 
is released, due to the presence of charged molecules in shell cross-section near the 
ruptures,  that  would  stitch  these  small  holes.  When  the  ruptures  are  formed 
repetitively during many cycles of oscillations, they probably get bigger and cannot 
heal evenly by electrostatic forces, therefore constant holes are formed. The fact, 
that  the  release  efficiency  changes  not  monotonously  with  the  portion  of 
nanoparticles embedded,  suggests  the existence of  some optimum, where least 
power is needed to release encapsulated cargo. This hypothesis is supported by 
existence  of  maximum of  release  for  lower  powers,  but  at  different  portion  of 
nanoparticles (Fig.  4.7b). Therefore, there is an optimum of nanoparticles portion, 
depending on the intensity of the ultrasound applied.
Somewhat  similar  results  were  obtained  earlier,155 where  time  to  breakage  was 
longer for the samples with more layers of nanoparticles. The authors of that paper 
propose, that it happens due to more even distribution of nanoparticles inside the 
polyelectrolytic shells.
Several factors that can play a role in the process could be proposed. The presence 
of  nanoparticles  in  the  shells  makes  the  shells  more  heavy,  which  can  have 
influence on how easily are the shells moved upon applying oscillating force to them 
(cavitation,  ultrasonic  wave propagation causing local  pressure changes).  It  is  a 
balance of mechanical rigidity and the weight of shells, which are to be moved, that 
governs the rupturing, as we believe. Then, the capsules are heated when being 
exposed  to  the  ultrasound  due  to  the  absorption  of  energy  of  ultrasound.  The 
nanoparticles,  having  the  thermal  capacity  much  higher,  than  the  one  of 
surrounding polymers, can behave as centres, consuming the heat, preventing fast 
warming  up  of  the  polymers,  which  can  also  slow  down  the  release,  as  the 
temperature-driven changes in shells structure would not happen rapidly.
106
4 Triggered release from microcapsules
4.1.5 Microcapsules concentration change upon irradiation
During  initial  research,  the  concentration  change  was  investigated  by 
haemocytometry. Figure 4.8 shows the microcapsules concentration dependence on 
time of ultrasonication at 0.319 W/mL power intensity. LSCM and SEM and optical 
microscopy pictures show even more small  ruptures of  the microcapsules shells 
after  such  a  long  period  of  treatment.  Therefore,  even  relatively  small  power, 
applied for a long time, can make almost all (90%) microcapsules break into small 
pieces.
When several samples were studied, with different nanoparticles embedded into the 
shells, concentration decrease was found not to depend much on portion or size (20 
nm and 5 nm nanoparticles compared) of nanoparticles. However, surprisingly this 
was almost the same for the sample without nanoparticles. At the same time, the 
release, as measured by fluorimetry, was still higher for samples with nanoparticles 
in the shells.
Figure 4.8: Microcapsules concentration change 
after 3.19 W 850 kHz ultrasonic irradiation.
The decrease in microcapsules concentration after 10 minutes of irradiation was 
never  more  than  3  times  and  if  the  data  on  fluorescence  is  also  considered 
(particularly the fact that it becomes constant after 10 minutes of sonication) then it 
can be stated, that ultrasound appears to “thin” the shells or makes them more 
porous. The absence of an increase in fluorescence after a given time, coupled with 
the continuous increase of destroyed microcapsules portion after it suggests, that 
all of the protein, which was able to dissolve in dispersion, is released before the 
capsules were totally broken. This has some analogy with laser-stimulated release.99
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4.1.6 Conclusions
In this study the feasibility of releasing encapsulated protein from polyelectrolyte 
multilayer  microcapsules  by  ultrasound  irradiation  at  power  and  frequency 
applicable  in  current  medical  practise  has  been  demonstrated.  The  release 
efficiency (i.e., the amount of protein in the supernatant after irradiation) was found 
to depend on the nanoparticles portion in microcapsules' shells. It has been shown, 
that the presence of nanoparticles inside the shells can make release more than 4 
times  more  effective,  releasing  1/3  of  initially  encapsulated  protein  into  the 
supernatant. As the number of ruptured capsules doesn't seem to grow as fast as 
the release with the time of sonication, it is concluded, that the release takes place 
even when capsules are not visually ruptured and have therefore become more 
permeable due to defects in the polyelectrolyte multilayers. At the same time, a 
substantial portion of the capsules population was found to be ruptured and broken, 
as seen by confocal microscopy and SEM. This suggests, that inner surface of their 
shells,  containing adsorbed protein,  became exposed to environment,  promoting 
further release.
Thus, polyelectrolyte multilayer capsules represent a viable drug delivery systems 
which  allow  encapsulation  of  proteins  and  other  biologically  active  compounds. 
These  could  possibly  be  navigated  in  a  magnetic  field  due  to  the  presence  of 
appropriate nanoparticles within the shell, and encapsulated substances could then 
be released remotely. These capsules can be engineered in biocompatible way as 
reported  in  cell  level  and  in  animal  study.  Herewith,  organism  friendly  use  of 
external triggering for protein release is illustrated.
High-frequency ultrasound, in contrast with low-frequency one, has the advantage 
of  focusing  capability,  so  that  the  microcapsules  can  be  exposed  to  irradiation 
exactly  at  point  of  interest,  with  minimum  side  effects.  Also,  tissues  are  only 
exposed to relatively high irradiation at the focus point only. In comparison with 
other excitation mechanisms (laser, for example, even in IR range), high-frequency 
ultrasound has  much deeper  penetration  (unless  obstructed by  bones)  and this 
could  therefore  expand  the  areas  of  remote  drug  release  comparable  to  light 
irradiation.
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4.2 Intracellular laser-induced release from microcapsules,  
functionalized with Au nanoparticles
Intracellular  trafficking  is  an  important  functionality  of  living  creells  and  living 
organisms. A number of interrelated processes take place providing vital functions 
of  living  cells.  Recently,  intracellular  delivery  and  controlled  release  of  small 
peptides (SIINFEKL), which binds to the MHC Class I  proteins, presumably in the 
erythrocytic reticulum, forming the complex was reported by collaborators.216 The 
complex  was  then  observed  to  presenting  at  the  cells  surface  –  an  important 
condition  in  immunology  for  T-cells  activation  and attack  of  infected  cells.  This 
knowledge is of fundamental importance to immunology. In regard to neuroscience, 
intracellular  delivery  and  transport  can  reveal  important  information  on  neuron 
activity. Neuron activity both triggered and spontaneous is a very intense field of 
research  also.  Currently,  neuron  activity  internally  is  generally  triggered  using 
perfusion  micropipette  systems217 which  can  be  rather  elaborate,  necessarily 
requires damage to cell membrane and can also lead to leakage of solution into 
extracellular  environment.  However,  it’s  desirable to be able to load material  of 
interest  with as little  interference to  cell  activity  as possible  and to release the 
material  with  high precision both in  terms of  amount and also spatially  without 
damage to the cell membrane.
A study of uptake by neurons of polyelectrolyte microcapsules with subsequence 
intracellular release of a model substance (dextran molecules) was carried out. The 
uptake  of  microcapsules  was  confirmed  by  confocal  and  electron  microscopy. 
Dextran release was carried out using an infra-red laser radiation. Furthermore, it 
was interesting to observe microcapsules, made of biocompatible polymers, inside 
the cells. Separate experiments were carried out in order to study their behaviour.
This work was carried out together with Dr. André G. Skirtach (Max-Planck Institute 
of  Colloids  and  Interfaces,  Potsdam,  Germany),  Dr.  Andrei  V.  Sepelkin,  Xinyue 
Huang, Ken P'ng (Queen Mary, University of London, UK). SEM imaging of CaCO3 
particles  internalization was performed by Xinyue Huang,  a  Master's  student  by 
supervision of  Dr.  Andrei  V.  Sapelkin,  with help of Ken P'ng, Nanovision electron 
microscopy centre at Mile End campus of Queen Mary, University of London staff. 
Triggered release experiments were performed under supervision of Dr. André G. 
Skirtach.
4.2.1 Samples preparation
For  release  experiments,  silica-templated  {PDDA/PSS}4 microcapsules  with  pre-
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aggregated Au nanoparticles inside the 5th layer were prepared. TRITC-dextran was 
encapsulated by heat-shrinkage.  For observation of  biodegradable microcapsules 
inside the cells, CaCO3 based microcapsules with {PLA/DS}4 were prepared, with 
TRITC-PLA instead of PLA for the 5th layer to make it  visible in confocal images. 
Microcapsules of  both types were prepared according to  procedure  described in 
Chapter 3.2.3.
Before introducing the capsules to the cells, the microcapsules were redispersed in 
cell medium (1% FBS). The capsules were introduced to the cells in the evening and 
left overnight to perform release experiments next day.
Fig.  4.9a  shows  TEM  image  of  prepared  hollow  synthetic  capsules  before 
encapsulation  of  dextran.  Fig.  4.9b  shows  LSCM  image  of  filled  synthetic 
microcapsules.  It  can be seen from LSCM image,  that most  part  of  the labelled 
dextran is stuck to the shells surfaces. It happens because of using relatively low 
molecular weight protein, as debris were formed when using high-molecular weight 
dextran.  These  debris  become an issue  when  observing  capsules  together  with 
cells, though they don't when one only needs microcapsules imaging. Dark spots on 
bright red circles of the shells correspond to the gold nanoparticles aggregates.
Figure 4.9: Synthetic microcapsules images: a) TEM, empty capsules, b) LSCM,  
after TRITC-dextran encapsulation by heat-shrinking.
The fact that most of the labelled protein is sitting on the shell is also ascribed to 
the charge of the TRITC dye, which interacts with the polyelectrolytes in the shells. 
To assure this is the case, the AF488 dextran was encapsulated by exactly the same 
procedure. The LSCM images of the microcapsules with TRITC and AF488 dextrans, 
encapsulated in the same batch, are presented in Fig. 4.10. As it can be seen from 
the picture, the AF-488 capsules are evenly filled with fluoresceing media, whereas 
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TRITC-dextran are not. From this we conclude, that attraction of TRITC-dextran to 
the shells is caused not by experimental  errors or any impurities,  but rather by 
electrostatic effects.
Figure 4.10: LSCM images of a) Alexa-Fluor 488 and b) TRITC-dextran filled capsules.
4.2.2 Uptake of microcapsules into the cells
Schematic of the intake process is described shortly in Fig.  4.11a. The uptake and 
internalisation of capsules by the cells was confirmed by SEM, light and confocal 
microscopy. It was found that capsules are confined to the soma of a cell and in 
some cases are also found in axon hillock. Presence of the capsules does not seem 
to affect cell viability on the time scale of our experiments (24-48 hrs).
Figure 4.11: a) schematics of laser-induced release from synthetic microcapsules,  
b) schematics of experiment with biodegradable microcapsules, c) LSCM image  
(overlay) of a microcapsule inside the cell.
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In order to confirm capsules intake by cells  by means of  SEM, cells were given 
CaCO3 particles with polymeric shells, similar to those of microcapsules described. 
Having the  core,  those particles  are  rigid,  and well  seen in  SEM images.  Being 
internalized by cells, the particles form embossments, as the cells by themselves 
are not very high. Fig. 4.12a shows SEM images, demonstrating the cell with particle 
inside. Fig.  4.12b shows the same place after ion beam etching. In the Fig.  4.12c, 
the close-up of Fig.  4.12b, cross-section of CaCO3 core is well seen, demonstrating 
characteristic porous structure96 of the core. Therefore, it was shown, that the cells 
can internalize relatively big (3-5 μm) and, mostly important, rigid objects.
When hollow capsules were introduced to cells, the latter tended to internalize as 
many capsules, as they could reach. 
One other method of intake confirmation was use of LSCM with stained cytosol and 
labelled  microcapsules.  For  this,  the  cells  were  given  the  microcapsules  for 
overnight,  then fixed using glutaraldehyde (giving the same sample  preparation 
protocol as for the SEM investigations), and then fixed cells cytosol was stained with 
1  mg/mL  solution  of  DiOC18(3)  dye  in  ethanol.  After  staining  the  sample  was 
analysed under LSCM microscope. The results are presented in Fig. 4.13.
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Figure 4.12: SEM images of particle inside B50 cell: a) a bulge on a cell, b) this bulge  
lanced by ion beam etching. c) close-up of b), clearly demonstrating porous CaCO3 
core. Images obtained by Xinyue Huang, a Master's student by supervision of Dr.  
Andrei V. Sapelkin, with help of Ken P'ng, Nanovision electron microscopy centre.
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4.2.3 Intracellular laser-induced release
Experiments, regarding release from microcapsules, were performed with dextran 
filled  microcapsules,  by  irradiating  them  inside  the  cells  with  IR  laser.  The 
advantage of this approach is that cell membranes are largely unaffected by the 
wavelength  we used in  our  experiments  while  the  absorption  spectrum of  gold 
nanoparticles embedded into the shells is tuned to this region. As a result we were 
able to open microcapsules without damage to the cell  walls, once adjusted the 
beam power.
Figure 4.14: Cell membrane form change after laser treatment.
If the time or power of irradiation was too high, the capsule exploded inside the cell,  
forming a gas bubble, due to overheating. Obviously, such events influence the cell, 
causing consequences from a very slight membrane change (Fig.  4.14) to almost 
immediate cell death, depending on the scale of overheating.
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Figure 4.13: LSCM image of microcapsules in fixed cell with labelled cytosol. a)  
overlay of transmission and dyes channels, b) TRITC channel (microcapsule label) c)  
DiOC18(3) channel (cytosol stain).
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The LSCM image of a capsule inside the cell is presented in Fig.  4.11c. Images of 
cells  with  irradiated  capsules  are  presented  in  Fig.  4.15.  One  can  see  dextran 
flowing out from the capsule. While dextran is spreading rather uniformly in Fig. 
4.15a, in Fig.  4.15b thin spring of fluorescing dextran is formed, obviously, along 
some cell's  filament,  which is  quite interesting.  More importantly,  the release is 
localised and there is no leakage of dye into extracellular environment.
Figure 4.15: LSCM images of a cell with capsule inside after laser treatment: a), b)  
rather immediately after irradiation, c) 4 hours after irradiation.
The way the dextran is floating from the microcapsules seems to depend on the 
power and time of irradiation, caused the release. For more explosive-like opening 
of the capsules, when higher laser power was applied, the dextran is rapidly spread 
inside  the  capsule  (as  in  Fig.  4.15b).  As  time  passes,  the  dextran  is  spreading 
further, to be found almost in the whole cell (Fig. 4.15c).
4.2.4 Observing biocompatible microcapsules inside the cells
CaCO3 templates  were chosen for  constructing microcapsules,  as they are more 
biocompatible-like, than SiO2, demanding HF to dissolve. Encapsulated FITC-labelled 
dextran was meant to show what happens to the capsules with biodegradable shells 
inside  the  cells.  Microcapsules  were  introduced  to  the  cells  the  same  way,  as 
described above. To one sample the capsules were introduced in the eve, to the 
other – in the morning of observations day. Once started imaging, the dishes were 
kept inside microscope incubated cage, allowing the cells to leave for several hours 
without  enough amount  of  CO2.  By doing that,  we could observe microcapsules 
behaviour  for  about  20  hours  in  the  same  sample.  However,  as  the  cells  are 
gradually dying and changing their form, despite taking all the possible precautions, 
we could not picture the same cells for all time checks. Other series of experiments 
was performed, where the cells were monitored every 12 hour for total 72 hours. 
The flasks with cells were kept in the incubator between the observations.
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Fig.  4.16 shows LSCM images of  microcapsules  in  the  cells,  as  time goes.  First 
microcapsules  inside  cells  can  be  seen  after  about  4  hours  since  they  were 
introduced. After that, intake progresses steadily. However, not all the cells, having 
microcapsules  in  the  nearest  neighbourhood,  do  internalize  them even after  20 
hours of incubating (Fig. 4.16e). Also, it may be stated, that intake was not so active 
(especially, taking into account, that the number of introduced microcapsules far 
exceeded that in experiments with the synthetic ones).
Figure 4.16: LSCM images of biodegradable capsules in B50 cells: a) capsules, b) 4  
hr, c) 16 hr, d,e) 20 hr, f) 36 hr. Green is for FITC-dextran (cargo), red – for RBITC-
PLA (shells).  Dotted line designates cell margins. Position e) shows, that not all the  
cells having microcapsules in neighbourhood, internalize them.
Intensity of fluorescence inside the cells tends to raise with time and is more for 
ones,  that  have  internalized  microcapsules  (Fig.  4.16c,d).  We  suggest,  that  this 
happens as FITC-dextran from microcapsules is captured by the cells. Internalized 
microcapsules  tend  to  loose  green  fluorescence  (FITC)  with  time,  which  also 
proposes, that the dextran is leaking out from the capsules. Yellowish colour in the 
images  corresponds  to  the  areas  where  green  (FITC)  and  red  (TRITC)  channels 
overlap. This means, that some part of labelled PLA gets dispersed in the cytoplasm 
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as the shells degrade. Images are obtained using the same amplification settings, 
therefore  increase  of  fluorescence  intensity  evidences  increase  in  released 
substances concentration. The fact, that mostly red colour is seen in the capsules 
themselves can be explained by adsorption of dextran to the shells of microcapsules 
from inside, as explained for synthetic microcapsules in Fig. 4.10, therefore in these 
areas the signal from FITC-dextran is masked by more strong signal of TRITC.
However, after a certain time the intensity of the fluorescence inside the cells starts 
to decrease (see Fig.  4.17). This may be due to the bleaching of the FITC- label or 
consumption of the released dextran by the cells. It is also worth noting, that even 
after 72 hours, microcapsules and their ruptures could still be found in the cells, 
though much faded. This can give an idea on how rapidly the cells degrade the 
PLA/DS shells of the microcapsules. Another fact is that the cells survived rather a 
long period of time with the capsules inside, though no special arrangements were 
performed to minimize the risk of bacterial contamination, which brings us to the 
fact that the microcapsules made from biodegradable polymers are not toxic to the 
cells.
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Figure 4.17: LSCM images of B50 cells with biodegradable capsules after 72 hours of  
incubation. Top images show FITC channel from microcapsules cargo (FITC-dextran),  
whereas bottom ones are transmission images taken from the respective regions.
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4.2.5 Intracellular laser-induced release of pH-sensitive 
substances
SNARF  is  a  fluorescent  ratiometric  probe  that  allows  for  pH  quantification 
independently of probe concentration and/or laser intensity. As a dual-emission pH 
indicator, SNARF changes its fluorescence spectrum from yellow to red when the 
ambient  pH  changes  from  acidic  to  alkaline  (pKa  ~  7.5).  The  ratio  of  the 
fluorescence intensities from the dye at two emission wavelengths, typically 580 nm 
and  640  nm  depends  on  pH.  Thus,  the  ratio  of  intensities  obtained  at  both 
wavelengths provides a quantitative determination of pH.
Following  the  results,  reported  by  Kreft  et  al,194 a  series  of  experiments  were 
undertaken on intracellular  release of  encapsulated SNARF-labelled dextran.  The 
idea was to observe fluorescence spectrum change due to change of pH as the 
dextran travels inside the cells. Upon internalization, microcapsules find themselves 
inside  endosomes,  which  can  be  thought  of  as  small  cell  membranes.  The 
distinctive  feature  of  the  endosomes  is  pH  level  inside  them,  which  is  acidic 
compared to the cytosol. This is why SNARF is supposed to change fluorescence 
from red to green upon entering the cell and reverse interchange in colour when it is 
released from the microcapsule to the cytosol through endosome breakage.
Release was achieved by IR laser  irradiation,  using microcapsules functionalized 
with pre-aggregated gold nanoparticles, similarly to what was described in Chapter 
5.2.3. Two types of SNARF-dextran were utilized – with molecular weights of 10 and 
70 kDa. Microcapsules were resuspended in cell culturing medium and introduced to 
the cells flask by pipetting and left overnight to let the cells internalize the capsules. 
On the next day, the capsules inside the cells were irradiated with 840 nm IR laser 
to  release the encapsulated material  into  the  cytosol.  After  that,  the cells  were 
observed with confocal microscope to see any changes in fluorescence spectra of 
the capsules load.
In general, the observation of released fluorescent cargo into the cellular cytosol 
turned out to be challenging. Rather low concentration of released cargo into the 
cytosol compared to the high concentration which was still inside the capsules after 
capsule opening resulted from two effects a) the volume of the cytosol  is much 
bigger than the volume of a capsule and thus the cargo in the cytosol is diluted and, 
b) the capsules were not completely emptied after their wall disruption. The nature 
of capsules produced by template CaCO3 particles is quite well known. It has to be 
taken into account that a matrix of polyelectrolytes is formed due to the porosity of 
the calcium carbonate (pores have sizes about 35 nm).96 Therefore, this charged 
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matrix is likely able to interact with the cargo inside the cavity of a capsule and thus 
traps cargo inside after the light triggered disruption of the capsule. However, non-
complete release of cargo in-vitro has been observed in different systems such as 
capsules made with SiO2 template or  biodegradable capsules.10,197,216 In fact  it  is 
difficult to quantify the amount of released cargo.159,197 As a result of the different 
concentrations  of  cargo  in  the  capsules  and  the  cytosol  images  where  the 
fluorescence emission of  the  capsule is  saturated are necessary to  observe the 
cargo that has been released into the cytosol. In this context imaging release with 
confocal laser microscopy is particularly convenient compared to classical wide field 
fluorescence  microscopy.  A  high  laser  intensity  joint  with  an  increased  pinhole 
diameter and electronic gain available in the system facilitated the observation of 
the delivered fluorescent cargo. Herein the increased pinhole enlarged the thickness 
of the observed probe layer. Increasing the laser intensity and gain volume caused 
increased  fluorescence  emission  and  higher  detection  thresholds.  Nevertheless, 
overexposure of the dye-enriched capsules and increased background signals were 
the handicap results in this proceeding.
4.2.5.1 70 kDa SNARF-dextran release
For  this  set  of  experiments,  silica-based  microcapsules  were  used  with  shells 
structure  PDADMAC/PSS/PDADMAC/AuNP/PSS/PDADMAC/PSS,  prepared  following 
procedures described in Chapter 3.2.5. Gold nanoparticles (20 nm, Sigma) solution 
was mixed with 1 M NaCl at 1:1 proportion before adsorption to shift the plasmon 
resonance band to IR region. The cores were dissolved with HF after completion of 
LbL assembly and washed with water until pH of supernatants reached 6. Following 
that, 70 kDa SNARF-dextran was encapsulated by heat-shrinking. For this, capsules 
were incubated in 1 mg/mL solution of  SNARF-dextran for  20 minutes  and then 
heated at 65 °C for 15 minutes. After that, the capsules were washed 3 times with 
water to remove excess dextran.
B50 and 293T cells  were used for  the experiments.  Started with B50 cells,  but 
during confocal imaging, autofluorescence of the cells was observed. It was not an 
issue during the experiments with TRITC-dextran release due to higher intensity of 
TRITC fluorescence and shorter spectra band used for visualization. However, with 
SNARF-dextran, it became a problem, masking the fluorescence from dextran. This 
is why cells were changed to 293T, which solved the problem (Fig. 4.18).
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Capsules were redispersed in cell culturing medium and introduced to cells. After 
overnight incubation, the capsules were irradiated inside the cells with 840 nm IR 
laser focused with 100x microscope lens at power of ~50 mW. Following irradiation, 
confocal imaging was performed. Confocal images showing cells after irradiation are 
presented in Fig.  4.19. Release of material can be clearly seen in these images. 
However,  fluorescence spectra did not change accordingly to position of SNARF-
dextran. 
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Figure 4.18: LSCM images showing autofluorescence in B50 cells. Overlays of red and 
green channels (top) and transmission images (bottom).
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Figure 4.19: LSCM images, showing laser-triggered intracellular SNARF-dextran  
release in 293T cells. Images given in pairs, as overlays of green and red channels  
above transmission images.
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Even the capsules that were not irradiated, did not show any consistent behaviour 
in terms of their containment fluorescence spectra.  LSCM images of capsules in 
different locations (and even without cells) are presented in Fig.  4.20. It  can be 
seen, that some capsules appear to be red, while others are green, besides the fact 
that all of them should be at the same environmental conditions, i.e. pH level. This 
is a very strange fact.
As the fluorescence spectra did not change consistently with the position of the 
capsules  regarding  the  cells,  it  was  decided  to  see  whether  the  capsules  (i.e. 
SNARF-dextran) will change their fluorescence spectra when immersed into a buffer 
with  given  pH  level.  Confocal  imaging  of  capsules  dispersed  in  buffers  with 
controlled acidity (pH 4, 7, 9) did not show any changes in encapsulated SNARF 
fluorescence spectra..
From all the described observation it can be stated, that SNARF-dextran is released 
from the microcapsules inside the cells.  However,  there are some difficulties.  At 
first,  being of rather high molecular weight (70 kDa) this dextran is much more 
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Figure 4.20: LSCM images of capsules with 70 kDa SNARF-dextran. Overlays of red  
and green channels are shown above corresponding transmission images.
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difficult to be released. This is confirmed by the fact that after 30 minutes after 
irradiation it was not easy to find the spot of irradiation, as the leakage of dextran 
from  microcapsules  was  very  slow  and  thin,  which  contrasts  with  what  was 
observed in experiments with TRITC-dextran (4 kDa) and experiments with 10 kDa 
SNARF-dextran, where it tended to fill rather evenly entire cell cytosol after a short 
period  of  time.  It  especially  contrasts  with  10  kDa  SNARF-dextran  as  those 
experiments were performed with other type of microcapsules – based on calcium 
carbonate, which is known to produce thicker shells, so it should be less easy for 
macromolecules to leave the cavity through the ruptures in the shell.
Strange thing is that the dye does not change its fluorescence colour with pH of the 
environment it is immersed into. This is most probably caused by the characteristics 
of particular batch of the chemical obtained from Invitrogen.
4.2.5.2 10 kDa SNARF-dextran release
This work was performed by Susana Carregal-Romero, Markus Ochs, Pilar Rivera-Gil, 
Carolin Ganas and  Wolfgang J.  Parak (Fachbereich Physik and Wissenschaftliches 
Zentrum  für  Materialwissenschaften,  Philipps  Universität  Marburg,  Marburg, 
Germany) as a part of our scientific groups collaboration.
Experiments were performed with human lung carcinoma A549 and SH-SY5Y neuron 
cells using 10 kDa SNARF-dextran. SNARF–dextran was post-loaded due to the small 
size  and  the  thermal  stability  of  the  molecules.  Average  diameter  of  the 
microparticles ranged from 2.5 to 3.5 µm. Microcapsules shells were prepared by 
alternate deposition of PSS and PAH from 2 mg/mL solutions in 0.5 M NaCl. After 
self-assembly  of  two  bilayers  of  polyelectrolytes  {PSS/PAH}2,  gold  nanoparticles 
aggregates were embedded into the shells. Gold nanoparticles were pre-aggregated 
by  mixing  with  NaCl  (0.5M)  shortly  prior  to  adsorption.  Two  more  bilayers  of 
polyelectrolytes were sedimented on top of nanoparticles, yielding in shell structure 
{PSS/PAH}2/AuNP/{PAH/PSS}2. After shells assembly, microparticles were dissolved 
with EDTA (0.2M at pH 6.5 titrated by NaOH).
Labelled  dextran  was  encapsulated  into  ready  microcapsules  by  heat-shrinkage 
method. For that, microcapsules were incubated for 30 min in a highly concentrated 
solution  of  dextran  and  then  heated  up  to  65  ˚C  for  2  hours.  Following  that, 
microcapsules  were  thoroughly  washed  from  excess  of  dextran  by  series  of 
wash/centrifugation steps. Centrifugation was performed at 1800 rpm for 8 minutes, 
these parameters selected being optimal for the encapsulation procedure used.
Prepared  microcapsules  with  encapsulated  SNARF-dextran  were  imaged  using 
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confocal  microscopy at various pH. Figure  4.21 shows the images obtained from 
these  experiments,  confirming  that  SNARF  changes  emission  spectra  when 
immersed to various environments.
For triggered intracellular release experiments, A549 and SH-SY5Y neuron cell lines 
were used. Cells were incubated in Petri dishes at arbitrary concentration, providing 
ease  of  observations.  Microcapsules  were  introduced  to  the  cell  cultures  by 
pipetting  and  incubated  for  overnight  to  let  the  cells  internalize  the  capsules. 
Following that, microcapsules were irradiated intracellularly with focused IR laser at 
840 nm at 3.8 mW/µm2 intensity for few seconds. SNARF-dextran was released upon 
irradiation and distributed almost homogeneously in the cytosol. Emission spectra 
of SNARF shifted more to the red upon release (see Fig. 4.22). Red emission of the 
dye  indicates  neutral  pH,  which  proves  that  release  of  encapsulated  dye  was 
performed into the neutral cytosol. Images were taken at two exposure times for 
following quantification studies. Images for both exposures are presented.
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Figure 4.21: Confocal images of microcapsules with 10 kDa SNARF-dextran at  
different pH. Images obtained by  Susana Carregal-Romero.
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Figure 4.22: Laser-triggered release of encapsulated 10 kDa SNARF-dextran in A549 
and SH-SY5Y cells. Images taken at low (left) and high (right) exposure time are shown.  
The scale bar represents 20 µm. Arrows point at the opened capsules. Images obtained  
by  Susana Carregal-Romero
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Acidity of environment where SNARF-dextran was situated upon internalization and 
release was analysed through ratiometric image analysis performed in-situ at ROIs 
of individual SNARF-dextran loaded capsules and SNARF-dextran in the cytosol after 
release by means of confocal microscope. Images at low and high exposure time 
had  to  be  taken  and  two  separate  respective  calibration  curves  were  used  to 
quantify  the  pH  values  before  and  after  irradiation  in  the  capsules  and  in  the 
cytosol. 
Firstly,  calibration  curves  relating  the  ratiometric  fluorescence  read-out  (i.e.  the 
ratio of red to yellow fluorescence intensity) had to be recorded. Such ratiometric 
image analysis at ROI of individual SNARF-dextran loaded capsules and free SNARF-
dextran at low concentration was performed at different pH values. Two calibration 
curves were obtained as spectral parameters of SNARF-dextran. These curves were 
found to be different for free and encapsulated SNARF-dextran (see Fig. 4.23).
Figure 4.23: Ratiometric image analysis performed at ROIs of individual SNARF-
dextran loaded capsules (red spheres) and on drops of 2 µM solutions of free dextran-
SNARF (black squares). The concentration of free SNARF-dextran of 2 µM was chosen  
in accordance with the image settings that were necessary to use to observe SNARF-
dextran release into the cytosol. The intensity ratios of red (Ired) and green (Igreen)  
fluorescence are plotted versus pH. Each value corresponds to the mean value of 30 
measurements (i.e. different capsules or different drops) and error bars correspond to  
the standard deviation. Data points were fitted with a Boltzmann sigmoidal function.
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Free  SNARF-dextran  calibration  curve  is  relevant  to  released  SNARF-dextran  in 
cytosol,  while  capsule confinement changes fluorescence spectra characteristics, 
therefore separate calibration curve has to be measured.121,218 Ratiometric read-out 
depends on the local concentration of SNARF-dextran as well. It was observed that 
the pKa of the SNARF-dextran changes slightly upon encapsulation219 and has an 
additional slight shift depending on the concentration. Images of the cell  culture 
were taken before and after  IR laser irradiation of  the capsules at  two different 
imaging settings. Microcapsules have SNARF-dextran in a high concentration in their 
inner cavity and therefore the exposure time required for  observation is  shorter 
than  the  one  necessary  to  observe  the  diluted  SNARF-dextran  dispersed  in  the 
cytosol,  see Fig.  4.22. The colour of  microcapsules changed from yellow (before 
irradiation) to orange (after NIR exposure). Also, red fluorescence appeared in the 
cytosol after release. Ratiometric image analysis was performed for ten capsules 
and the cytosol  of ten different cells. Using the calibration curves the pH of the 
capsules before and after opening, as well as the pH around the released SNARF-
dextran were determined. The pH values for internalized capsules before opening, 
after irradiation and the cytosol were found to be 6.4, 7.1, and 7.4, respectively. The 
calculated  pH  values  clearly  indicate  that  cargo  does  not  stay  in  the  acidic 
lysosomal compartment but is released to the neutral cytosol upon laser irradiation. 
This confirms, that intracellular release of SNARF-dextran is achieved using focused 
NIR laser beam. Furthermore, laser also must locally perforate the endosome in 
which  the  capsule  resides  upon  internalization  by  cell.  Quantificational  image 
analysis was also performed for SH-SY5Y human neurons obtaining similar values of 
pH. This demonstrates that release of cargo to the cytosol  is not limited to one 
particular type of cell,  and acidity parameters of cell  compartments involved are 
rather similar between various cell types.
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4.2.6 Conclusions
General  ways for  cells  to  adsorb  materials  from extracellular  space are  passive 
(diffusion, osmotic pressure) and active (including endocytosis) transports.220 The 
latter  one  uses  special  “channels”  to  transport  materials  from one  side  of  the 
membrane to the other, a good example would be transport of minerals from dilute 
solutions in soil by plants against the direction of the concentration gradient. For 
obvious  reasons,  this  is  impossible  for  micron-sized  objects,  like  microcapsules. 
Therefore, the only natural way left for the microcapsules to get into the cell,  is 
endocytosis. Several variations of this mechanism are known, depending on the size 
of  the  vesicles  formed  for  internalization.221 Specific  form  of  microcapsules 
internalization is, however, phagocytosis,191 a process, where cell membrane binds 
and internalizes particulate matter larger than around 0.75 µm in diameter, with the 
material ending up inside the endosomes. The disadvantage of this process is that it 
is  characteristic  only  to  specific  cells,  including  macrophages,  dendritic  and 
aggressive  due  to  their  active  metabolism  cancer  cells.222  For  other  cells 
electroporation technique can be used.216 This process leads to perturbations in 
cell membrane, but the cells recover without affecting their metabolism.
In this study possibility of microcapsules phagocytosis by cells was shown. Uptake 
of polymeric microcapsules based on different template particles (SiO2 and CaCO3, 
presenting  two  very  distinct  in  many  senses  encapsulation  approaches) 
functionalized with aggregates of gold nanoparticles embedded into their shells by 
different types of cells is demonstrated in-situ, and confirmed by electron and laser 
scanning  confocal  microscopy.  Subsequently,  intracellular  release  of  dextran 
molecules into cytosol  of  cells  is  carried out using infra-red laser excitation and 
confirmed  by  confocal  microscopy.  This  work  demonstrates  a  possibility  to  use 
microcapsule  technology  for  payload  delivery  and  release  in  neuron  cells.  This 
should open new opportunities for neuron cell research where there is a demand for 
payload release with sub-cell precision.
The  biodegradable  microcapsules  were  observed  inside  the  cells  without  any 
irradiation for 72 hours from the moment the capsules are internalized by the cells. 
The  dextran  from the  microcapsules  seems  to  float  away,  as  the  cells  become 
fluorescent with time even if no capsules is internalized inside these very cells. With 
the time passing, the fluorescence intensity of  the dextran dispersed in the cell 
fades,  which probably  evidences the  consuming of  macromolecules  by the cells 
metabolism.
Light  mediated  heating  of  capsules  offers  a  controlled  way  for  time  specific 
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delivering  macromolecular  cargo  to  the  cytosol.  Upon  light  irradiation  capsules 
decorated  with  Au  nanoparticles  are  able  to  release  their  cargo  and  deliver 
encapsulated  material  directly  into  the  cytosol.  Thus,  illumination  of  cell 
impregnated with capsules can trigger intracellular process with externally delivered 
bioactive compound. Individual optical addressing of the internalized capsules offers 
the possibility to sequentially release cargo from different capsules inside the same 
cell. This is in contrast to delivery of cargo with biodegradable capsules where there 
is no trigger mechanism and delivery time is a factor of capsule wall composition 
and thickness. Also in case biodegradability the capsules is likely degraded inside 
lysosomal compartments while dislocation of cargo by light to cytosol prevents the 
cargo  from  undesirable  digestion  in  lysosomes  and  introduce  it  for  further 
intracellular processes. 
Triggered release of pH-sensitive compounds helps to investigate the environment 
of different cell compartments in various cell lines, providing a sensitive and precise 
measurements technique. This can be very useful for studies of cells chemistry.
However, with all these advantages, laser-induced release seems to be improbable 
for real medical applications, where a bigger number of microcapsules should be 
opened at  a  time.  The other  disadvantage of  the method regarding its  medical 
application is the need to visualize the target capsule and focus laser beam on it, 
which  is  hardly  possible  in  living  body.  Though  the  tissues  are  more  or  less 
penetrable for IR light, it is also hard to imagine that a focused IR laser beam will  
travel any considerable distance without being distorted.
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4.3 Laser-induced release from microcapsules, functionalized  
with photo-sensitive dye
Various classes of photosensitive substances are known and used for photodynamic 
therapy (PDT) nowadays, started with basal cell carcinoma treatment using eosin 
and light.223 Thousands of papers were published since then regarding PDT using 
myriad sensitizers. In 1993, regulatory approval was first granted in Canada for the 
use of PDT in clinic.224 The idea of using photo-sensitive dye for sensibilization of 
microcapsules  to  the  light  is  based  on  the  singlet  oxygen  generation  upon the 
irradiation, destructing the polyelectrolytic shells of microcapsules chemically rather 
than by melting them as in case  of  using nanoparticles.  This  can be useful  for 
thermally sensitive compounds,  such as DNA, etc.  Another distinctive feature of 
using  such  chemicals  is  that  the  process  of  shells  degradation  would  be  more 
gradual, less explosive-like. Such dyes should also need less energy to start action, 
than nanoparticles-based systems. Iron phtalocyanine and tetrapyrrolic dye meso-
tetrakis(4-sulfonatophenyl)porphine  (TPPS)  were  reported  to  be  successfully 
encapsulated.225
For  these  reasons,  there  is  an  interest  in  development  of  microcapsule  release 
system, based on photo-sensitive substances, acting in a chemical way. Common 
properties  of  a  good  sensitizers  include  chemical  purity,  minimal  dark  toxicity, 
strong adsorbance in the 600-800 range, where tissue penetration of light is at its 
maximum and the wavelengths of light are still energetic enough to produce singlet 
oxygen.224 One  of  such  species,  Al(III)  phthalocyanine  tetrasulfonate  (Al-PcS, 
molecule  structure  is  presented  in  Fig.  4.24)  was  used  in  this  research  to 
functionalize the microcapsules. This particular chemical, among other reasons, was 
used due to its adsorption band situated in red region of optical  spectre.  Al-PcS 
belongs to a group of  phtalocyanines, that are easily prepared and have water-
soluble  derivatives,  obtained  by  sulfonation  of  the  phtalocyanine  core.226 These 
substances are efficient generators of singlet oxygen with long-lived triplet states 
and have been found to be useful photosensitizers for PDT.226,227
This  work  was  carried  out  together  with  Anthony  Thaventhiran  (Queen  Mary, 
University of London, UK) as his M.Sc project work. I was supervising his work and 
helping him with most experiments.
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Figure 4.24: Structure formula of Al-PcS molecule.
In  2009 it  was discovered (Makwana J.,  unpublished),  that  Al-PcS interacts  with 
PDDA, and not only can be embedded to the shell of microcapsules this way, but it 
also stays within the cavity of the capsule, which is not characteristic at all for small 
molecules,  which  tend  to  escape  the  microcapsules.  Such  behaviour  was  not 
observed when PAH was used instead of PDDA. These features make Al-PcS even 
more interesting object for studying.
4.3.1 Samples preparation and irradiation
Photoresponsive dye Al-PcS was used as photosensitive agent in the microcapsules 
shells.  It  was  added  to  the  samples  combined  with  negatively  charged 
polyelectrolyte,  as  in  2009 J.  Makwana doing his  Master's  project  discovered its 
adsorption  to  depend  on  the  polyelectrolyte  (Fig.  4.25)  it  was  mixed  with.  The 
adsorption graph clearly shows the dye peaks around 660-680 nm with a small peak 
at 350 nm.
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Figure 4.25: Adsorption spectra of Al-PcS by itself and when 
bound with PSS, PAH and PDDA (as measured by Makwana J.,  
QMUL, 2009).
2 mg/mL polyelectrolyte (PSS) solution was mixed with 1 mg/mL Al-PcS solution in 
1:1 proportion and then used for the LbL assembly of the microcapsules shells upon 
4.99 μm silica cores, as described in Chapter 3.2.5. The shells were formed to have 
8 layers with {PDDA/PSS-Al-PcS}4 structure. The cores were then dissolved in 0.3 M 
HF, and AF488 labelled dextran was encapsulated by heat-shrinking. The AF488 dye 
is photo-stable, allowing to irradiate the sample without risk of bleaching the dye.
Irradiation experiments were performed in sealed chambers using 670 and 633 nm 
lasers diodes. Such wavelengths were taken according to adsorption bands of Al-PcS 
(Fig.  4.25). Upon irradiation, laser beams were focused with lens, 100x in case of 
670 nm and 40x in case of 633 nm laser. The irradiation times were selected rather 
arbitrary, but growing up to 10 minutes, when some effect was achieved, as nothing 
can  be  seen  happening  to  the  capsules  being  irradiated,  in  contrast  to  the 
microcapsules  with  gold  nanoparticles  treated with  IR  laser.  The  irradiation  was 
followed by confocal imaging to determine whether there is a difference between 
treated and untreated microcapsules.
4.3.2 Results
The  experiments  showed,  that  it  is  possible  to  release  dextran  from  the 
microcapsules  using  670  nm laser,  as  there  was  no  dextran  fluorescence  after 
irradiation the capsule for 10 minutes (Fig.  4.26).  The experiments with 633 nm 
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laser did not have any success.
Further  experiments,  involving  microcapsules  with  encapsulated  TRITC-dextran, 
showed interesting features in the shells (Fig.  4.27) after irradiation with 670 nm 
laser.  The  picture  on  the  right  shows  “channels”,  looking  like  holes  in  the 
microcapsules shell.
The  experiments,  involving  SEM  imaging  of  the  capsules  after  treatment  were 
carried out, but no assuring evidence of the holes formation was found.
Attempts to do intracellular release (B50 cells, proceeded as described in previous 
sections) did not show anything clearly, as after introducing the capsules to the 
cells the latter had a strong fluorescence by themselves. The same situation was 
observed when experimentation with encapsulated 70 kDa SNARF-dextran.
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Figure 4.26: LSCM images of the capsules with AF488 dextran before (left) and after  
(right) treatment with 670 nm laser radiation. Red on the right image is produced by Al-
PcS itself. Green is from AF488 dextran.
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After the experiments were completed, a paper was published by Zeng et al on the 
use  of  Aluminum  phthalocyanine  tetrasulfonate  chloride  (Al-PcS4Cl)  to  create 
microcapsules for  photodynamic therapy.228 The paper discusses incorporation of 
the  dye  into  the  shells  by  a  different  protocol,  where  Al-PcS4Cl  was  used  as  a 
negatively  charged  polyelectrolyte  in  LbL  assembly,  yielding  in  shell  structure 
{PAH/PSS}5/PAH/Al-PcS4Cl  on  calcium  carbonate  cores.  These  capsules  were 
irradiated with 670 nm light (500 W tungsten lamp with a narrowband filter). The 
authors performed cytotoxic studies using the prepared capsules on Human breast 
adenocarcinoma (MCF-7) cells.
It was found that AlPcS4Cl was electrostatically deposited on capsules as evidenced 
by UV-visible absorption spectra, EDX spectrum and AFM images. The ESR spectra 
provided a direct observation on the generation of 1O2 from photosensitive capsules 
under  visible  light  irradiation.  Furthermore,  with  increasing  light  irradiation,  the 
generation of 1O2 cytotoxic to cancer cells exhibited an increased trend.
However,  with  the  successful  singlet  oxygen  generation  under  the  light 
irradiation,  the  authors  do  not  report  any  changes  in  microcapsules  shells 
structure,228 that  could accompany release of  encapsulated substances.  This 
confirms  the results  obtained in  this  work,  where  no changes in  the  shells 
structure was observed.
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Figure 4.27: LSCM images of the capsules with TRITC-dextran before (left) and after  
(right) irradiation. Lines show “channels” in shell structure found in capsules after  
irradiation.
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4.3.3 Conclusions
By now it is not well documented whether a good release can be achieved using Al-
PcS  and  laser  irradiation.  Release  was  observed,  as  can  be  judged  from LSCM 
observations. However, this was not happening to all the irradiated microcapsules. 
The feature of laser-induced release is that it acts only upon a small number of 
capsules, and therefore the release cannot be measured by macroscopic methods, 
such  as  fluorimetry  as  in  case  of  ultrasonic  treatment.  At  the  same  time,  the 
proposed mechanism of  release itself  suggests,  that microcapsules shells should 
undergo  almost  no  visible  structural  changes  throughout  all  the  treatment.  The 
pores in the shells could be too small to be visualized by SEM method. However, 
confocal imaging of “channels” arising in the shell containment suggest that there 
still is a leakage of materials from the microcapsules. All in all the system probably 
is working, just in the way it was supposed to be – slowly, seamlessly and gradually, 
and it  may be the  main  reason why it  cannot  be  measured or  observed in  an 
appropriate manner.
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Most of the encapsulation studies reported by the moment investigate physical and 
chemical  properties  of  microcapsules,  using  rather  simple  chemically  and 
biologically  inert  model  substances to  fill  the  capsules  and monitor  release and 
other processes happening to the containment of microcapsules cavities. There are 
also publications on encapsulation of bioactive substances, but not in much detail.8 
However,  for  real  life  applications  the  substances  carried  by  microcapsules  will 
obviously demonstrate some activity, as they are intended to show some effect at 
the site of interest. At the same time, the encapsulated substance should not be 
very active before it is delivered to the target.
For these reasons studies on feasibility of incorporation of enzyme and plasmid DNA 
into  the  microcapsules,  retention  of  their  activity  and  biological  function  upon 
encapsulation were undertaken. Variations in shell structure of microcapsules were 
performed to investigate their  influence on enzyme and plasmid DNA molecules 
from outside. Kinetics of enzyme activity and DNA transfection in microcapsules of 
various structures was compared.
Firefly luciferase was selected as an enzyme, and luciferase encoding plasmid DNA 
as nucleic molecule. This made these two studies, though having their own specific 
features, even more closely bound and relevant to each other, joined by the same 
characterisation method. Both substances have a biological function, which should 
be preserved inside the capsules, but while luciferase emits light just in presence of 
other necessary components, DNA actually needs to find its way from internalized 
microcapsules to nuclei, making the task even more tough.
Protection of enzyme by microcapsules shells from trypsin, which cleaves proteins, 
was  also  studied  utilizing  bioluminescence  and  SEM  techniques.  For  these 
experiments shells microcapsules made of synthetic and biodegradable polymers 
were subjected to treatment of various degrees, and effect of treatment was studied 
to see if variations of shell structure and enzyme position in microcapsules would 
lead to any variations in the degree of protection provided by shells. Attempt of In-
vivo delivery of microcapsules with enzyme to muscles of swiss mice was performed 
to  check  if  the  capsules  can  be  visualized  inside  the  living  body  for  possible 
navigation and triggered release applications.
Plasmid DNA transfection from microcapsules was shown in this study on 293T cells 
from  microcapsules  of  various  structures.  Transfection  rate  and  kinetics  was 
compared to that of commonly used techniques. Influence of DNA location inside 
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the microcapsules (in the core or in the shells) on transfection rate was also studied. 
Role  of  PEI  as  endosome  release  agent,  reported  previously  for  conventional 
delivery techniques, was confirmed for microcapsules. Experiments on transfection 
of  GFP  encoding  plasmid  DNA upon IR-laser  triggered intracellular  release  from 
microcapsules were also performed to provide transfection efficiency increase of up 
to 50%.
This  work  was  carried  out  in  collaboration  with  David  Gould  (Bone  and  Joint 
Research  Unit,  Barts  and  The  London,  Queen  Mary's  School  of  Medicine  and 
Dentistry, Charterhouse Square, University of London, London, UK).
5.1 Investigations on activity of encapsulated enzyme
As a bioactive protein firefly luciferase (photinus pyralis) was utilized, which is an 
enzyme derived from fireflies that converts luciferin to oxy-luciferin along with the 
light  emission  in  presence  of  ATP  (see reaction  in  Fig.  3.7b).  Because  the  light 
generated is readily monitored it is fairly simple to monitor activity of luciferase 
using a luminometer. Upon addition of substrate to a solution of luciferase enzyme a 
flash of light is emitted which decays with a half life time of approx 20 min (Fig. 5.1). 
Therefore, luciferase is an enzyme which activity can be measured very easily and 
in-situ,  making it  an  ideal  choice  for  experiments  where  enzyme activity  under 
various circumstances is investigated.
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Figure 5.1: Profile of light emission after addition of 50 μL of  
assay substrate to 20 μL (10 ng/mL) of recombinant luciferase  
enzyme prepared in PLB.
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5.1.1 Samples preparation and characterisation
All experiments were performed using biodegradable and synthetic microcapsules 
assembled  upon  CaCO3 microparticles,  following  the  procedures  described  in 
Chapter 3.2.5. Microcapsules constitution is shortly described in Table 5.1. For some 
samples (LucI,  L1, LP1 and LS1), luciferase was encapsulated by co-precipitation 
into the cores, while for others it was sedimented as one of the layers into the shell 
provided by the fact that luciferase molecules have significant negative charge. For 
LucII.1 and LucII.2 microcapsules luciferase was situated both in the shell and in the 
cavity. For LucI.1 and LucI.2 samples the shells were labelled by adsorption of FITC-
PLL instead of one of PLA layers.
Luciferase containment in microcapsules was quantified by measuring the amount 
of luciferase left in supernatants collected after layers adsorption and CaCO3 cores 
dissolvation  and  subtracting  this  figure  from  amount  of  luciferase  initially 
introduced.  Quantification  was  performed  for  L1-LS3  samples  both  for  co-
precipitated and adsorbed luciferase and incorporation ratios were believed to stay 
the same for other samples due to similarity of preparation techniques.
Sample 
name
Core Shell structure Luciferase 
containment
LucI.1 luciferase {PLA/DS}2/FITC-PLL/DS/PLA/DS 30 μg
LucI.2 luciferase {PLA/DS}2/FITC-PLL/{DS/PLA}2 30 μg
LucII.1 luciferase {PLA/DS}3/luciferase/DS 95 μg
LucII.2 luciferase {PLA/DS}3/luciferase/DS/PLA 95 μg
L1 luciferase {PLA/DS}3 250 μg
L2 - PLA/DS/PLA/luciferase/PLA/DS 250 μg
L3 - {PLA/DS}2/PLA/luciferase 250 μg
LP1 luciferase {PLA/DS}3/PEI 250 μg
LP2 - PLA/DS/PLA/luciferase/PLA/DS/PEI 250 μg
LP3 - {PLA/DS}2/PLA/luciferase/PEI 250 μg
LS1 luciferase {PAH/PSS}2/PAH/luciferase/PEI 250 μg
LS2 - PAH/PSS/PAH/luciferase/PAH/PSS/PEI 250 μg
LS3 - {PAH/PSS}2/PAH/luciferase/PEI 250 μg
Table 5.1: Description of microcapsules prepared for experiments with  
luciferase. Estimated containment of luciferase in microcapsules (as prepared)  
is given.
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Quantification  of  luciferase  containment  in  supernatant  meant  that  a  separate 
calibration curve was needed for each type of supernatant. Then it was discovered, 
that  PAH,  PSS  and  PEI  even  at  low  concentrations  have  a  significant  effect  on 
luciferase activity (see Fig.  5.2). Despite extensively using polyelectrolyte-enzyme 
complexes229 (initially for purification reasons) and reports on high activity retention 
in these complexes229,230 and even in microcapsules,111 it  is  obvious that  activity 
retention depends both on the enzyme and polyelectrolyte used, and suppressing 
effect of polyelectrolyte on enzyme was also reported.231 This fact was taken into 
account  when  dealt  with  calculations  of  luciferase  concentration  in  each  of 
supernatants analysed.
For each of L1-LS3 samples (see Table  5.1), 2 mL of Na2CO3 and 2 mL of CaCl2 at 
0.33M  concentration  were  mixed  to  prepare  templates,  and  to  that  amount  of 
calcium  carbonate  microparticles  250  μg  of  luciferase  was  co-precipitated  or 
deposited. The measurements have shown, that about 99% of initially introduced 
luciferase stayed in the capsules.  Such high incorporation ratio proposes lack of 
luciferase to cover all the surface of microparticles and to fill all their pores. Thus, if 
the  amount  of  luciferase  introduced  would  be  more,  encapsulation  ratio  would 
decrease. If a mean diameter of microparticles is 4 μm, it gives S0=πD2/3=16 μm2 
surface area of individual microparticle. In dispersion synthesized there was about 
600 millions of them, which yields in ~0.01 m2 of total surface area. With 250 μg of 
luciferase adsorbed, it would give 25 mg/m2 mass/surface ratio. Despite the usual 
adsorption density is believed to be 0.1-1.5 mg/m,2,49 this figure varies for different 
substances used, and densities of up to 26 mg/m2 were reported previously.232 Also, 
adsorption density for same material is known to decrease with ionic strength,233 so 
for  conventional  polyelectrolytes  adsorbed  from  NaCl  solution,  it  should  be 
potentially lower. In case of co-precipitation, however, total surface area available 
for luciferase to adsorb, situated in the pores of CaCO3 microparticles, is obviously 
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Figure 5.2: PAH, PSS and PEI effect on luciferase activity, related to activity of  
luciferase at the same concentration without doping.
5 Encapsulation of bioactive substances
much  larger.  At  the  same  time,  incorporation  ratio  is  known  to  increase  with 
molecular weight, and it was shown that for 66 kDa BSA incorporation of 92.6% can 
be achieved.115 Firefly luciferase has comparable 62 kDa molecular weight, and it is 
obvious that incorporation rate would depend on the amounts of substances used 
for co-precipitation and adsorption.
It is believed, that PEI is not fully protonated under physiological conditions, so can 
be  still  protonated  in  cells,  when  it  enters  increasingly  acidic  endosomal 
compartments, and may act as a “proton sponge”, adsorbing some of the entering 
protons.234,235 This  proton  sponge  effect  is  considered  to  facilitate  release  of 
polyplexes  from endosomes  thus  resulting  in  high  transfection  efficiencies.  This 
behaviour of PEI was studied both experimentally and theoretically.236
As  we  were  interested  in  measuring  activity  of  luciferase  in  microcapsules 
internalised by cells,  and ATP-dependant assay substrate capable of  penetrating 
through cell membrane is used for such experiments, it was decided to employ PEI 
for  creation  of  outermost  layer  in  microcapsules  shells  to  facilitate  opening  of 
endosomes and release of microcapsules to cytosol of cells upon internalisation, so 
that ATP from cytosol and luciferin from substrate added would be accessible for 
luciferase and light could be emitted. Single layer of PEI was adsorbed as last layer 
on microcapsules for most of samples investigated.
It was assumed, that the number of CaCO3 microparticles synthesized when co-
precipitating luciferase in similar to that of empty ones. Thus, it allowed us to 
compare results obtained from using the same number of microcapsules for 
various samples. For that, microcapsules concentrations for each sample were 
measured  by  haemocytometry  and  adjusted  to  similar  one.  Then,  equal 
volumes of samples taken for experiments provided possibility to compare the 
results quantitatively.
Luciferase  assay  is  described in  detail  in  Chapter  3.2.8.3.  Briefly,  10  μL  of 
microcapsules dispersion was added to wells of 96 well measurement plate. To 
the same wells, 50 μL of luciferase assay substrate (Promega) was added, and 
light  emission  was  recorded  for  10  seconds  starting  after  2  seconds  of 
incubation.  In  first  experiments  activity  of  luciferase  in  microcapsules  is 
compared to activity of free luciferase in solution of passive lysis buffer (PBL). 
The reason for using PBL is that when luciferase activity is measured from cells 
transfected  luciferase  encoding  plasmid  DNA  (in  experiments  described  in 
Chapter 5.2), the cells are lysed with PBL prior to measurements, therefore 
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luciferase is diluted in it. So, to make those two situations comparable, PBL was 
chosen as a solvent for free luciferase when its activity was compared to that in 
encapsulated state.
5.1.2 Encapsulated Luciferase enzyme activity
Initial experiments were performed with LucI and LucII  samples to study general 
effect of encapsulation on the activity of luciferase.
5.1.2.1 Capsules with enzyme in the cavity
In the first capsules assembled (LucI.1, LucI.2) luciferase was incorporated into the 
capsule core. Two versions of these microcapsules were prepared which only differ 
in the charge of the outermost layer. 30 μg of luciferase was precipitated into cores 
for each of these samples' preparation.
Kinetics study, similar to described above (Fig.  5.1), was performed to determine 
activity of the encapsulated luciferase and the accessibility of the substrate to the 
enzyme.
The kinetics of luciferase activity in these microcapsules (Fig. 5.3) shows that access 
of substrate to the enzyme is restricted, so a gradual increase in luciferase activity 
is  observed  over  time.  Importantly  this  experiment  demonstrated,  that 
encapsulated luciferase retains its activity. In previous studies microcapsules have 
been shown to be disrupted in solutions of high salt concentration. To examine the 
effect of high salt concentration on luciferase activity, these microcapsules were 
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Figure 5.3: Profile of light emission after addition of substrate to 20 μl of LucI.1 (left)  
and LucI.2 (right) capsules in PLB.
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resuspended in PLB and NaCl (final concentration 0.16 mM) and incubated for 10 
minutes prior to addition of luciferase substrate.
As predicted from previous studies,124 addition of salt (NaCl 1M during the 10 min 
incubation then 166 mM after substrate addition) makes the capsules more leaky. 
With the LucI.1 capsules there is a dramatic increase in luciferase activity which 
after 2 hours is 60 fold higher than activity from capsules maintained in the PLB 
alone whilst the increase in activity with LucI.2 capsules is lower at 2 fold. This may 
be due to the fact that the LucI.1 capsules have a negative outer charge compared 
to a positive charge on LucI.2 microcapsules. Therefore, addition of salt changed 
ionic  strength  of  solution  and  made  the  shells  more  permeable,  and  luciferase 
encapsulated more accessible to substrate components.
5.1.2.2 Сapsules with enzyme both in the cavity and in the shell
In order to further increase the luciferase activity in the microcapsules in addition to 
incorporating the enzyme into the core of the capsule it was also incorporated into 
one of the capsule layers, being sedimented as 8th layer of the shell (LucII.1 and 
LucII.2 samples). To ensure that all the positive charge of the previous PLL layer was 
overcompensated, DS was also sedimented over luciferase. Once again, 2 samples 
were prepared,  differing by the shell  outermost layer (actually,  prepared as one 
sample, splitted into halves after sedimenting 6th layer). For each sample, 95 μg of 
luciferase was incorporated into the shell as the 6th layer, and another 95 μg was 
precipitated into the cores, resulting in total 190 μg per sample. For experiments, 20 
μL of capsules were resuspended in PLB prior to addition of substrate.
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Figure 5.4: Light emission from LucI.1 (left) and LucI.2 (right) capsules in PLB and 
0.16mM NaCl (diamonds) compared to PLB alone (squares).
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The data clearly shows increased light emission when luciferase is included in a 
layer of the microcapsules. In LucII.1 where the luciferase is in the outermost layer it 
is  readily  available  for  reaction  with  the  substrate  resulting  in  a  sharp  peak  of 
activity which shows a very gradual decline compared to the decline observed with 
a free solution of luciferase (Figure 5.1). In the LucII.2 microcapsules where there is 
an outer layer of PLL there is a much slower rate of reaction with the substrate that  
clearly indicates that this single outer layer significantly inhibits interaction of the 
substrate with luciferase.
5.1.3 Influence of luciferase enzyme location in capsules on 
activity kinetics
As seen from the previous experiments, encapsulation results in reduced enzyme 
activity  compared  to  free  enzyme.237 However,  the  great  advantage  of 
microencapsulation technique is that there are several properties to play with. It can 
be  seen  from  comparison  of  graphs  above,  that  position  of  luciferase  in  the 
microcapsules influences kinetics of measured activity curve. This  is  why it  was 
decided to make several samples that would differ by the place where the luciferase 
is put and compare the response of enzyme produced.
For  these  experiments  samples  L1-LS3  were  used  (see  Table  5.1).  These 
microcapsules were produced in a way to keep them as similar as possible, so the 
only thing variated would be the position of luciferase in the layers. L1, LP1 and LS1 
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Figure 5.5: Light emission from the first (circles) and second (triangles) batches of LucI  
(left) and LucII (right) capsules in PLB.
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had enzyme in the cavity, encapsulated by co-precipitation, while the others had 
luciferase in the middle of the shell (L2, LP2, LS2) and close to the outer surface (L3, 
LP3,  LS3).  Supernatants  measurements  suggested that  the amount  of  luciferase 
encapsulated was the same for all the samples, so for experiments similar number 
of microcapsules was used.
For measurements, 10  μL of microcapsules dispersions, containing about 100000 
capsules, were put into a well, and then 50  μL of luciferase assay substrate was 
added. After 2 seconds since that, luciferase activity in the samples was repetitively 
measured,  integrating  for  10  seconds.  Results  of  these  measurements  are 
presented in Fig. 5.6. The graphs show dependence of enzyme activity for different 
microcapsules construction on time since the substrate introduction. For ease of 
observations, each curve is related to its maximum value, so the data is presented 
in percentage of highest activity measured.
It can be clearly seen, that there is almost similar pattern in curves. The closer is 
luciferase to the outermost surface of the capsules, the faster it is accessed by the 
substrate, so the peak occurs at shorter time. When the enzyme is situated at the 
outermost layer, peak activity is reached during the first minute of measurements, 
while for the case of luciferase encapsulated to the cavity of microcapsules, the 
peak occurs after about an hour.
Peak activities are shown in the same graphs as bars on the right. Axis scale in RLU 
is given on the right sides of graphs. Again, the pattern is the same for all 3 groups 
of samples, showing that the activity is higher when the luciferase is situated closer 
to  the  outer  surface  of  microcapsules.  It  should  be  noted,  that  the  activity  for 
synthetic microcapsules is much less, than for others. It can be well attributed to 
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Figure 5.6: Kinetics of luciferase activity when enzyme is situated in various locations  
in capsules with different constitution. Activity is related to the maximum value of each  
curve. Peak activities for each curve are given as bars on the right side of each graph.
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the  fact  that  synthetic  polyelectrolytes  have  a  huge  suppressing  effect  on  the 
luciferase activity, as it was found when determining the encapsulation ratios for 
different microcapsules types (see Fig. 5.2).
5.1.4 Luciferase activity inside the cells
Our next step was to study luciferase activity in microcapsules internalized by cells. 
This is interesting not only from point of view of bioactive substances delivery to 
cells. For luciferase to emit the light, it needs luciferin and ATP. In experiments with 
microcapsules both were supplied from the substrate, whereas for experiments with 
cells ATP-dependant substrate was used, with the idea that ATP would be available 
only inside the cells, so the microcapsules located outside the cells will not add to 
measured  luciferase  activity.  This  fact  introduces  some  more  difficulties  to  the 
system, as luciferase should be preserved and delivered to the cells, and then it 
needs to find some ATP in order to demonstrate any activity.
For these studies 293T cells and HeLa cells were utilized together with the L1-LS3 
microcapsules. Microcapsules were introduced to the cells cultured in 96 well plates 
at  20000  cells  per  well.  100000  microcapsules  (same  quantity  as  for  the 
experiments  described  above)  were  injected  by  pipetting  to  each  well.  For 
measurements, ATP-dependant luciferase substrate was added to wells, which can 
enter  the  cells.  Then  the  activity  was  measured.  However,  sensitivity  of 
luminometer, used for previous experiments, was found too low to get any readings 
from the wells. For this reason, the plates were visualized with high-sensitivity CCD 
camera in darkness to register the signal caused by luciferase luminescence. Image 
obtained from CCD camera overlaying the photo of the 96 well plate is shown in Fig. 
5.7.  It  should  be  noted,  that  the  ATP-dependant  substrate,  used  for  these 
measurements,  does  not  work  in  absence  of  ATP,  which  is  the  case  when  the 
microcapsules are outside the cells. When the microcapsules enter the cells, they 
should gain access to intracellular ATP sources, thus luciferase activity should be 
demonstrated by light emission in presence of substrate.
CCD camera readings were then quantified and graphs of luciferase activity were 
plotted, presented in Fig. 5.8. The reason for the measured luciferase activity to be 
much lower than in case of free microcapsules is not clear. Factors, that may explain 
this behaviour, include ATP and substrate accessibility inside the endosomes, where 
the capsules are trapped upon internalisation, and degradation of luciferase inside 
the cells.
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Figure 5.7: Overlay of 96 well plate photos and CCD camera readings from it for 293T 
cells (top) and HeLa cells (bottom) with various microcapsules at different time points.  
Blue light is caused by luciferase luminescence.
The figures obtained, again, are rather low, however, some data for comparison still 
can be acquired,  particularly  for  the capsules with PEI  on top,  which,  as  shown 
above,  demonstrate  the  highest  activity  when free  capsules  are  measured.  The 
kinetics  pattern  throughout  the  samples  is  rather  similar,  but  again,  for 
microcapsules with enzyme inside the cavity, raise happens a little bit later. As for 
the maximum activity shown, the capsules with luciferase In the middle of the shell 
seem to be the lowest, while the case with luciferase in the centre is the highest, in 
contrast to the case of free capsules. This can be related to the fact that inside the 
cells luciferase is less accessible fo substrate and ATP it needs to produce the light, 
so potentially it is the unbound luciferase, which is found in the core, that has most 
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chances to do it. Enzyme that is located in the shells, is bound by polyelectrolytes, 
especially the iine in the middle of the shell, and that is exactly the thing that is 
observed – these capsules produce least light intensity.
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Figure 5.8: Luciferase activity in microcapsules inside 293T and HeLa cells,  
quantitised from CCD camera readings.
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The fact, that PEI-containing capsules are the most efficient, can be explained by 
protonation of endosomes, which surround the capsules, and, therefore, release of 
the capsules into the cytosol. It probably means, that encapsulated luciferase, while 
situated inside the endosomes, is hardly accessible for ATP that is sourced from the 
cell,  and  substrate.  This  mechanism,  that  actually  was  taken  in  mind  when 
constructed the microcapsules, could potentially enhance the activity of luciferase 
in addition to that promotion seen just by presence of PEI.
Graphs  presented  in  Fig.  5.8 show,  that  luciferase  activity  in  microcapsules 
delivered into the cells does not depend much on the cells type used. This proposes 
same ATP and substrate distribution among cell compartments and rather similar 
luciferase availability to these components when microcapsule is internalised. The 
fact,  that  the  figures  obtained  from measurements  inside  cells  are  significantly 
lower, suggests that availability of substrate and, most probably, ATP in the cells is 
much worse, than when measuring free microcapsules or enzyme solutions. This is 
also  confirmed by  much slower  kinetics  of  luciferase  activity,  compared to  free 
microcapsules. It should also be noted, that experiments with cells were performed 
using alive cells, that are not lysed, as in case of DNA transfection experiments.
Most activity is observed from luciferase located in the cavity and at the outer layer 
of the shell, higher for the first case. This contradicts with results obtained from 
measurements of activity in free microcapsules, which suggests differences in a way 
luciferase is available to luciferin and ATP. Another possible reason could be that 
amount  of  external  components  needed  for  reaction  is  much  lower  in  case  of 
internalized cells.
5.1.5 Degradation of encapsulated enzyme
The last study undertaken approaches the problem from the opposite end. Effect of 
trypsin, which cleaves peptide chains mainly at the carboxyl side of the amino acids 
arginine and lysine. This means, that trypsin would destroy the microcapsules shells, 
made  of  biodegradable  polyelectrolytes  (which  include  poly-L-arginine  and  poly-L-
lysine),  and  luciferase.  The  idea  is,  that  placing  enzyme  to  various  locations  in 
microcapsules assembly, one could vary the degree of protection against the trypsin. 
Expressing  it  in  more  general  terms,  these  studies  were  intended  to  show  the 
protection microencapsulation technique can give to the bioactive compounds against 
external environment.
Trypsin has rather large molecular weight of ~ 20 kDa. This means, that it cannot 
penetrate the shells directly, so in order to get to inner layers or to the cavity of 
microcapsules, it has to cleave the polymers constructing the shell to form pores it 
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can penetrate.
For  experiments,  10  μL  of  microcapsules  dispersion,  containing  100000 
microcapsules,  were pipetted to the wells of 96-well  plate. Then, 40  μL of  trypsin 
solution were introduced and plate was incubated at 37 °C for some particular time. 
Then, 50  μL of 10% cell culturing medium were added to each well to stop trypsin 
action.  Immediately  following  that,  the  wells  were  repetitively  analysed  by  usual 
luminometer technique, adding 50  μL of luciferase assay substrate to get the same 
type of dependencies as for the studies described above. Experiment was made in 
triplicates  to  get  statistically  meaningful  data.  For  comparison,  untreated  samples 
were also measured, where water was added to the wells instead of trypsin.
Concentration of trypsin and time of exposure were the two factors varied. Obviously, 
these two are closely connected. Maximum trypsin concentration used was “1x”, the 
one which is usually used for cell culturing. Results were, that for 1X concentration of 
trypsin even after 5 minutes of incubation all the activity almost totally disappears. 
This made clear, that the concentration of trypsin used is high enough to cleave all 
the  luciferase  in  all  the  capsules,  so  it  must  be  lowered  to  get  any  data  for 
comparison.
Thus, one more experiment was undertaken, where concentration of trypsin was 
varied and capsules were treated for 5 minutes. Concentrations employed included 
0.001x,  0.01x,  and  0.1x  related  to  one  used  for  data  above  and  cell  culturing 
manipulations.  Trypsin  was  diluted  with  deionized  water  and  introduced  to 
microcapsules dispersions in 96 well plate. After 5 minutes of incubation at 37 °C, 
the reaction was stopped by addition of culturing medium. Immediately after that 
activity of luciferase in each well was measured using luminometer. Data obtained 
is presented in Fig. 5.9 (note, that Y axis is in logarithmic scale).
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Flattening  of  the  luciferase  activity  curves  happens  gradually  with  increase  in 
trypsin  concentration.  It  can  be  clearly  seen,  that  for  different  microcapsules 
constructions  this  flattening  and overall  decrease  happens  in  different  ways.  To 
better present data, luciferase activities after 20 minutes since introduction of assay 
substrate were related to respective values for untreated samples and plotted as 
bars in Fig. 5.10 as percentages. Timepoint of 20 minutes was taken as one which is 
least sensitive to any occasional factors – it can be seen, that after that time the 
curves go much more evenly than it happens at zero time.
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Figure 5.9: Activity of luciferase in capsules treated for 5 minutes with trypsin at  
different concentrations (semi-logarithmic scale).
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These bars show a very interesting picture. At first, it is evident,  that for higher 
concentrations of trypsin used drop of the intensity grows. We can also conclude, 
that when the luciferase is situated in the cavity of the microcapsule, it is in most 
cases least protected. In case of synthetic shells, the most protected position is in 
the  middle  of  the  shell,  surrounded  by  neighbouring  layers  of  polyelectrolytes, 
which is consistent.
Single layer of  PEI  on top of  luciferase when the latter  is  situated close  to  the 
surface,  does  not  give  much protection,  but  this  can  be explained by  probable 
impurities in the layer structure,  caused by the presence of  luciferase,  which is 
distinct from the PAH, PSS and PEI. Also, it can be a factor that due to low amount of 
luciferase (judged by 99% encapsulation ratio) the charge overcompensation at the 
step of luciferase adsorption was not full, which made it impossible for PEI to form a 
confluent layer.
The fact  that not much difference can be seen for  biodegradable microcapsules 
when the enzyme is situated in the shells, probably means that single layer of PEI 
does not give much protection, as trypsin can get to the luciferase from the side of 
cleavable poly-L-arginine. Least protection of luciferase when in the core can be 
explained by the fact that there the enzyme is not bonded to any polyelectrolyte, so 
is most accessible to trypsin.
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Figure 5.10: Peak activity of luciferase in microcapsules treated with trypsin at various  
concentrations. Activity measured after 20 minutes since substrate introduction was  
taken for each sample and related to that of untreated sample at the same time point.
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For experiments, 40 μL of capsules dispersion was mixed with 60 μL of trypsin at 
appropriate concentration in 1.5 mL microcentrifuge tube and left for reaction for 
specific time in 37 °C incubator. Following that, 100 μL of 10% culturing medium 
was  introduced.  Immediately  after  that  the  capsules  were  washed  by  three 
centrifugations to get rid of  all  the substances present,  as they would ruin SEM 
imaging,  together  with  bringing  uncertainties  to  the  experiment.  Aliquotes  of 
washed dispersions were put on a glass slide attached to the sampleholder with 
conductive cement and dried.  Next  morning the specimens were sputtered with 
gold and analysed by SEM.
SEM  images  presented  in  Fig.  5.11 show,  that  despite  there  is  actually  no 
remarkable  difference  in  the  whole  structure  of  microcapsules  before  and  after 
treatment,  just  as  it  was  supposed,  some  small  pores  formed  in  shells  of 
biodegradable  microcapsules  can  be  seen,  which  cannot  be  found  in  synthetic 
capsules. Also, though a bit subjective, it seems that roughness and aggregation 
degree vary a bit after different treatments. In common, these pictures prove that 
there are very slight changes in shell  organization, and these changes are more 
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Figure 5.11: SEM images of capsules with luciferase in the core at their initial state  
(left) and after treatment with trypsin for 30 minutes (right).
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pronounced  for  biodegradable  microcapsules,  that  make  encapsulated  enzyme 
accessible  from  outside  for  big  molecules.  From  images  taken  after  shorter 
incubations (not presented) it is clear, that loss of enzyme activity is observed a 
little before pores can be found in the shells using SEM. This again fits to the picture 
seen with ultrasonic irradiation release, where encapsulated substances leave the 
capsules before any changes in shell organization can be found using microscopic 
observation methods.
5.1.6 In-vivo delivery of luciferase microcapsules
In-vivo delivery and visualisation of  delivered microcapsules  was attempted.  For 
this, microcapsules with encapsulated luciferase were delivered intermuscularly to 
swiss mice to see if the light produced by enzyme upon injection of substrate could 
be registered by luminometer. This experiment, requiring work with animals (mice), 
was  performed  by  Dr.  David  Gould,  including  both  microcapsules  injection  and 
imaging.
As the highest luciferase signal was achieved with the LucII.1 capsules, we utilized 
these  microcapsules  in  an  in-vivo experiment.  In  this  experiment  250  μL  of 
microcapsules were spun and resuspended in 90 μL of saline (NaCl 0.15M). These 
capsules were then injected intramuscularly into 3 Swiss mice (30 μL each) and 
after  1  hour  D-luciferin  substrate  was  administered  (IP)  and  bioluminescence 
imaging performed using the IVIS 100 system (Fig.  5.12). Imaging was repeated 3 
days later but no luciferase signal was detected in these mice.
Feasibility  of  registering  microcapsules  inside  living  body  using  standard 
instruments is, of course, fascinating. This means, that there is a ready solution for 
microcapsules  observation  in-vivo,  which  doubtlessly  will  be  needed  for  further 
experiments in this direction, allowing for targeted navigation of microcapsules to 
desired  site  inside  the  organism  and  triggering  release  there  after  substantial 
number of microcapsules is gathered. The fact that signal disappears after 3 days 
can be related to several factors.
The fact that bioluminescence disappears after 3 days of incubation (still,  rather 
long period)  can be related to  several  factors.  At  first,  as  seen from previously 
published results,93,190 and from work  presented in  Chapter  4.2.4,  microcapsules 
appear notably digested after such long exposure to cells or living body, therefore 
luciferase can mostly get out from the microcapsules by that time, and will not be 
observable due to low average concentration. Luciferase can also be cleaved upon 
microcapsules degradation, especially if microcapsules are attacked by phagocytes. 
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Another factor may be, that microcapsules are dispersed among large areas, which 
probably also will make their registration difficult.
Figure 5.12: In vivo imaging for detection of luciferase  
containing microcapsules. The image shows a  
bioluminescent image collected for 3 minutes on a large  
pixel setting overlaid on a b/w photo. Images obtained by  
Dr. David Gould.
Therefore,  it  can  be  stated,  that  microcapsules  can  be  observed  in-vivo using 
bioluminescence technique, and it can be applied for targeted delivery experiments, 
provided  that  the  concentration  of  microcapsules  and  amount  of  encapsulated 
species, producing light, is enough to fit sensitivity of the machine.
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5.1.7 Conclusions
It  was  found,  that  it  is  possible  to  incorporate  the  biologically  active  enzyme 
luciferase  into  microcapsules  with  retained  activity,  and  the  kinetics  of  the 
luciferase activity  is  clearly  influenced by it’s  location within  the  microcapsules. 
Kinetics of reaction were slowest when the luciferase was located in the core of the 
nanoparticles,  with  a  layer  of  luciferase  in  the  capsule  shell  the  kinetics  were 
increased and  when luciferase  was  located  in  the  outermost  layer  the  reaction 
kinetics  were  further  increased.  Capsule  permeability  and,  therefore,  enzyme 
activity is altered by salt concentration which can make internal  capsule protein 
more  accessible  to  external  substrate.  Activity  of  luciferase  was  shown also  to 
depend on the polyelectrolytes used. This includes the effect of substance itself and 
also the construction of the shell.
Protection of luciferase against trypsin treatment was studied using several shell 
compositions, where enzyme was located in the cavity of the microcapsules and in 
the shells. It was shown, that luciferase is preserved best when it is in the middle of 
the  shell  surrounded  by  other  layers,  especially  in  case  when  synthetic 
polyelectrolytes are used. SEM imaging showed presence of small pores in shells of 
biodegradable shells after trypsin treatment, which confirms that trypsin is cleaving 
the polymers on its way through the shells towards the encapsulated enzyme, and 
synthetic polyelectrolytes, not susceptible to cleaving by trypsin obviously preserve 
the enzyme better. However, in all instances the reaction kinetics were significantly 
slower than with free luciferase in solution, while peak activity was also lower. This 
is inevitable drawback of the enzyme being isolated and bound inside the shell of 
microcapsules.  On  the  other  hand,  microcapsules  propose  a  very  universal 
mechanism of combining several agents in a single container, and these agents can 
act together in a different more sophisticated way than they could do in free form.
Feasibility of observation of microcapsules in-vivo using bioluminescence was shown 
by injecting microcapsules dispersion with enzyme and substrate for luminescence 
reaction  into  the  muscles  of  swiss  mice.  This  gives  important  means  of 
indestructible  monitoring  delivery  of  microcapsules  to  the  specified  site  from 
outside living body.
Information gathered in these experiments is very important for further studies on 
microcapsules  as  targeted  drug  delivery  system,  as  they  give  information  on 
bioactivity of encapsulated species,  as well  as protection encapsulation gives to 
them. Feasibility of microcapsules visualization by already used techniques is also 
very promising.
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5.2 Transfection of encapsulated DNA
DNA is a negatively charged molecule so can be readily integrated into capsules 
through charge interaction required for LbL assembly. Thus, it can be delivered into 
the  cells  encapsulated  and  to  produce  transfection  of  the  encoded  enzyme  or 
protein. Besides, it can also be encapsulated into the cavities of microcapsules. In 
both cases, the molecules will stay there more or less isolated from the environment 
until they are released somehow.
Plasmid DNA can be used as very interesting model species for release technique 
studies. Not only it is a bioactive substance, changing the behaviour of the cell it 
gets into, but it is also rather fragile, which makes encapsulation and release rather 
a challenging task. The fact, that DNA molecules are charged, also suggests the 
release to be rather complicated, as DNA will stick to the positively charged regions 
of microcapsules shells, in case the release is not due to environment conditions 
change, that disassemble the shells themselves (pH, ionic strength). Given all these 
reasons, successful transfection of plasmid DNA would be a good proof of a delivery 
system, based on encapsulation, together with the research described in Chapter 3.
This  study  was  directed  to  investigate  the  feasibility  and  efficiency  of  the 
transfection happened when the encapsulated DNA was introduced to  the cells. 
Different  compositions  of  the  capsules  shells  were  utilized  to  see  whether  they 
influence the transfection efficiency. Transfection was measured and compared to 
that  happening  using  common  transfection  protocols  with  free  plasmid  DNA 
molecules  when the  equal  portions  of  DNA are  used.  Influence of  plasmid DNA 
positioning  inside  microcapsules  on  transfection  rate,  and,  most  importantly, 
influence  of  PEI  as  transfection  promoter  when  it  is  used  as  outer  layer  on  a 
microcapsule,  was  studied.  An  effort  was  also  undertaken  to  achieve  triggered 
release  of  DNA  from  microcapsules,  functionalized  with  AuNP  after  IR  laser 
irradiation.
There  are,  of  course,  other  various  methods  of  DNA transfection,  and they  are 
proven to be much more efficient in this study. However, versatility of microcapsules 
opens  great  perspectives  for  their  use  for  this  purpose.  Outer  surface  of 
microcapsules could potentially be functionalized with signal proteins that would 
gain access for microcapsules to specific types of cells. By doing so, it is possible to 
create an artificial virus, that would have DNA inside to transfect, penetration agent 
on the top and any other features needed for specific purpose in the middle.
Plasmid  DNA,  encoding  an  optimized  luciferase  (pcLuc+)  and  green  fluorescent 
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protein  (pcEGFP)  from a  constitutive  cytomegalovirus  promoter208  were  used  for 
these experiments as active substances. Cells, used in the study, were 293T human 
epithelial cells, widely used for transfection experiments, and raw cells. Different 
agents  (chloroquine,  ATA)  were  used  to  enhance  transfection  activity,  as  such 
influence was reported when transfecting free DNA in different cell types.238
This  work  was  carried  out  in  collaboration  with  Dr.  David  Gould  (Barts  and the 
London,  Queen Mary,  University  of  London,  UK),  who synthesized plasmid  DNA. 
Transfection experiments and measurements were mostly made together with him 
under his supervision.
5.2.1 Samples preparation and characterization
Plasmid DNA was synthesized according to the protocols described in Chapter 3.2.8. 
Its concentration was measured by adsorption at 260 nm. Usual concentrations of 
DNA solutions were in range 700-4200 μg/μL (measured by adsorption at 260 nm 
and using Qubit  fluorimeter),  however amount used for  co-precipitation and LbL 
assembly did not vary so much and was 150-210 μg. In some cases, for visualization 
reasons, plasmid DNA was labelled with DRAQ5 dye (maximum excitation 645 nm, 
can be excited with 488 nm, maximum emission at 681 nm, ranging from 665 to 
about 800 nm) by mixing them at 1:1 ratio prior to encapsulation.
Microcapsules were assembled upon sacrificial  CaCO3 particles,  according to  the 
procedures described in Chapter 3.2.5.. The particles were synthesized by mixing 
0.33 M solutions  of  CaCl2 and Na2CO3.  For  encapsulation,  plasmid DNA was co-
precipitated into the particles. A usual co-precipitation procedure would take 1 mL 
of each salt (CaCl2 and Na2CO3) and 100 μL of ~ 1 mg/mL DNA solution. Particles 
were washed three times with water prior to shells construction. At this time the 
particles usually showed a high grade of aggregation, which probably happened due 
to rather high concentration of DNA in the cores – during the particles synthesis and 
LbL processes all the supernatants were collected to measure the concentration of 
DNA afterwards. This was the case, when especially precise measurements were 
necessary,  as the concentration of DNA molecules in the supernatants was very 
small. DNA encapsulation efficiency when DNA was encapsulated into the cavity of 
microcapsules by co-precipitation was measured (by subtraction of value obtained 
from multiplication of total supernatant volume by the concentration of DNA in it 
from  amount  of  DNA  initially  introduced  at  the  particle  synthesis  step)  by 
spectrometry at 260 nm to be around 95%, which is rather high when compared to 
usual 75-80% in case of BSA. Such high encapsulation ratio explains the strange 
behaviour of particles immediately after synthesis, as their surface properties were 
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significantly  altered  by  the  presence  of  long  charged  DNA  molecules.  This 
abnormality disappeared after adsorption of first 1-2 layers of polyelectrolytes.
For  cases  when  DNA  was  used  for  LbL  assembly  as  one  of  the  layers,  its 
incorporation  ratio  was  also  determined.  First  attempts  to  measure  it  using 
conventional 260 nm absorbance technique lead to inconsistent results, probably 
due to presence of unbound polyelectrolytes and salts in supernatants, therefore 
Qubit fluorimeter (Invitrogen) was utilized, which employs assay reagent, reacting 
with double stranded DNA forming fluorescent product,  and then fluorescence is 
measured at 485/530 nm, producing much more reliable data. It was found, that 
when 420 μg of pcLuc+ was added to microparticles synthesized by mixing 2+2 mL 
of 0.33 M CaCl2 and Na2CO3 solutions, incorporation ratio was 34% and 45% for 4th 
and 6th layers, respectively. This difference probably can be explained by growing 
shell  structure quality as more layers are adsorbed.60 Incorporation ratio of  DNA 
when adsorbed as a layer is lower than in case of  DNA co-precipitation is most 
probably due to the fact that surface available for DNA molecules to adsorb onto is 
much more when it is co-precipitated, as all the pores formed are available to fill, 
whereas in  case  of  LbL  assembly DNA can only  be  adsorbed on top surface  of 
microparticles. Obviously, the space in the pores is still limited, therefore if more 
DNA would be used for co-precipitation, incorporate ratio would also decrease. As 
for microcapsules with luciferase (see chapter 5.1.1), we can estimate adsorption 
density.  Number  of  particles  prepared  in  that  particular  synthesis  used  for 
adsorption  of  DNA  as  one  of  the  layers,  was  ~600  millions.  With  individual 
microparticle surface area S0=πD2/3=16 μm2 it gives total surface area of ~0.01 m2. 
Onto this surface, maximum of 94 μg of DNA was adsorbed, which gives about 10 
mg/m2 ratio. This number is again higher than 1 mg/m2 commonly used estimation, 
but may probably be explained by a higher molecular weight of DNA compared to 
polyelectrolytes  commonly  used  for  LbL  assembly.  Adsorption  of  DNA  was  also 
confirmed  by  Zeta-potential  measurements  performed  during  assembly  process 
(see Fig.  5.13a,b), that show evident charge overcompensation after adsorption of 
pcLuc+ molecules.
Knowing encapsulation efficiency is crucial to know how much DNA is introduced 
(inside the capsules) to the cells for transfection. This was used when comparing 
encapsulated DNA transfection activity to commonly used transfection protocols. 
With known amount of DNA in the whole dispersion of capsules and the number of 
capsules in it (measured by haemocytometry), it is possible to say, how much of 
DNA is present in a single capsule or in a given volume of dispersion, provided that 
the  dilution  remains  constant.  This  technique  was  used  to  make  results  of 
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transfection  measurements  comparable  both  to  known  methods  of  transfection 
when same amount of DNA was used, and also between microcapsules of distinct 
constitution used for the same experiments. As similar parameters were used for 
encapsulation of DNA into the cavity, incorporation ratio was measured once and 
assumed to be equal for such microcapsules.
Microcapsules shells were formed by LbL assembly using synthetic (PAH, PSS) and 
biodegradable  (PLA,  DS)  polyelectrolytes.  Biodegradable  polyelectrolytes  were 
dissolved in 0.15M, and synthetic ones in 0.5M NaCl water solution at concentration 
of 2 mg/mL.
For the same reasons as described in Chapter 5.1.1, namely capability of PEI to 
protonate endosomes thus releasing entrapped objects into the cytosol,  PEI  was 
used to facilitate delivery of encapsulated plasmid DNA to nuclei. It is also known, 
that PEI has high transfection efficiency when used as a gene delivery vector and 
was  used  extensively  in  the  design  of  sophisticated  delivery  vectors.234,239 This 
effect, besides endosome protonation, happens also due to greater protection from 
enzyme  degradation  offered  by  PEI  compared  to  other  polyamines,240 since 
positively  charged  groups  of  PEI  provide  high  charge  density,  enabling  strong 
interactions with negatively charged DNA. For these reasons PEI was adsorbed as an 
outermost layer for  some microcapsules,  and its  influence on encapsulated DNA 
transfection rate was studied.
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Figure 5.13: Results of zeta-potential measurements of shells assembly with pcLuc+ 
(left, middle), ATA and Chloroquine (right) proving successful shell formation when  
using those substances as building blocks for LbL assembly.
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ATA and chloroquine were also used for LbL assembly in some cases, provided that 
their  molecules  are  charged  negatively  and  positively,  respectively.  They  were 
adsorbed from in 2 mg/mL aqueous solution.  After  shell  formation,  CaCO3 cores 
were dissolved in 0.2M EDTA solution at pH 7 (titrated with 1M NaOH), which was 
followed by 3 washing steps in EDTA and 3 more washings in water.
To use ATA and chloroquine for LbL assembly, design of stable shell structure was 
necessary.  Several  compositions  were  investigated,  to  have  PEI  on  top  of  the 
microcapsules to induce opening of endosomes and to keep the total layers number 
as low as possible. The process of sedimentation of polyelectrolytes was studied by 
Zeta-potential measurements, and the viability of the shells was assessed by optical 
microscopy after  cores  dissolution.  Figure  5.13 shows the  Zeta-potential  change 
after sedimentation of layers for the successful shell structure. Different types of 
shells were constructed, varying by the presence of both substances.
A separate set of samples, biodegradable bGFP and synthetic sGFP, was prepared 
for triggered release experiments. It had encapsulated GFP-encoding plasmid DNA, 
which  was  intended  to  be  released  by  IR-laser  irradiation  and  produce  GFP  on 
transfection which could be registered by means of confocal microscopy afterwards. 
Shell design was kept simple to prevent the DNA from being released too easily and 
too hardly. PEI also was not employed to prevent breakage of endosomes, as it was 
not needed for the triggered release.
The structures for all the samples are described in table 5.2. Samples prepared for 
single sets of experiments are joined by similar background colour. Amount of DNA 
incorporated is also shown together with encapsulation ratio. Incorporation of DNA 
was actually measured for D1-DP1 samples. It can be seen, that incorporation ratio 
is  different  for  D1  and DP1 samples  (which  actually  were  prepared as  a  single 
sample, split only immediately prior to PEI layer adsorption). This happens due to 
losses  of  DNA  happening  upon  dissolvation  of  the  cores.  A  layer  of  more  stiff 
(compared to PLA or DS layers used for the rest of shell) synthetic layer of PEI on 
top  of  the  assembly  helps  to  entrap  DNA  molecules  inside,  therefore  the 
incorporation factor is a bit higher for this case (LP1 sample). For the rest of the 
samples incorporation rate was assumed to be 95%, as the encapsulation technique 
was kept the same.
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Sample Cavity Shell constitution DNA containment
DNA1 pcLuc+ {PLA/DS}2/FITC-PLL/DS/PLA/DS 238 μg (95% assumed)
DNA2 pcLuc+ {PLA/DS}2/FITC-PLL/DS/PEI 142 μg (95% assumed)
DNAL
DRAQ5-
pcLuc+
{PLA/DS}2/FITC-PLL/DS/PEI 142 μg (95% assumed)
D1 pcLuc+ {PLA/DS}3 203 μg (96% measured)
D2 - PLA/DS/PLA/pcLuc+/PLA/DS 71 μg (34% measured)
D3 - {PLA/DS}2/PLA/pcLuc+ 94 μg (45% measured)
DP1 pcLuc+ {PLA/DS}3/PEI 208 μg (99% measured)
DP2 - PLA/DS/PLA/pcLuc+/PLA/DS/PEI 71 μg (34% measured)
DP3 - {PLA/DS}2/PLA/pcLuc+/PEI 94 μg (45% measured)
S0 pcLuc+ {PAH/PSS}3/PEI 142 μg (95% assumed)
SC pcLuc+ PSS/PAH/PSS/chloroquine/PEI 142 μg (95% assumed)
SA pcLuc+ ATA/PAH/PSS/PAH/PEI 142 μg (95% assumed)
SAC pcLuc+ ATA/PAH/PSS/chloroquine/PEI 142 μg (95% assumed)
B0 pcLuc+ DS/PLA/DS/PLA/PEI 142 μg (95% assumed)
BC pcLuc+ DS/PLA/DS/Chloroquine/PEI 142 μg (95% assumed)
BA pcLuc+ ATA/PLA/DS/chloroquine/PEI 142 μg (95% assumed)
BAC pcLuc+ ATA/PLA/DS/chloroquine/PEI 142 μg (95% assumed)
bGFP pcEGFP {PLA/DS}3 162 μg (95% assumed)
sGFP pcEGFP {PAH/PSS}3 162 μg (95% assumed)
Table 5.2: Description of samples produced for experiments on encapsulated  
plasmid DNA transfection. Shading is used to separate samples used for  
different experiments. DNA containment shows final mass of DNA  
incorporated together with encapsulation ratio (measured or assumed to be  
equal to previously measured).
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5.2.2 Cells and transfection techniques
Two types of cells were used for transfection studies — Human Embryonic Kidney 
293T and Raw 264.7 (Mouse leukaemic monocyte macrophage cell line).  The cells 
were cultured in Dulbecco’s minimum essential media supplemented with 10% FBS 
and penicillin-streptomyosin (1%), at 37 oC and 5% CO2:95% air. Cells were cultured 
in 96-well plates, with initial concentration of 10000 or 40000 cells/well (controlled 
by haemocytometry) for comparable results.
Microcapsules  were  introduced to  the  cells  by  pipetting after  centrifugation  and 
resuspension in the cell medium. The number of capsules, introduced to each well, 
was controlled by haemocytometry and chosen to match the amount of DNA, added 
in the investigations with other transfection techniques. In case of laser-triggered 
release studies, the cells were left for overnight to let them internalize capsules 
before laser irradiation.
For Fugene-6 induced transfection, Fugene-6 was mixed with serum-free medium, 
vortexed for 1 second, incubated for 5 minutes at room temperature. After that, 
DNA was introduced to this solution, vortexed once again and incubated for 1 more 
minute.  After  that,  equal  portions  of  solutions  were  introduced  to  the  cells  by 
pipetting. Transfection protocols using Amaxa nucleofector and calcium phosphate 
methods are described in Chapter 3.2.8.2.
Transfection of pcLuc+ was measured by illuminometry, using MLX Microtiter Plate 
Luminometer. To study transfection kinetics, cells were lysed at various time points 
with 100 µL of PLB and frozen at -20 ºC. All the lysates were then measured at a 
single  time.  For  that,  the  lysates  were  slowly  de-frozen,  centrifuged  with  ALC 
Multispeed Centrifuge PK121, for 2 minutes at 1800 rpm and aliquoted (10 µL) to 
disposable  measurement  plate.  For  measurement,  50  µL  of  luciferase  assay 
substrate solution in luciferase assay buffer was added to each well, containing 10 
µL of lysate, and light emission was integrated through 10 seconds 2 seconds after 
addition of substrate.
For  triggered  release  experiments,  pcEGFP  was  used.  After  16  hours  from 
introduction, which is enough for cells to internalize the capsules (as it was shown in 
previous  studies),  the  capsules  inside  the  cells  were  individually  irradiated with 
focused IR laser beam at powers up to 90 mW. Following another 24 hours the cells 
were observed with confocal microscope to see whether GFP was synthesized.
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5.2.3 Transfection experiments
In the first microcapsules generated (DNA1) the plasmid DNA was incorporated into 
the CaCO3 cores by precipitation, as it was described for luciferase.
When the DNA1 microcapsules showed low transfection efficiency, it was decided to 
construct microcapsules that contained the transfection reagent polyethyleneimine 
(positive  charge)  with  the  aim  of  improving  transfection  efficiency.  Capsules  in 
which plasmid DNA was labelled with the dye DRAQ5 which binds to DNA with high 
affinity and can visualized at the wavelength 633 nm were also prepared (DNAL) for 
visualization purposes. Labelling was performed by simple mixing of DNA and dye 
solutions in 1:1 proportion. To make the shells of microcapsules more penetrable for 
DNA,  number  of  layers  was  reduced  to  6  (excluding  outermost  PEI+  layer), 
compared  to  8  layers  for  previous  samples  (DNA1  and  samples  used  for 
experiments with luciferase).
In order for these microcapsules to deliver DNA to cells for expression of luciferase 
they must enter the cells and deliver the plasmid DNA to the nucleus, the site of 
gene transcription. In this study we utilized 2 cell types 293T cells which are a cell  
line of human kidney epithelial cells and Raw cells that are mouse macrophages. 
293T  cells  are  more  readily  transfected  and  are  able  to  replicate  plasmid  DNA 
containing the SV40 ori which is present in pcLuc+. By contrast Raw cells are hard to 
transfect.  In  initial  experiments  we  attempted  to  transfect  cells  with  DNA  or 
particles  alone  or  in  combination  with  chloroquine  (inhibits  acidification  of 
endosomes)  or  nucleofection  (promotes  nuclear  transfer  of  DNA  by  an  electric 
pulse).
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Figure 5.14: Fluorescent microscopy image 
of DNA1 microcapsules. Magnification x40.
5 Encapsulation of bioactive substances
Efficient  transfection  of  293T  cells  can  be  achieved  by  the  calcium  phosphate 
precipitation method so this was attempted with the pcLuc+ DNA alone and with the 
microcapsules containing the DNA (Fig.  5.16a). This experiment indicated that the 
microcapsules  do  contain  intact  plasmid  DNA  encoding  luciferase  but  clearly 
delivery by this technique is reduced compared to naked DNA alone. In a similar 
experiment DNA and microcapsules were treated with the lipid transfection agent 
Fugene 6 prior to incubation with 293T cells (Fig. 5.16b).
Figure 5.16: Transfection of 293T cells with pcLuc+ DNA or DNA1 microcapsules  
containing the same DNA amount delivered by the calcium phosphate transfection  
method (a) and using Fugene-6 (b).
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Figure 5.15: Transfection of Raw and 293T cells. Incubation of Raw cells (left) or 293T 
cells (right) with DNA or pcLuc+ containing DNA1 microcapsules in the absence or  
presence of chloroquine (C, 10 μM) did not lead to cell transfection. By contrast  
transfection of pcLuc+ plasmid by nucleofection using Amaxa did achieve transfection  
with luciferase expression (center) but not when pcLuc+ was incorporated in  
microcapsules.
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Both the results with the calcium phosphate method and Fugene-6 indicate that the 
microcapsules can deliver plasmid DNA to cells when they are combined with other 
transfection reagents, but efficiency of delivery remains low. Thus the capsules with 
outermost PEI layer (DNA2, DNAL) were composed to try to induce the intake and 
transfection process.
Figure 5.17: Confocal images of DNAL microcapsules. Individual microcapsules are  
illustrated in positions a-g and show plasmid DNA stained with DRAQ5 in red and the  
FITC-PLL shell in green and where colours overlap they become yellow. Clearly, the  
distribution of DRAQ5 and FITC is not homogeneous in all capsules and some capsules  
have more DNA (d) whereas other are absent of DNA (f). There are also aggregates of  
capsules (g and h) which could affect their functionality.
Both  samples  for  this  experiment  (DNA2,  DNAL)  had  7  layers,  with  positively 
charged outermost layer, created with PEI. 150 μg of DNA solution was precipitated 
for each sample. Assuming once again 75% incorporation, we get about 55 ng of 
DNA  in  every  1  μL of  microcapsules  dispersion  at  2  mL  of  total  volume.  The 
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presence of labelled plasmid DNA in the microcapsules was confirmed by means 
of LSCM (Fig. 5.17).
Confocal  images of  microcapsules show, that the DNA was located close to  the 
shells, and this behaviour is consistent with what was observed in Chapter 4.2 (see 
Fig. 4.10), most probably due to the highly charged nature of the DNA.
Figure 5.18: Confocal microscopy of 293T cells incubated with DNAL microcapsules.  
Cells were incubated with plasmid containing microcapsules for 2 and 24 hours (a and 
b respectively) and Raw cells in c and d were similarly treated. FITC labelled  
microcapsules are seen in green and cell nuclei are blue. DRAQ5 stained DNA is not  
clearly seen in any image.
These capsules were also incubated with 293T and Raw cells in order observe cell  
uptake. The confocal images (Fig. 5.18) give the impression that capsules were able 
to enter cells so we were interested in examining whether these PEI coated capsules 
would also achieve cell transfection. 293T cells and Raw cells were incubated with 
microcapsules and 24 hours later expression of luciferase was determined.
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This transfection experiment clearly shows (Fig. 5.19) a dose dependent increase in 
luciferase expression with microcapsule number in 293T cells, whilst the results with 
Raw cells highlights the relative difficulty in transfecting these cells. Nonetheless 
with the 60 μL volume of microcapsules there is some evidence of cell transfection 
with luciferase expression above background which demonstrated that it is feasible 
to  deliver  plasmid  DNA  to  the  cell  nucleus  of  Raw  cells  with  the  PEI  coated 
microcapsules. Raw cells are macrophage cells, therefore they tend to phagocyte 
foreign substances and destruct them inside the lysosomes. This explains why they 
are so hard to transfect using microcapsules, though these cells easily internalize 
them.
A final experiment was performed in mice by injecting PEI coated pcLuc+ containing 
microcapsules in Swiss mice and performing bioluminescent imaging after 72 hours 
to detect luciferase expression but none was detected (data not shown).
5.2.4 Effect of DNA position in microcapsules on transfection 
rate and kinetics
Just  as  with  luciferase  containing  microcapsules,  a  set  of  experiments  was 
undertaken to see how positioning of DNA in the capsules influence transfection. A 
separate serie of microcapsules was assembled, differing by situation of pcLuc+ - 
inside  the  cavity,  as  the  middle  layer,  and  close  to  the  outer  surface  of  the 
microcapsule. These microcapsules were assembled with (DP1, DP2, DP3 samples, 
see Table 5.2) and without (D1, D2, D3) PEI coating on them. D1, DP1 and D2, DP2, 
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Figure 5.19: Transfection with PEI coated DNA2 microcapsules: a) 293T cells showed 
increasing expression of luciferase when incubated with increasing volumes of  
microcapsules; b) transfection efficiency of Raw cells was very low.
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D3, DP3 microcapsules were assembled as single samples,  split  into halves just 
prior to adsorption of last PEI layer (for DP1, DP2 and DP3).
As results obtained on microcapsules were supposed to be compared to each other, 
extreme care was taken for maintaining the same number of capsules added to 
each well, and amount of DNA in them. For this purpose, haemocytometry and DNA 
incorporation measurements were performed, and microcapsules dispersions were 
adjusted to similar concentrations of microcapsules and DNA.
For experiments, 20000 cells per well were plated to each well of 96 well plate, and 
after 8 hours 10 µL of microcapsules dispersions were introduced in triplicates, at 1 
and 10 microcapsules/cell ratios. Following that, cells were lysed every day for 6 
days to measure transfection kinetics. Lysates were centrifuged, and then 10 µL of 
them  was  transferred  to  measurement  plate,  where  50  µL  of  luciferase  assay 
substrate was introduced and bioluminescence measured after 2 seconds for  10 
seconds.  Results  are  presented  in  Fig.  5.20 for  all  the  samples  and  both 
microcapsules concentrations.
It is obvious, that differences are more pronounced for higher number of capsules 
(10  per  cell),  which  is  consistent,  as  when the  number  of  capsules  is  not  high 
enough, most of the cells will not transfect, as the number of cells grows with time. 
Quite important, microcapsules with PEI demonstrate much better transfection with 
up to 2.5 fold higher peak luciferase activity measured. These results, together with 
described in Chapter 5.1.4, confirm role of PEI for endosomal escape of internalized 
microcapsules, which was previously shown for free DNA transfection.234,239
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It can also be seen, that highest transfection is achieved when DNA is located in the 
cavity or at the outer surface of microcapsules. This contrasts with results obtained 
for  free  luciferase  microcapsules  (Chapter  5.1.3),  where  highest  activity  was 
measured from microcapsules having enzyme as a top and (much lower) middle 
layer,  but  is  fully  consistent  with  results  of  activity  measurements  from 
microcapsules introduced to the cells (Chapter 5.1.4).
5.2.5 Effect of ATA and chloroquine presence on DNA 
transfection rate
As it was seen, transfection of encapsulated DNA is not very high, when compared 
to conventional delivery methods, therefore it was decided to make an attempt to 
enhance it using some transfection agents. Several papers238 showed positive effect 
of using ATA and chloroquine (formulae presented in Fig.  5.21) for transfection, so 
incorporation of these low-molecular substances into the shells was interesting. PEI 
was chosen to be the outermost layer to help breaching the endosome after the 
capsule was internalized, to induce transfection efficiency.
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Figure 5.20: Transfection kinetics of microcapsules with pcLuc+ in cavity and in the 
shell, performed for microcapsules with (right) and without (left) PEI coating at  
microcapsules:cells ratio 1 (top) and 10 (bottom) in 293T cells.
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The templates for all the microcapsules groups (synthetic S* and biodegradable B* 
capsules, see table 5.2) were synthesized in single procedure, involving mixture of 
2.5 mL of  0.33M CaCl2,  2.5mL of  0.33M Na2CO3 and 800 µL of  766 µg/mL DNA 
solutions.
The  efficiency  of  DNA  encapsulation,  as  determined  by  measuring  of  DNA 
concentration in post-synthesis  supernatant by adsorption at  260 nm, was 95%. 
This  figure  was  used  for  estimation  of  amount  of  DNA,  introduced  inside  the 
capsules to the cells.
Experiments were performed using microcapsules made up using synthetic (S0, SA, 
SC,  SAC samples from Table  5.2)  and biodegradable (B0,  BA,  BC,  BAC samples) 
polyelectrolyte.  Synthetic polyelectrolytes were utilized for 2 reasons: they make 
more stable shell,  which could be important when using ATA and chloroquine in 
shells,  and they won't  be  degraded in  triggered release experiments,  that  were 
planned to perform using samples with promotion agents.
Transfection experiments were performed on 293T cells using microcapsules and 
Fugene-6  transfection  agent  for  comparison.  The ratio  of  DNA to  Fugene-6  was 
selected to be 1:3, following the instructions. 60 ng of DNA was introduced to each 
well. The number of capsules, introduced to each well, was selected to contain the 
same amount of DNA. 8 time-points were investigated, ranging from 1 to 10 days. 
170
Figure 5.21: Structural formulae of chloroquine (left) and ATA (right) used for shell  
assembly to enhance DNA transfection.
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For each unique combination of shell structure and incubation time, 3 similar wells 
were kept. All the wells were read at the same time after the longest incubation.
Figure  5.22 shows the transfection results using Fugene-6 transfection agent and 
synthetic microcapsules (S0, SA, SC, SAC) of various construction made up using 
synthetic polyelectrolytes.
Transfection of DNA from the microcapsules showed unexpected negative effect of 
presence  of  ATA,  which  can  be  levelled  by  chloroquine.  Microcapsules  with 
chloroquine show more rapid transfection, as compared to “0” capsules.
One  more  transfection  experiment  was  carried  out,  where  “0”  and  “C” 
microcapsules were introduced to the cells (initial concentration 40000/well, number 
of capsules per cell was maintained the same as in previous experiments) and left 
for incubation for 24 hours. Higher number of cells and, subsequently, capsules, was 
selected to get more rapid transfection and higher readings to get more reliable 
data. ATA was added with medium at 4 different concentrations: 1 nM, 100 nM, 10 
µM and 1 mM. Such values were taken according to the previously published paper, 
where concentration of 100 nM was used.
Estimation of amount of ATA inside the capsules shells, as measured by adsorption 
of  supernatant  after  sedimentation of  ATA,  gives  a  figure  of  ~ 1-10 mM of  ATA 
supplied by presence of it in capsules' shells in each well. At the same time, the 
concentration of ATA in single cell, when provided by capsules, will be much higher, 
than the average concentration when diluted in medium, as it would be very local. 
Moreover, the amount of ATA, incorporated into a single cell, would depend greatly 
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Figure 5.22: Transfection of DNA using Fugene-6 (left) and microcapsules with  
synthetic shells (S0, SA, SC, SAC) with ATA and chloroquine in 293T cells.
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on the number of capsules intaken.
The effect of the ATA inside the capsules and when dissolved in cell medium can be 
different  by  two  ways.  At  first,  when  using  microcapsules,  macroscopic 
concentration of ATA in the medium would be very minor, if any. At second, when 
the ATA is dissolved in the medium, the mechanism of getting of ATA inside the cells 
not very clear – whether it penetrates through the membrane, or gets only inside 
the capsule (as, being low molecular weight, it can penetrate microcapsules shells). 
ATA was added immediately together with capsules, after 4 hours of introducing the 
capsules and after  6 hours.  These times were selected following the knowledge 
about  the  timings  of  intake  process.  As  it  was  observed  before,  capsules  start 
appearing intaken after ~4 hours of incubation. This is why 4 and 6 hours were 
selected.  It  was  supposed,  that  ATA  may  demonstrate  non-specific  inhibition  of 
various enzymes, so can slow down all the processes inside the cell. This is why 
there was some time left for the capsules to be internalized, without ATA in the 
medium. Figure 5.23 shows the effect of addition of ATA to the cells with capsules, 
at different concentrations and introduced at different time.
Negative  effect  of  ATA,  when  the  ATA  is  added  immediately  together  with  the 
capsules is observed, as well as negative effect of higher concentrations of ATA.
Similar  studies  were  performed  using  biodegradable  microcapsules  containing 
chloroquine and ATA in hope that biodegradability of shells would induce differences 
in behaviour of various shell constructions, providing higher average gene delivery 
ratio. Transfected luciferase activity measured after 48 and 72 hours of incubation 
for different amounts of microcapsules introduced is presented in Fig. 5.24.
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Figure 5.23: Effect of ATA in medium on DNA transfection from S0, SC microcapsules  
in 293T cells.
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It  can  be  seen  though,  that  effect  of  addition  of  ATA  and  chloroquine  to 
microcapsules is again unstable and inconsistent at different timepoints.
In attempt to further promote different behaviour of ATA and chloroquine loaded 
microcapsules, transfection was stimulated by addition of mixture of cytokines and 
bacterial wall protein, which are commonly used for this purpose: Interleukin-1β (20 
ng/mL),  Tumour  necrosis  factor  α (20  ng/mL)  and  lipopolysaccaride  (3  μg/mL). 
Again, transfected luciferase activity was monitored at 24 and 48 hours timepoints. 
Figure  5.25 shows  comparison  of  transfection  activities  with  and  without 
stimulation.  It  is  evident,  that  despite  every  effort  undertaken,  transfection  of 
pcLuc+ DNA from microcapsules  does not  vary  much with  including  of  ATA and 
chloroquine  layers.  This  could  be  attributed  to  differences  in  action  of  these 
substances  in  solution  and  when  inside  microcapsules,  where  both  DNA  and 
inhibitors are trapped, and local  concentration is unknown. It  could happen that 
better results can be achieved by variation of ATA and chloroquine position and 
containment in relation to DNA.
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Figure 5.24: Luciferase activity measured from transfection of DNA in 293T cells from 
biodegradable microcapsules with ATA and chloroquine at 48 and 72 hours time points.  
Experiments performed as single points.
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Thus it was found, that transfection promoters act completely different when using 
encapsulated  plasmid  DNA,  compared  to  their  action  when  conventional 
transfection systems are utilized. In case of ATA, even inhibition of transfection was 
observed. These differences are most probably related to the fact that both agents 
and DNA are bound inside the capsule, and as DNA is slowly released, promoters 
can hardly follow it. It may also be the case, that ATA and chloroquine stiffen the 
shells, making it a bit more like made of synthetic polyelectrolytes, preventing DNA 
to leave microcapsules easily.
5.2.6 Laser-triggered transfection of encapsulated DNA
As ATA and chloroquine did not show significant promotion effect on plasmid DNA 
transfection, attempt to enhance transfection of DNA by triggered releasing it from 
microcapsules  internalized  by  cells  was  undertaken.  For  that,  293T  cells  were 
cultured in Ibidi 35 mm μDish plates, and microcapsules were introduced on next 
day after cells plating following the same procedures as used for triggered release 
experiments with B50 cells (see Chapter 4.2) and left for 16 hours. Following that, 
the capsules were intracellularly irradiated with focused beam of 840 nm IR laser at 
initial power varied up to 100 mW at a specific region. In general, irradiation was 
performed using same methods as described in Chapter 4.2 for intracellular laser 
triggered release of encapsulated substances, but the power of irradiation raised a 
bit to ensure rupturing of microcapsules shells and endosomes. Next day the cells in 
the same region were visualized with confocal microscope to see transfection.
Two types of microcapsules were used for experiments – biodegradable bGFP and 
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Figure 5.25: Luciferase activity achieved by stimulation of transfection of DNA from 
biodegradable microcapsules containing ATA and chloroquine in 293T cells.
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synthetic sGFP (see Table  5.2). As it was demonstrated in Chapter 5.2.4, ATA and 
chloroquine do not help transfection much, therefore they were not included into 
the shells, although there was such intention at the start. Overall shells structure 
was kept simple with 6 layers. No PEI layer was adsorbed, as we were interested in 
potential  of  laser  irradiation  triggering  for  release  of  microcapsules  from 
endosomes, and as we already know, presence of PEI would help it.
For synthetic microcapsules sGFP no fluorescence was found In cells next day after 
irradiation.  Confocal  microscopy  images  recorded  from  biodegradable  bGFP 
microcapsules at the same time are presented in Fig. 5.26. Positions a and b show 
cells  that  were  not  irradiated  with  laser,  i.e.  outside  the  region  being  treated. 
Position c and d show cells from the region where laser irradiation was performed. 
Note, that microcapsules were introduced to both treated and untreated cultures, 
therefore both cultures transfect the encapsulated plasmid DNA, and it is the rate of 
transfection that was different.
As the cells constantly grow and divide, it is not possible to find exactly the same 
cells that was treated on the next day, this is why a small region was selected in the 
chamber with cells (several  mm2 of surface area),  and most of capsules located 
inside the cells  within this  selected region were irradiated with focused IR laser 
beam to induce release of  DNA material  from microcapsules and endosomes to 
promote transfection.
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Obviously,  with  biodegradable  microcapsules even cells  that  were  not  irradiated 
with laser demonstrate some transfection, as there is a fluorescence caused by GFP 
filling the cells. This is why some quantification of transfection was necessary to 
compare fluorescence in treated region to that in the region where the cells were 
not treated. Two approaches were used for this: direct counting of transfected cells 
and measurement of average fluorescence intensity in the image using the confocal 
microscopy software. The results of both approaches are presented in Fig. 5.27a,b.
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Figure 5.26: Confocal images of 293T cells transfecting GFP from encapsulated  
plasmid DNA. Left images (a.b) show cell culture that was not irradiated with IR laser  
to release the DNA from microcapsules, while right (c,d) images show cells with  
microcapsules that were irradiated with laser. 
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Both these quantification methods have their drawbacks. From images presented in 
Fig. 5.26 It is clear, that GFP can be found at various concentrations inside different 
cells. Therefore, when judging on transfection activity using number of bright cells 
per  image,  it  is  a  human who decides  to  which  of  two groups  (transfected/not 
transfected) a cell belongs, and it is hard to set a level of brightness found inside 
the  cell  which  would  serve  as  a  threshold.  For  that  reason,  this  approach  is 
subjective.  On  the  other  hand,  when  determining  average  brightness  level 
throughout the image, background intensity starts to play its role. Moreover, this 
approach would show no  difference between two transfected cells  and a single 
transfected  cell  twice  as  large.  For  these  reasons,  results  obtained  using  both 
methods  are  presented  here,  supposing  that  the  true  transfection  rate  lies 
somewhere in between.
It  can be seen,  that  irradiation with laser  to  release encapsulated DNA gives  a 
moderate effect of up to 50%. This means that in general the technique seems to 
be working, though it is obviously necessary to adjust parameters of encapsulation 
to improve the release upon treatment. The main difficulty seems to be the fact that 
DNA are rather large molecules, and even when capsule shells and cell endosome 
are ruptured they would not flow away to the cytosol without sticking to the charges 
of the inner shell walls and also those formed at the edges of shell ruptures. This 
means,  that it  is necessary to develop a technique of DNA encapsulation where 
nucleic acid molecules would be bound as loosely as possible to the interior of the 
capsule shells.
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Figure 5.27: Transfection rate of triggered and non-triggered (control) capsules in  
293T cells as calculated from LSCM images.
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5.2.7 Conclusions
The  studies  have  shown  feasibility  of  incorporation  of  DNA  molecules  into 
microcapsules with retention of biological activity, which is confirmed by the fact of 
successful transfection when introduced to 293T cells. When DNA was included in 
capsule  construction  in  was  clear  that  it  was  not  targeted  to  the  core  of  the 
microcapsule but associated with the microcapsule shell. It was found that this kind 
of  DNA incorporation into microcapsules is  not sufficient to  achieve transfection 
when incubated with cells. In contrast, microcapsule coated with PEI were able to 
delivery plasmid DNA to the nuclei of 293T cells for gene transcription provided by 
the fact that amine residues of PEI will be protonated inside endosomes where the 
capsules situate after internalisation by cells. This results in influx of counter-ions 
and causes osmotic swelling and endosomal burst with release of their contents into 
the cytoplasm. DNA can then diffuse to the nucleus for  gene transcription. This 
ability to endow microcapsules with multifunctional properties highlights their great 
potential  for  gene  delivery.  With  a  more  optimised  microcapsule  additional 
functional  properties  can  be  added  with  consequent  improvement  in  gene 
transfection.
Use of ATA and chloroquine which are reported to induce transfection when using 
other methods of delivery rather than microcapsules, did not show consistent effect 
on transcription activity, though a faster kinetics of transfection was observed in 
case  of  microcapsules  with  chloroquine.  This  fact  once  again  confirms  that 
behaviour of encapsulated substances differs much from that of free species.
Attempts of triggered DNA release by use of focused IR laser shown that up to 50% 
increase  of  transfection  rate  can  be  achieved  on  biodegradable  microcapsules, 
while no effect was found for synthetic ones, which seem to bind macromolecules 
much  stiffer.  Most  probably,  effect  of  irradiation  can  be  enhanced  by  adjusting 
microcapsules shells constitution.
Just as in the studies of enzyme encapsulation, overall efficacy of microcapsules for 
transfection  is  much  lower,  than  that  achieved  using  conventional  techniques. 
However,  the  main  advantage  of  microcapsules  is  their  multifunctionality,  i.e. 
feasibility of joining several agents and species inside single microcontainer.
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6 Navigation of cells impregnated with magnetic 
microcapsules
One of major tasks for the development of drug delivery systems is the navigation 
of the drug towards the desired site.  Several  ways of solving this problem were 
proposed in recent publications,  including high-frequency ultrasound.151 However, 
use of magnetic field seems to be the most straightforward and least problematic 
way of navigating the drug carriers, when speaking about the microcapsules.
Vast  number  of  papers  is  published  on  using  nanoparticles  for  targeted  drug 
delivery, which is known as nanomedicine, where nanoparticles are supposed to be 
introduced to cells.241 Various nanoparticles are proposed to use for both imaging, 
biosensing,242 therapy243 and drug delivery, provided by their unique physical and 
chemical  properties.  Imaging  can  be  performed  by  quantum  dot  based 
photoluminescence,244 optical microscopy,245 photoacoustic imaging,246 and several 
other  techniques.  Magnetic  nanoparticles  are  one  of  the  most  well-established 
nanomaterials because of their biocompatibility.247 Magnetic nanoparticles have a 
great advantage – they can be used for magnetic resonance imaging (MRI), both as 
contrast  agent  and  for  their  visualization.248  Developments  of  using  magnetic 
nanoparticles for mammalian cells manipulations that fall into several categories: to 
capture cells for diagnosis;249 to label cells for in-vivo monitoring or targeting;250 to 
attract or arrange cells in patterns or three-dimensional cell culture251 are massively 
reported. In 2004 in-vivo trafficking and targeted delivery of magnetically labelled 
stem cells using magnetic field was shown in rats,252 followed by 2005 publication 
by  de  Vries  et  al on  successful  MRI  tracking  of  dendritic  cells  labelled  with 
magnetite  in  melanoma  patients  for  monitoring  of  cellular  therapy.253 These 
publications characterise use of  nanoparticles as highly developed technique for 
medical applications.
However, we think, that microcapsules could join the advantages of both systems. 
All the methods of imaging and trafficking (MRI, navigation by magnetic field), used 
for nanoparticles, can be applied for microcapsules. From the other side, system can 
benefit  from  multifunctionality  of  microcapsules,  that  can  include  not  only 
nanoparticles,  used  as  delivery  agents,  but  also  drugs  and  other  bioactive 
substances. This approach seems to be promising, as recent publication by Noh et 
al reports use of ovalbumin protein, magnetite as resonance imaging contrast agent 
and near-IR fluorophores, joined together in multifunctional polymer nanoparticles 
prepared by double emulsions method, for  in-vivo tracking of dendritic cells and 
priming  of  an  antigen-specific  immune  response.254 As  shown in  Chapter  4.2.2, 
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microcapsules are easily internalized by cells, so they also can be used for tracking 
and delivery. At the same time, use of nanoparticles for cells labelling needs precise 
concentration  adjustments,  both  to  make  cells  susceptible  to  irradiation  and  to 
prevent  unwanted  aggregation  of  nanoparticles.247 Microcapsules,  in  turn,  allow 
easy control on amounts of encapsulated substances before they are introduced to 
the cells. For these reasons it was decided to perform experiments on navigation of 
cells with internalized magnetic microcapsules by magnetic field.
Magnetic  properties  of  microcapsules  themselves  when  functionalized  with 
magnetite  were  reported  elsewhere.  However,  when  trapped  by  the  cell,  a 
microcapsule becomes much more biocompatible, as it does not interact with the 
whole environment, being isolated until release of encapsulated substances (either 
triggered or gradual) starts. This is why the aim of this study became the use of 
magnetic field to control the movement of the cells that have microcapsules inside. 
Use  of  cells  as  the  shells  for  the  microcapsules  would  also  solve  some  other 
problems. At first, the capsules could be injected into the blood without the risk of 
being stuck in a small vessel, as ordinary microcapsules without special treatment 
would.255 At second, the capsules can be injected to any convenient spot of the 
organism and navigated to the desired place, with no harm to the organism.
Figure 6.1: Idea of in-vivo navigation of cells with magnetic  
microcapsules by magnetic field.
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Together with performing experiments on movement, cell viability studies were also 
carried out. These would be of high importance for the in-vivo research, because it 
is essential, that the cells, carrying microcapsules, survive for considerable time to 
ensure the successful delivery of the drug to the site.
Several experiments on movement of cells with microcapsules inside by magnetic 
field  were  performed on different  types of  cells,  including B50 and 293T in  the 
attached state of the cells. However, no effect was observed. This is why trypsinized 
cells were chosen to be moved by magnetic field, which can be used for floating 
cells navigation, such as it would happen with carriers in bloodstream. The other 
method studied was the influence of magnetic field on the cells that have a loose 
adhesion to the surface they are incubated on.
6.1 Experimental details
6.1.1 Nanoparticles
Magnetite  nanoparticles  were  synthesized  according  to  protocol,  described  in 
Chapter 3.2.2. TEM images of nanoparticles are presented in Fig. 6.2. It can be seen, 
that the nanoparticles are not monodisperse, but it is not very important for the 
experiments conducted. Their size was measured by zeta-sizer to be around 55 nm, 
which seems rather different to what can be seen from TEM images most probably 
due to aggregation of nanoparticles. Zeta-potential was measured to be around -50 
mV, which gives a good possibility to use them as a building block in LbL assembly. 
These parameters were slightly changing from synthesis to synthesis, but not too 
much.
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Figure 6.2: TEM images of Fe3O4 nanoparticles from different batches.
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After synthesis, nanoparticles dispersions were dialysed against distilled water to 
remove  any  unreacted  substances  and  then  kept  under  argon  atmosphere  to 
prevent their oxidation, which would lead to changes in their stability and magnetic 
properties.
6.1.2 Magnetic microcapsules
Several  batches of microcapsules were prepared for the experiments,  in general 
following procedures described in Chapter 3.2.5. All the samples were created using 
CaCO3 sacrificial microparticles, synthesized by mixing of 0.33 M Na2CO3 and CaCl2 
in 1:1 volumetric proportion while vigorously stirring. In most cases, RBITC-BSA or 
TRITC-dextran was co-precipitated into the cores at synthesis stage. For this, 1-2 
mg/mL solution of protein or dextran was added to CaCl2 before addition of Na2CO3 
at 1:1 proportion. In one case, magnetite nanoparticles were co-precipitated into 
calcium carbonate cores together with RBITC-BSA.  After  microparticles synthesis, 
they were immediately washed 3 times with water and then polyelectrolytic shell 
was assembled by LbL assembly technique using PAH as positively and PSS and 
magnetite  as  negatively  charged  polyelectrolytes.  When  nanoparticles  were 
included into the shell,  one more layer of PSS was deposited after nanoparticles 
layer to ensure full previous layer of PAH charge overcompensation and seamless 
shell  build-up.  Upon deposition of  all  layers,  CaCO3 was dissolved in 0.2M EDTA 
solution, titrated to pH 7.
Short description of all the samples used for study of magnetic field influence on the 
cells migration is provided in Table 6.1. Main differences are the containment of the 
shell cavity and the presence of magnetic nanoparticles in the shell. Diameter of the 
capsules,  determined by  the  size  of  calcium carbonate  templates,  was  3-5  µm, 
varied throughout single batch and also between batches,  which is common for 
such microparticles. RBITC-BSA, encapsulated in samples “IN” and “OUT” was used 
mainly for visualization reasons, to make the microcapsules visible for fluorescent 
and confocal microscopes.
Samples with most diverse shell structures were prepared for viability tests, as it 
was  essential  to  get  idea  about  what  is  causing  cell  toxicity,  if  any  would  be 
observed.
For experiments on movement of trypsinized cells, samples similar to “OUT” were 
prepared, which had magnetite in shells. 
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Sample Cavity Shell
B1 Empty Parg/DS/FITC-PLL/DS/PArg/DS
00 empty {PAH/PSS}3
0F empty PAH/PSS/PAH/Fe3O4/PSS/PAH/PSS
B0 BSA {PAH/PSS}3
BF BSA PAH/PSS/PAH/Fe3O4/PSS/PAH/PSS
D0 Dextran {PAH/PSS}3
DF Dextran PAH/PSS/PAH/Fe3O4/PSS/PAH/PSS
NP Fe3O4 none
IN Fe3O4+RBITC-BSA {PAH/PSS}3
OUT RBITC-BSA PAH/PSS/PAH/Fe3O4/PSS/PAH/PSS
Table 6.1: Description of microcapsules samples constructed for experiments  
on cells navigation by magnetic field.
In experiments with dendritic cells, two types of microcapsules were prepared (“IN” 
and “OUT”), differing by the position of magnetite nanoparticles in their structure – 
one containing nanoparticles in the cavity, and the other – in the shell. RBITC-BSA 
was  co-precipitated  into  the  templates  for  both  types  of  the  microcapsules  for 
visualization reasons.
Nanoparticles  were  co-precipitated  to  CaCO3 particles  in  one  case  in  order  to 
increase  the  number  of  nanoparticles  per  capsule,  following  the  earlier 
publications.256 To quantify the difference between the two types of microcapsules, 
UV-Vis  measurements  were  performed,  that  measured  the  absorption  of  the 
microcapsules dispersion at 364 nm. This particular wavelength was taken as it is a 
local maximum of the adsorption of nanoparticles solution (Fig. 6.3a). This region is 
selected also due to the absence of adsorption by PAH and PSS, that also are found 
in  the  shells.  Therefore,  this  wavelength  can  be  used  for  microcapsules 
characterisation.  The  concentrations  of  the  nanoparticles  solution  and  of  the 
microcapsules  dispersions  for  measurements  were  selected  to  be  in  the  linear 
region of  the calibration curve for  magnetite  solution.  Several  measurements  at 
different concentration were performed to ensure the linearity of  the adsorption 
change with the concentration variations.
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The concentration of  nanoparticles  (w/v)  was determined by weighing the dried 
nanoparticles from the known volume of the dispersion. Therefore, by measuring 
adsorption  of  a  solution  it  is  possible  to  calculate  mass  concentration  of 
nanoparticles in it.
Microcapsules of both types were diluted to the same concentration and dissolved 
with 2M NaOH (dissolvation checked with optical microscope). After that, adsorption 
of the solutions obtained was measured at 364 nm to determine the containment of 
the magnetite in the capsules. The results of the measurements are presented in 
Fig.  6.4.  Knowing the initial  concentration of microcapsules and concentration of 
nanoparticles (as measured by adsorption) in the solution, mass of nanoparticles 
per single capsule was determined.
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Figure 6.4: Amount of nanoparticles in the capsules.
Figure 6.3: Measurements of nanoparticles containment in microcapsules: a)  
Adsorption spectra, b) calibration curve for magnetite NPs solution.
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The amount of nanoparticles inside the cavity was found to be less, than in the 
shells, though the initially introduced volume of magnetite dispersion was equal in 
both cases. These measurements are confirmed by TEM imaging (Fig.  6.5).  This 
means, that if microcapsules would be created with several layers of magnetite in 
the shells, they would perform even better In terms of their sensibility to magnetic 
field.
Figure 6.5 shows TEM images of microcapsules with magnetic nanoparticles within 
the cavity and in the shells. Distinct character of nanoparticles dispersion in the 
capsules  can  be  seen  -  they  are  dispersed  more  evenly  in  capsules  that  have 
nanoparticles  in  the  shells.  Also,  microcapsules  with  nanoparticles  in  the  shells 
seem to have more nanoparticles, which agrees with the results of nanoparticles 
concentration measurements by spectrometry.
Prior to introducing microcapsules to the cells, the capsules were autoclaved at 120 
°C for 1 h 30 min to sterilize them. Heating have stretched the capsules a bit, but it  
can  be clearly  seen from SEM images  (Fig.  6.6)  that  they did not  undergo any 
significant structural changes.
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Figure 6.5: TEM images of microcapsules with magnetite. a) inside cavity, b) embedded  
into the shells.
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It can also be noted, that the capsules with the nanoparticles embedded into the 
shells  are  slightly  aggregated  after  autoclaving,  which  can  be  seen  from LSCM 
images (Fig.  6.7).  This  may happen due to  the  changes of  polyelectrolytes  and 
nanoparticles  positions  in  the  shells,  as  the  nanoparticles  would  not  shrink, 
compared to the polyelectrolytes. However, the degree of aggregation is not too 
high to make the capsules useless for the experiments.
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Figure 6.7: LSCM images of microcapsules with magnetic nanoparticles: inside the  
cavity (a,b) and in the shells (c,d), before (a,c) and after (b,d) autoclaving.
Figure 6.6: SEM images of microcapsules with magnetic nanoparticles: inside the  
cavity (a,b) and in the shells (c,d), before (a,c) and after (b,d) autoclaving.
6 Navigation of cells impregnated with magnetic microcapsules
6.1.3 Microporous scaffolds
Methacrylamide-modified gelatin with a DS of 65 % was synthesized by Liesbeth De 
Cock,  PhD student  from Department  of  Pharmaceutics,  Ghent  University,  Ghent, 
Belgium, according to the method described by Van Den Bulcke et al.257 30 g gelatin 
type B was dissolved in 300 mL phosphate buffered saline (PBS, pH 7.4) at 50°C 
followed by slow addition of 3 mL methacrylic anhydride. After 1 hour reaction, the 
mixture was diluted with 300 mL water and dialysed against distilled water during 4 
days at 37°C. Finally the methacrylamide-modified gelatin was obtained as a dry 
powder after lyophilization.
A  microporous  3D  hydrogel  of  methacrylamide-modified  gelatin  was  obtained 
through a water-in-water emulsion of methacrylamide-modified gelatin and PVP. PVP 
(6.5 % (w/v)) and methacrylamide-modified gelatin (18.56 % w/v) were mixed and 
sonicated at 10 % power output using a tip-sonicator. Radical polymerization of the 
methacrylamide functions was obtained by adding KPS (50 mg/mL) and TEMED (pH 
neutralized  with  4M HCl).  The  reaction  was  carried  out  during  1  hour  at  room 
temperature followed by incubating the scaffolds in 1 L of water during 3 days to 
leach out the PVP. Gels were frozen in liquid nitrogen followed by lyophilization to 
obtain dry scaffolds. Schematic of the synthesis process is presented in Fig.  6.8a. 
Positions below (B1, B2, C1, C2) show LSCM and SEM images of ready scaffoldings. 
Porous structure of scaffoldings can be clearly seen from these images.
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Figure 6.8: Microporous scaffolds preparation. Reprinted from the paper, recently  
submitted by Liesbeth De Cock et al. A) synthesis schematic, B1, B2 present LSCM,  
while C1, C2 – SEM images of prepared scaffolds. 
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6.1.4 Cells
B50, 293T, macrophage, dendritic and fibroblast cells were used for experiments. 
Cells were incubated according to the protocols described in Materials and Methods 
section. Initially cultured in 25 cm2 flasks and 6 well plates, prior to the experiments 
cells were transferred to the desired chambers that suit for the particular operation 
(imaging, viability studies, magnet placement). After a period of time for cells to 
attach to the surface of a new flask, autoclaved microcapsules were introduced by 
pipetting at relatively high concentration (usually ~3∙1010 cm-3)  and low volume 
(~50  μL),  redispersed  in  cell  culturing  medium,  to  minimize  the  risk  of 
contamination and toxicity.
For cell viability studies, microcapsules were introduced to cultures of macrophage 
and fibroblast cells. After that, the cells were monitored for 6 days following pNPP 
cell viability assay.
Dendritic cells, used for migration studies, were cultured in 6-well plates. After 2-3 
hours after introduction of microcapsules, cells were transferred to Lab-Tek®II 8-well 
chamber #1.5 German coverglass system (Nalge Nunc International). This allowed 
placing the magnet closer to the cells and observation with high magnification lens 
on  the  microscope  provided  by  very  thin  chambers  basement.  For  studies  on 
migration through scaffolds, scaffolds (~ 5x10 mm size disks) were placed to the 
chamber immersed into cell culturing medium and cells were added carefully on top 
of the scaffold.
When  needed  for  visualization,  alive  or  fixed  cells  were  stained  using  DAPI 
(VectaShield), DiOC18(3) (Invitrogen) or CellTracker (Invitrogen) labels. Cells fixation 
was  performed  after  washing  with  PBS  using  formaldehyde  or  glutaraldehyde 
solution for 2 hours.
For  FACS  measurements  samples  (dendritic  cells  with  microcapsules)  were 
measured on a FACSCalibur (BD Pharmingen) flow cytometer and analysed using 
CellQuest software.
To characterise distribution of cells along the axis of magnetic field applied, cells 
were fixed and labelled,  and then series of  fluorescent microscopy images were 
taken along the axis. These images were stitched together forming a panoramic 
image of cells and capsules in the chamber studied. Then this large image obtained 
was divided into 3 columns and rows of 100 μm length. Cells with capsules were 
counted directly inside the cells of table obtained (Fig. 6.9).
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Three  neighbouring  lines  (columns  of  the  table)  are  then  presented  in  graphs 
together with one line averaged from these three columns. Usually imaging was 
performed along several independent lines in each chamber to get more meaningful 
data.
6.1.5 Magnets
Two different magnets were used for experiments with dendritic cells and floating 
B50  cells.  Photographs  of  both  magnets  are  presented in  Fig.  6.10.  The bigger 
magnet has a canal, where the glass tube with microcapsules dispersion fits in flow 
cytometry experiments. Magnetic field created by both magnets in region where the 
chambers with cells were placed for migration experiments was measured by Kombi 
B-Sonde  (LD  Didactic  GmbH,  Germany)  Hall  probe  attached  to  Universal 
Measurement  Instrument  Physics  (LD  Didactic  GmbH,  Germany)  at  various 
distances from the magnet. Graphs of the measured magnetic field are presented in 
Fig.  6.10. Graphs contain measured points (as markers) and dashed extrapolation 
data (exponential interpolation function).
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Figure 6.9: Fluorescent microscopy image taken from fixed dendritic cells with  
capsules, used to calculate cells distribution depending on distance from the magnet.
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6.2 Cells viability tests
Cells viability was measured using pNPP assay, where cells were incubated in 96 
well plate (20000 cells/well) in 10% serum culturing medium and adsorption at 405 
nm was measured after 24, 48 and 72 hours since the microcapsules introduction. 
Different volumes of redispersed in cell culturing medium microcapsules, ranging 
from 1 to 10 μL (15000-150000 capsules per single cell), at controlled concentration 
of 300 M/cm3 were introduced to each well by pipetting. Cells viability tests were 
performed by Liesbeth De Cock.
Microcapsules  with  various  shell  structure  and  loading  along  with  nanoparticles 
dispersion  (NP)  were  used  for  these  investigations  to  determine  what  part  of 
assembly is toxic to the cells (if toxic). Results of cell viability studies on different 
capsules are presented in Fig.  6.11. It can be seen, that cells viability depends on 
the number of capsules introduced, and fibroblast cells seem to be more sensitive 
to the addition of microcapsules. Influence of microcapsules amount on viability is 
better  pronounced for  macrophages.  Another feature  of  these cells  is  that  their 
viability fades after 2 days of incubation, and recovers after 3 days, so effect of 
microcapsules seems to have a temporary effect on cells health, so the readings for 
all the capsules types and all the concentrations of capsules, except the highest 10 
μL one, are almost the same, equal to 100%, which means that there's no effect of 
microcapsules after 3 days.
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Figure 6.10: Photographs (left) and dependence of magnetic field on distance from the  
magnet as measured using Hall probe (right) of magnets used for experiments.  
Measured points are shown as markers on the graph, together with extrapolation curves  
for both magnets utilized.
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When BSA or dextran are present in the capsules, they seem to enhance a bit cells 
activity in some cases, which can be probably explained as delivery of nutritious 
molecules into the cells. 
It could also be noted, that at the concentration of microcapsules used (3•108 mL-1), 
total number of capsules is very high even for the smallest volume introduced.
6.3 Effect of magnetic field on dispersed cells
In these studies, effect of magnetic field on cells dispersed in culturing medium was 
studied. Experiments were performed using dendritic, B50 and 293T cells. For this, 
capsules were introduced to cells, cultured in flasks, left for several hours (2 hours 
for dendritic and 8-12 hours for B50 and 293T cells), and then detached from the 
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Figure 6.11: Viability test results on different capsules and cells. Data obtained by  
Liesbeth De Cock.
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surface (by rinsing for dendritic cells and trypsinization for B50 and 293T cells). 
Magnetic field was applied to dispersed cells and their movement was studied by 
various methods.
6.3.1 Trypsinized B50 and 293T cells
Once constructed,  the microcapsules were resuspended in cell  medium with 1% 
serum  and  introduced  to  the  cells,  incubated  in  25  cm2 cell  culture  flasks  for 
magnetic experiments and in 35 mm μ-Dishes for confocal imaging. Concentration 
of  microcapsules  was  adjusted  to  get  rather  even  coverage  of  cells  with 
microcapsules and depended on the cells number, which was controlled mainly by 
optical microscope observation, as there was no need to maintain exact number of 
cells and/or microcapsules. The cells were left overnight to intake the capsules.
Fig.  6.12 shows confocal images of capsules introduced to the B50 cells culture. 
Images have transmission and fluorescent (RBITC, red) channels,  and overlay of 
both. Some of the capsules appear intaken, while others are still free, situated on 
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Figure 6.12: Confocal images of the B50 cells with microcapsules, containing magnetic  
nanoparticles inside.
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the bottom of the dish. Intake usually took place during 4-6 hours since capsules 
introduction to culture.
At first,  rather simple set of  experiments was undertaken to see if  there is any 
movement  of  cells  with  capsules  under  magnetic  field.  Cells  were  thoroughly 
washed with PBS to remove all the free capsules from the flask and leave only cells 
there. Then, cells were detached from the surface by trypsinization and transferred 
to a 4.5 mL plastic spectroscopy cuvette (1 cm) and a magnet was put to the wall of 
a  cuvette  for  a  couple  of  minutes  to  gather  the  floating cells  with  capsules  by 
magnetic field on the side of the cuvette (see Fig. 6.13). It can be clearly seen from 
comparison of different magnets influence on the cells, that the cells are mainly 
attracted to the regions of highest magnetic field gradient.
This experiment proved that it is possible to control the movement of dispersed 
cells by applying magnet to the side of the vessel. The influence is strong enough to 
gather the cells throughout at least ~ 1 cm.
193
6 Navigation of cells impregnated with magnetic microcapsules
194
Figure 6.13: Photo of cuvette filled with trypsinized B50 cells with magnetic  
microcapsules inside after it being put to close proximity of a magnet.
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After these studies it was decided to perform some more experiments, where this 
influence would be investigated deeper (see Fig. 6.14 for schematics).
Again,  cells  were  cultured  in  25  cm2 flask  and  microcapsules  at  ~10 
microcapsules/cell concentration were introduced for overnight. After that period of 
time, enough for most of the microcapsules to be internalised, cells were trypsinized 
following the usual protocol, with intensive prior wash with PBS to remove most of 
free capsules. Trypsinized cells were transferred to a rectangular 2-wells chamber 
(Nulge Nunc, Germany), that allows a magnet to be placed close to the cells. 1% 
serum culturing medium was added to the chamber to stop trypsin action and give 
nutrition to the cells. After that, the chamber was placed to the incubator with a 
magnet close to one of its sides until next morning. Different commercially-available 
magnets were used for experiments. During that time, the cells were supposed to 
sediment on the surface and move under magnetic field towards the magnet, so 
that a gradient of attached cells would be present, provided that most of cells have 
magnetic capsules inside.
Next morning cells were fixed with formal saline, stained with DiOC18(3) dye and 
visualized with fluorescent microscope equipped with CCD camera. Two channels 
were recorded – red for the capsules and green for cells stain. A series of images 
was taken along a line perpendicular to magnet and then the images were stitched 
together to form a panorama (Fig.  6.15). From this image distribution of cells with 
microcapsules  along  the  distance  from  the  magnet  was  determined  by  direct 
calculation of cells, taking only cells with capsules inside into account, as it was 
explained in Fig. 6.9.
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Figure 6.14: Trypsinized cells migration study 
schematic.
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It can be noted, that the distribution is significantly uneven, having a large group of 
cells in the left part of image, close to the magnet position. Also, many cells were 
sticked to the side wall of the chamber, as it is shown in Fig. 6.13. These cells can 
not be seen here, as they were not attached well and lost when rinsing the culture 
from medium prior to fixing and staining.
It should also be noted, that it can be seen from the fluorescent microscopy image, 
that there are almost no cells immediately after this huge group of cells on the left. 
It probably means, that the cells with magnetic capsules capture empty cells in their 
migration  to  the  magnet.  This  is  an  interesting  feature  in  behaviour  of  cells  in 
dispersion, meaning that one doesn't  actually need to sensibilize all  the cells of 
interest to magnetic field to make them travel in desired direction.
Distribution  statistics  calculated  from  the  fluorescent  microscopy  images  is 
presented in Fig. 6.16. It is evident, that the cells with magnetic microcapsules are 
sensitive  to  magnetic  field  across  distances  of  approximately  up  to  8  mm (the 
distance shown in the graph is counted from the inner side of chamber wall, which 
is about 2 mm away from the magnet surface). Magnetic induction at this point is 
measured to be ~ 150 mTl (see Fig. 6.10b).
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Figure 6.15: Fluorescent microscopy image of B50 cells that were trypsinized and put  
to the magnet (left).
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6.3.2 Flow-cytometry of dendritic cells
Microcapsule with magnetite nanoparticles were used to separate dendritic cells in 
flow cytometry setup. Figure 6.17 shows schematics of experiments. Microcapsules 
with magnetic nanoparticles were introduced to dendritic cells and left for 2-3 hours 
for internalisation (which was found to be enough for cells to incorporate significant 
amount  of  capsules).  Following that,  cells  were  washed into  the  dispersion  and 
subjected to flow cytometry procedure with a capillary tube inside a magnet on its 
way. Numbers of cells with capsules that passed through the magnet and the ones 
that stick to the walls of the tube near the magnet were determined.
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Figure 6.17: Flow cytometry experiment with dendritic cells schematic.
Figure 6.16: Distribution of B50 cells with magnetic microcapsules after irradiation.  
Distribution presented on the left was averaged from 3 neighbouring columns (thin  
black lines). Right curve was derived from the left one by averaging the values between  
3 neighbouring distance points to smoothen the peaks. Magnet was near to x=0 point.
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However, the very first thing to do was to ensure that microcapsules with magnetite 
could be internalised by dendritic cells. For that, microcapsules B1 were used, that 
had  FITC-labelled  Poly-L-Lysine  layer  in  their  shells,  along  with  magnetite 
nanoparticles. Microcapsules were introduced to the cells and left still  for several 
hours. After that, the cells were labelled using DAPI and CellTracker dyes to visualize 
membrane  and  nuclei,  and  fluorescent  microscopy  images  were  obtained,  that 
confirmed internalisation of magnetic microcapsules by dendritic cells (Fig. 6.18).
For main set of experiments, three different amounts of “B1” capsules were added 
to the dendritic cells: 5, 10 and 15 µl (300 M/cm3). Fluorescence assisted cell sorting 
flow cytometry studies performed showed that respectively 28 %, 50 % and 66 % of 
the dendritic cells internalized capsules. When the cells were send over the magnet 
all cells with magnetic capsule stuck to the magnet as the flow cytometry data only 
showed  cells  without  capsules.  When  the  magnet  was  removed  the  cells  that 
initially stuck to the magnet were collected and flow cytometry showed that around 
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Figure 6.18: Confocal images of dendritic cells with microcapsules. Green corresponds  
to FITC (capsules), blue - DAPI (nuclei), red - membrane stain. Images obtained by Dr.  
Bruno De Geest.
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90% of the cell contained capsules (see Fig. 6.19).
Figure 6.19: FACS statistics on flow cytometry data of  
dendritic cells with magnetic microcapsules.  
Measurements performed by Dr. Bruno De Geest.
6.4 Effect of magnetic field on cells attached to the surface
These studies were performed in Ghent University (Belgium) during my visit there. 
Dendritic cells cultures were kindly provided by Dr. Stefaan De Koker (Department of 
Molecular  Biomedical  Biology).  Microporous  gelatin  scaffolds  were  prepared  by 
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Liesbeth  De  Cock.  All  my  work  there  was  supervised  by  Dr.  Bruno  De  Geest 
(Department of Pharmaceutics).
The  idea  of  the  experiments  was  to  apply  magnetic  field  to  the  cells,  that  are 
loosely  attached  to  the  surface  they  are  incubated  on.  Provided,  that  such 
experiments with 293T and B50 cells were unsuccessful, we believed that it is the 
adhesion of  the  cells  to  the  substrate  prevents  the  cells  from movement under 
applied magnetic field. Therefore, a type of cells was selected, that demonstrates 
low adhesion.
The experiments performed were the same in their nature, that the ones described 
with B50 cells. However, one extra feature in form of porous structure was added. 
These  microstructures  are  designed to  better  mimic  the  environment  of  in-vivo 
tissues. Not only cell behaviour is different in 2D in-vitro circumstances,258 but it is 
particularly desirable for the sort of experiments we were doing to study  in-vivo 
behaviour of magnetic capsules. So, use of these structures for experiments can 
give an idea of how would the cells with capsules behave  in-vivo without doing 
actually  in-vivo work.  Recently,  several  types  of  such  mimic  structures  were 
proposed,259 and the microporous scaffolds that we used are among them.
A magnet was placed in close proximity to the chambers (see Fig. 6.20) and left in 
the incubator overnight. Next morning, cells were fixed with formaldehyde for two 
hours. After that Vectashield® Mounting Medium with DAPI (DAPI concentration 1.5 
μg/mL, Vector Laboratories, Cat. No. H-1200)260 was applied for several minutes in 
order to stain the cells nuclei and also help to hold the cells and capsules in their 
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Figure 6.20: Experiment on dendritic cells migration. a) photograph of chambers and  
magnet, b), c) experiment schematic for migration on flat surface and through the  
scaffolds, respectively.
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places  while  observing  with  microscope,  as  the  chambers  where  turned  upside 
down for observations.
The cells were observed with fluorescent microscope, along the lines perpendicular 
to  the  longer  chambers  size  (see  blue  rectangles  in  Fig.  6.20 -  they  denote 
observation  zones).  As  controls,  cells  on  the  opposite  to  the  magnet  side  were 
observed. 
6.4.1 Cells migration on flat surfaces
After overnight incubation of cells with magnetic microcapsules, the cells were fixed 
with formaldehyde and their nuclei were stained with DAPI to allow for fluorescent 
microscopy imaging. Series of images were obtained from the chambers with cells, 
covering whole space between the chamber's side walls stitched then to a single 
large panoramic image, from which the distribution of cells was directly calculated, 
as  shown  in  Fig.  6.9.  Each  line  analysed  contained  at  least  200  cells.  Several 
repetitions of experiments were undertaken to adjust magnet location relatively to 
the chamber for the most pronounced effect of magnetic field on cells distribution. 
In each experiment, cells were counted along 3 parallel lines (horizontal  rows of 
“table” in Fig. 6.9) for each well to address the issue of non-uniformity of magnetic 
field created by the constant magnet used and to get statistically meaningful result, 
though it still stays semi-quantitative. Each separate “point” (“table” cell length in 
Fig. 6.9) at distance axis was selected to be 100 μm. Number of cells found in each 
cell of the “table” was related to the total amount of cells in the “row” and thus 
percentage values were obtained for each “table” cell. By doing so, distribution of 
cells along horizontal rows was established as percentage values of total number of 
cells found along that particular row.
Experiments were performed using samples with magnetic nanoparticles inside the 
cavity and in the shell  (“IN” and “OUT”, respectively).  In first experiments,  cells 
distribution was compared to one of untreated chambers. The results are presented 
in Fig. 6.21 for both “IN” and “OUT” microcapsules, showing number of cells found 
at various distance from the side of chamber to which magnet was put. Black lines 
correspond to distributions calculated from individual  “columns” (see grid in Fig. 
6.21), while coloured bold lines are averaged values for three “columns”. Graphs 
are provided for  2 cells  cultures that were subjected to magnetic  field  and one 
control untreated culture (lower graphs). To normalize Y-axis values, total number of 
cells throughout the whole analysed region was calculated, and for each “point” 
(rectangle with 100 μm side) percentage number of cells in it, related to that total 
number, was determined and plotted in the graphs.
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It can be clearly seen from the figures presented, that there is distinct patterns in 
treated and control  cultures,  and this  difference is  more  pronounced in  case  of 
“OUT” microcapsules, which is in confirmation with the measurements of magnetite 
nanoparticles containment in microcapsules of different constitution.
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Figure 6.21: Dendritic cells distribution along the magnetic field lines, perpendicular  
to magnet surface (fiirst experimental data). Graphs are shown for both microcapsules  
types used – with nanoparticles inside the cavity (“IN” sample, left), and in the shells  
(“OUT” sample, right). Distributions measured from 3 distinct lines of treated chamber  
and 1 line of untreated control are shown (bold colour lines, bottom graphs). Each line  
presented was averaged from 3 neighbouring columns (thin black lines). Magnet was  
near to x=0 point.
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Following these investigations, several sets of experiments were performed, where 
distribution  of  cells  with  magnetic  microcapsules  inside  was  calculated  along 
greater distances from the magnet. Data was processed in the same way to get the 
graphs presented in Fig. 6.22.
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Figure 6.22: Distribution of dendritic cells with magnetic microcapsules after  
irradiation. Graphs are shown for both microcapsules types used – with nanoparticles  
inside the cavity (“IN” sample, left), and in the shells (“OUT” sample, right).  
Distributions measured from 3 distinct lines of treated chamber shown (bold colour  
lines). Each line presented was averaged from 3 neighbouring columns (thin black  
lines). Magnet was near to x=0 point.
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It can be clearly seen, that there is a decrease in number of cells with distance from 
the magnet,  and this  decrease is  different  for  “IN” and “OUT” microcapsules.  It 
should also be noted, that the effect of magnetic field depends greatly on mutual 
orientation  of  magnet  and  chamber  with  cells,  this  probably  explains  some 
differences between graphs for different sets of experiments.
Figure  6.23 shows the same experimental  data averaged in each point between 
three neighbouring points to get a bit smoother curves, as the distribution of cells 
along  the  axis  is  not  very  even.  Curves  for  all  sets  of  experiments  are  shown 
together for “IN” and “OUT” capsules.
From the graphs it can be stated, that the cells are sensitive to magnetic field at 
distances from 6-9 mm for “IN” capsules to 9-10 mm for “OUT” capsules (about 2 
mm from magnet surface to the inner side of chamber wall), which is in a good 
agreement with the data on the amount of nanoparticles in these microcapsules. 
From measurements of magnetic field, created by the magnet, we know, that these 
distances correspond to  magnetic  induction  of  60-100 mTl.  This  shows,  that  by 
changing the amount of nanoparticles,  it  is possible to change the sensitivity of 
microcapsules and, therefore, the cells, to magnetic field. Potentially, this amount 
can be even higher than in the samples analysed here, as nanoparticles can be 
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Figure 6.23: Distribution of dendritic cells with magnetic capsules, averaged between 3  
neighbouring distance points to smoothen the peaks. Data shown for both  
microcapsules types – with nanoparticles in cavity (left) and in the shell (right). Three  
distinct lines of imaging are presented in each graph, that correspond to the lines  
presented in Fig. 6.22.
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included into several layers of microcapsules shells, instead of single layer in “OUT” 
capsules. 
The fact that dendritic cells seem to be more sensitive to magnetic field than the 
trypsinized B50 cells can be explained by two reasons. At first, B50 cells cannot 
move while attached to the surface, so they can move only during the time while 
they are unattached, and this time is probably much shorter, than overnight period, 
during which DCs were irradiated with magnetic field. At second, the magnet used 
for B50 cells, though stronger, but produces less even magnetic field, which can 
also be a factor. Also, many of the cells actually go towards the wall of the chamber 
and stay there sticked to the surface and can not be counted on the images.
6.4.2 Migration through the microporous scaffolds
To study cell  migration through the  scaffolds,  the latter  were immersed in cells 
medium to hydrate, and the cells were introduced onto the top of the scaffolds, 
situated in 8 well chambers. The chamber was put onto the magnet for overnight to 
let the cells with capsules travel through the scaffolds towards the bottom of the 
chamber (see Fig. 6.20c).
After incubation for overnight, cryosections of Tissue Tek (Sakura) were cut at 10 μm 
thickness  and  stained  with  DAPI  for  fluorescent  analysis.  No  migration  of  cells 
towards the magnet was observed on microtomes. This probably happened due to 
high resistance of scaffolds pores to the movement of the cells under the low force 
of magnetic field, provided by the fact, that initial position of cells on top of the 
scaffolds was close or even beyond the limit of sensitive distance, as measured 
from the migration of cells on flat surface, provided by the fact that the magnet was 
situated  below  the  scaffold  and  the  bottom  of  the  chamber  (5-6  mm  total). 
Therefore, the force of magnetic field was not high enough at these distances. The 
other reason is that magnetic field forces capsules to go right towards the magnet, 
without allowing the cells go sideways to be more able to find a way through the 
scaffold,  as  if  in case of  something forcing the cells  to migrate using biological 
mechanisms of influence, where the cell would try to find a way by itself, rather 
than just stick to the nearest wall encountered on its direct way to the source of 
magnetic field.
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6.5 Conclusions
In this study the possibility of internalisation of microcapsules by various types of 
cells was shown. Cell viability studies show, that for fibroblast and macrophage cells 
microcapsules at concentration exceeding ones necessary to make cells sensitive to 
magnetic  field,  do not  produce critical  toxicity,  which means that microcapsules 
with magnetite nanoparticles can be used as carriers and sensitizers to magnetic 
field. Polymer material in capsule wall can be FDA approved and prevent magnetic 
nanoparticles  to  desorb  or  iron  ions  to  leak  and  interfere  with  intracellular 
processes. 
Experiments have shown, that internalization of 3-5  μm capsules results in ability 
for cells to be moved and collected with a magnet. Dendritic cells taken ex-vivo can 
be  up  to  90%  impregnated  with  magnetic  capsules  and  being  addressed  and 
accumulated in certain  location with magnetic  field.  Movement of  the cells  was 
shown to be very efficient when the cells are dispersed in liquid, allowing for almost 
total separation of charged cells in flow cytometry experiments. Results for dendritic 
cells, loosely attached to the surface, are a bit worse, but still show possibility to 
control the movement at maximum distances of about 10 mm. Technology of LbL 
capsule  fabrication  allows  to  define  the  amount  of  magnetic  nanoparticles  per 
capsules  and  tuning  capsule  size  and surface  could  make  capsule  staying  long 
enough in the cell after internalisation providing sufficient time for cell delivery and 
retention in preferred location without being secreted. These factors can possibly 
enhance the sensitivity of cells loaded with magnetic microcapsules to magnetic 
field for in-vivo applications.
However,  not much effect of magnetic field on cells was found when cells were 
cultured in gel scaffoldings, which are mimic to tissues found in living organisms. 
This probably means, that the approach of using cells as outer carriers for drug-
loaded magnetic microcapsules is applicable only for free dispersions of cells, such 
as  in  blood  stream.  Drug  molecules  can  be  loaded  inside  capsules  and  be 
transported together with cells to targeted organs and tissues. Release of drug can 
be  initiated  externally  by  various  methods,  including  electromagnetic  radiation, 
which would result magnetic nanoparticles to heat and destroy capsule wall  and 
then the cell  followed by drug release into surrounding medium. Debris  of  cells 
(being from the same organism) will be digested.
When combined already developed techniques of  trafficking reported for  in-vivo 
experiments with dendritic cells,261 provided by multifunctionality of microcapsules, 
they would create a great drug delivery system.
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LbL microcapsules are not unique in being carriers for substances. There is a vast 
number of dispersions of all kinds with various sizes, densities, volumetric fractions, 
etc.  Besides  solid  sacrificial  particles,  other  types  of  templates  can  be  used, 
including  gas  bubbles  generated  by  cavitation262 or  hollow  CaCO3,  TiO2,  Co2P 
spheres  upon  O2,  PH3,  CH4 gas  bubbles,263 alginate  microspheres,264 PLGA 
microparticles.265 One  of  encapsulation  methods  that  is  actively  developing 
nowadays is microemulsions, where liquid cores are generated by ultrasound in 2 
phase system (oil  in water) and then stabilized by LbL shells.266 Obviously these 
different  templates  allow  encapsulation  of  various  substances.  For  example, 
emulsions can be used when water-insoluble or small molecular weight materials 
need  to  be  encapsulated.266 Therefore,  there  is  a  variety  of  encapsulation 
techniques,  each  having  its  distinct  features  and  possible  applications. 
Microencapsulation is one of more developed methods, that happily is rather simple 
when following established procedures, and not demanding any special equipment 
or chemicals. For these reasons, microencapsulation is a versatile, developed and 
promising technique for targeted drug delivery systems.
This  work  was  intended  to  make  a  step  further  on  the  way  to  using 
microencapsulation  technique  for  targeted  drug  delivery  in  living  body.  Though 
potential applications of this multifunctional technique are far from being limited by 
that, it is application for drug delivery which is ultimate goal of many researchers. A 
drug delivery system would include such parts as containers, means of navigation 
and triggered or sustained release. Studies described here were mostly performed 
in-vitro with many cell culture investigations. Despite that, the point was to explore 
methods  and  techniques  that  actually  fit  those  parts  of  delivery  system. 
Encapsulation  of  bioactive  substances  was  investigated  and  influence  of 
microcapsules  composition  on  the  retained  activity  of  the  species.  Methods  of 
irradiation  that  potentially  are  applicable  in  living  body  provided  by  their 
penetration deep enough and harmlessness were employed to release encapsulated 
substances,  including  experiments  with  cell  cultures  and  bioactive  compounds. 
Experiments studying feasibility of microcapsules internalized by cells navigation by 
magnetic field and microcapsules visualization in living body were also performed.
Studies of release mechanisms included use of focused IR and red laser beams and 
high frequency ultrasound for burst-release of encapsulated species. Experiments 
performed  using  synthetic  microcapsules  with  labelled  protein  inside, 
demonstrated, that it is possible to use much less powerful irradiation of higher 
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frequency  than  previously  reported  probe  ultrasonication  to  release  up  to  60% 
compared  to  low  frequency  treatment,  up  to  1/3  of  total  protein  encapsulated. 
Effect was shown to be enhanced by including of nanoparticles into the shells of 
microcapsules, and the dependence of the treatment efficacy was observed to have 
a peak at some certain amount of nanoparticles in the shell. This is probably due to 
balance  of  weight  and  rigidity  of  microcapsule  shell  exposed  to  mechanical 
oscillations and cavitation. Electron microscopy investigations proved that release 
happens  before  the  capsules  are  visibly  ruptured,  which  suggests  formation  of 
rather  small  pores  upon  ultrasonic  irradiation.  High  frequency  ultrasound  can 
penetrate deep inside living tissues, and several transducers can be used at the 
same  time  to  create  small  zones  of  high  ultrasound  oscillations  intensities  by 
summing irradiation of single transducers at certain point. This technique known as 
HIFU is  already applied for  medical  treatment.  All  these factors make ultrasonic 
irradiation  a  very  promising  candidate  for  release  mechanism for  microcapsules 
delivering  drugs  inside  human  body.  Results  achieved  in  this  study  are  very 
interesting and promising for medical applications, compared to reported earlier use 
of high-power ultrasound probe, inapplicable to living body.12,13
Release of encapsulated substances was also shown intracellularly on a new kind of 
cells  –  neuronal  ones  by  irradiation  with  focused  IR  laser  of  microcapsules 
functionalized  with  pre-aggregated  gold  nanoparticles.  This  opens  huge 
perspectives for control of neuronal cultures by releasing signalling substances at 
specific points at desired time without harm for cells. This triggered release was 
then  compared  to  rather  sustained  release  happening  from  biodegradable 
microcapsules upon disintegration of their shells. PH-sensitive dye was also released 
from microcapsules upon laser irradiation, breaking the endosome, and allowing to 
measure  acidity  of  intracellular  compartments.  These  results  introduce  new 
promising type of cells (neuronal) to already investigated area,10,197 and complete 
the chain encapsulation – delivery – release – sensing for pH-sensitive substances.194
Attempt of  using photosensitive dye Al-PcS for  release from microcapsules upon 
irradiation with 670 nm focused red laser beam were undertaken.  The dye was 
included electrostatically  into  the  shells  of  microcapsules  to  destroy  them upon 
irradiation. The results shown that after treatment less of encapsulated substance 
can be found inside the microcapsules, but no structural changes of microcapsules 
shell were observed. So, the effect of irradiation is not very pronounced, but should 
be  definitely  studied  deeper,  maybe  by  using  microscopic  methods  of 
measurements.  One advantage of  the  method is  that  much lower  intensities  of 
irradiation could possibly be used, which makes the method even better applicable 
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for medical  treatments than IR laser, that despite deeper penetration of IR light 
through tissues, needs higher intensity, that are hard to deliver. Another one is that 
such substances are an alternative to nanoparticles, that can be harmful and toxic 
to living body, whereas the photodynamic dyes can be synthesized in bio-friendly 
form, such as chlorophyll.  Until  now no successful  applications to this promising 
method of release were reported, however, there are publications where Al-PcS was 
encapsulated to generate singlet oxygen upon irradiation.228
Luciferase  was  successfully  encapsulated  into  microcapsules  with  various  shell 
structures  and  changes  of  enzyme  activity  were  measured  by  bioluminescence 
technique.  Feasibility  of  response  kinetics  adjustment  by  including  luciferase  to 
certain positions in microcapsules was shown. Effect of various polyelectrolytes on 
the activity of enzyme was observed, which demonstrates importance of precise 
design and engineering of microcapsules for certain needs. Protection of enzyme by 
microcapsules was investigated by immersing the microcapsules to trypsin which 
cleaves proteins. It was shown that synthetic microcapsules provide more protection 
than biodegradable ones, and right placement of luciferase in the microcapsules 
again can be used to achieve desired level of protection.
Other  bioactive  substance  to  encapsulate  was  plasmid  DNA.  Its  successful 
encapsulation and transfection upon internalisation by 293T cells was achieved by 
deposition of PEI as outermost layer of microcapsules to help the microcapsules get 
out from the endosome where it ends up immediately upon internalisation. It was 
known problem that it is hard to achieve transfection of genes because nucleic acid 
cannot leave microcapsules and endosomal cavity. Effect of including chloroquine 
and ATA which were reported to enhance transfection when using other methods, to 
microcapsules with DNA was studied. No consistent behaviour of these species was 
observed.  Studies  of  transfection  of  DNA  upon  its  triggered  release  from 
microcapsules by focused IR laser irradiation were also performed to show up to 
50%  increase  in  transfection  activity  of  DNA  encapsulated  to  biodegradable 
microcapsules in 293T cells.
In  both  cases  with  bioactive  compounds  encapsulated  –  luciferase  and  DNA  – 
activity  upon  encapsulation  was  considerably  lower  compared  to  conventional 
methods used for respective species. This is inevitable disadvantage, which follows 
from  isolation  by  microencapsulation,  providing  protection  against  the  outside 
environment. However, it was shown, that by variation of structure and methods 
used  it  is  possible  in  some  cases  to  retain  activity  at  levels  that  are  at  least 
comparable to ones demonstrated by other techniques. At the same time, feasibility 
of encapsulation of several compounds simultaneously to the single capsules gives 
209
7 General Conclusions
much flexibility, possibilities and control.
The  study  performed  concerning  bioactive  substances  may  not  be  looking  too 
fascinating, but is, however, a very detailed investigation on fate of such species 
upon encapsulation. Earlier publications on that matter usually reported more or 
less successful incorporation of cargo to microcapsules, and in some cases, simple 
checks on their activity retention, without detailed investigations on factors that 
influence this measured activity.92,111,164,183-186 The study performed has shown, that it 
is possible to control  accessibility of materials  to environment and their gradual 
release rate by fine adjustments in microcapsules construction. We also found, that 
while microcapsules allow several compounds to be placed together, and even to 
different compartments inside single capsule,114 behaviour of substances that are 
encapsulated together is not always easy to predict.
One of the most promising investigations performed was focused on feasibility of 
employing  magnetic  field  to  move  microcapsules  internalised  by  cells. 
Microcapsules were prepared functionalized with magnetite nanoparticles to make 
them sensitive to magnetic field. It was shown that cells dispersed in solution (like 
leycocytes or heamocytes) can be navigated by magnetic field of 150 mTl. Dendritic 
cells,  which loosely  attach to  the  substrate they sit  on,  were  also shown to  be 
susceptible to navigation by magnetic field at even lower intensities. Separation of 
cells with internalised magnetic microcapsules by application of magnet to the tube 
was also shown in flow cytometry experiments. This opens great perspectives for 
using magnetic field as a navigation force for drug delivery applications, provided 
that intensities and irradiation used are harmless for human body. The research is 
based upon previously reported magnetic microcapsules that can be also used for 
triggered release by high-frequency electromagnetic field.172,173 There are also many 
publications on functionalizing cells with magnetic nanoparticles to achieve more or 
less the same goals, but this approach suffers from the fact that after some time 
nanoparticles are exocytosed from the cells.245-248
On my opinion, it is high frequency ultrasound and photodynamic techniques that 
are most probable candidates for  release mechanisms for  drug delivery system. 
These two can penetrate biological tissues deep enough and do not require harmful 
levels of intensity to work. This proposes employing of more macroscopic methods 
of irradiation and characterisation in further investigations, which may be a step 
towards real application, where it is hard to imagine targeting single microcapsules. 
Studies at  micro level,  however,  are also very important  as  they provide better 
understanding and astonishing playground for investigations on new mechanisms 
and ideas, new inventions.
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